Package 'DACT'

November 8, 2026

Version 1.0.4

Title Design and Analysis for Clinical Trials

Author Ping Gao [aut, cre]

Maintainer Ping Gao <support@innovatiostat.com>

Description The applications and evaluation of the operating characteristics of many statistical methodologies require the use of
sophisticated software or extensive simulations. 'DACT' is designed to serve a wide range of innovative statistical designs and analyses.
The primary objective of the 'DACT' software is to promote the understanding and application of cutting-edge statistical solutions in
clinical trials. For this reason, the software is free for non-commercial scientific research, including but not limited to academic
researchers and research/teaching institutions. Computing codes are available upon request.
For more details see P. Gao (2024) <doi:10.1080/10543406.2024.2341673>.
Gao, P., Zhang, W. (2024) <doi:10.1080/10543406.2024.2358796>.
P. Gao & Y. Li (2024) <doi:10.1080/10543406.2023.2233590>.
P. Gao, Y. Li (2024) <doi:10.1080/10543406.2024.2342518>.
Gao, P., L. Liu, and C. Mehta. (2013) <doi:10.1002/sim.5847>.

Depends clinfun, mvtnorm, doParallel

License MIT + file LICENSE

Encoding UTF-8

Imports foreach, dplyr, jsonlite, MASS, survival, parallel, stats, utils

Config/roxygen2/version 8.0.0

URL https://github.com/innovatiostat/rcode

BugReports https://github.com/innovatiostat/rcode/issues

NeedsCompilation no

Repository CRAN

Date/Publication 2026-11-07 23:20:08 UTC

Contents

asd_ci_est_back . . . 6
asd_ci_est_one_arm_2_stage . . . 8
asd_ci_est_one_arm_3_stage . . . 9
asd_new_design . . . 11
asd_new_design_survival . . . 13
asd_new_design_theta . . . 14
asd_new_design_theta_survival . . . 16
asd_power_simu_binary . . . 17
asd_power_simu_neg_binomial . . . 19
asd_power_simu_normal . . . 21
asd_power_simu_poisson . . . 23
asd_power_simu_survival . . . 25
asd_simu_OC_binary . . . 26
asd_simu_OC_neg_binomial . . . 29
asd_simu_OC_normal . . . 32
asd_simu_OC_poisson . . . 34
asd_simu_OC_survival . . . 37
EXP_3_stg_sz . . . 39
fixed_rej_nbglm_simu . . . 40
fixed_rej_rate_binary . . . 41
fixed_rej_rate_normal . . . 42
fixed_rej_rate_poisson . . . 43
fixed_rej_rate_surv_cox . . . 44
gsd_ci_est . . . 45
gsd_ci_est_2_stage . . . 46
gsd_ci_est_3_stage . . . 47
gsd_power_simu_binary . . . 48
gsd_power_simu_negbinom . . . 50
gsd_power_simu_normal . . . 51
gsd_power_simu_poisson . . . 53
gsd_power_simu_survival . . . 54
hybrid_fixed_prior_rej_binary_simu . . . 56
hybrid_fixed_prior_rej_negbinom_simu . . . 58
hybrid_fixed_prior_rej_normal_simu . . . 60
hybrid_fixed_prior_rej_poisson_simu . . . 62
hybrid_fixed_prior_rej_survival_simu . . . 64
hybrid_random_prior_rej_binary_simu . . . 66
hybrid_random_prior_rej_negbinom_simu . . . 68
hybrid_random_prior_rej_normal_simu . . . 71
hybrid_random_prior_rej_poisson_simu . . . 73
hybrid_random_prior_rej_survival_simu . . . 75
hybrid_sz . . . 77
interim_analysis . . . 78
masd_est_back_no_drop . . . 80
masd_est_back_with_drop . . . 82
masd_est_ci . . . 84

masd_new_samsz . . . 86
masd_new_samsz_survival . . . 88
masd_new_samsz_theta . . . 91
masd_new_samsz_theta_survival . . . 93
masd_power_simu_adapt_binary . . . 96
masd_power_simu_adapt_neg_binomial . . . 98
masd_power_simu_adapt_normal . . . 100
masd_power_simu_adapt_poisson . . . 102
masd_power_simu_adapt_survival . . . 104
masd_simu_OC_binary . . . 105
masd_simu_OC_neg_binomial . . . 108
masd_simu_OC_normal . . . 110
masd_simu_OC_poisson . . . 112
masd_simu_OC_survival . . . 115
midpnt_sz . . . 117
MSD_power_alsp_boundary_binary_diff . . . 118
MSD_power_alsp_boundary_neg_binomial . . . 120
MSD_power_alsp_boundary_normal . . . 122
MSD_power_alsp_boundary_poisson . . . 123
MSD_power_alsp_boundary_survival_Schoenfeld . . . 125
MSD_power_OF_boundary_binary_diff . . . 127
MSD_power_OF_boundary_neg_binomial . . . 129
MSD_power_OF_boundary_normal . . . 130
MSD_power_OF_boundary_poisson . . . 132
MSD_power_OF_boundary_survival_Schoenfeld . . . 134
msd_power_simu_binary . . . 136
msd_power_simu_neg_binomial . . . 137
msd_power_simu_normal . . . 139
msd_power_simu_poisson . . . 140
msd_power_simu_survival . . . 142
MSD_Sample_size_alsp_boundary_binary_diff . . . 143
MSD_Sample_size_alsp_boundary_neg_binomial . . . 145
MSD_Sample_size_alsp_boundary_normal . . . 147
MSD_Sample_size_alsp_boundary_poisson . . . 149
MSD_Sample_size_alsp_boundary_survival_Schoenfeld . . . 151
MSD_Sample_size_OF_boundary_binary_diff . . . 153
MSD_Sample_size_OF_boundary_neg_binomial . . . 155
MSD_Sample_size_OF_boundary_normal . . . 157
MSD_Sample_size_OF_boundary_poisson . . . 159
MSD_Sample_size_OF_boundary_survival_Schoenfeld . . . 161
new_sample_size_hybrid . . . 162
one_arm_ad_3_stg_binary . . . 164
one_arm_ad_two_stg_binary . . . 166
one_arm_rej_2_stg_binary . . . 167
one_arm_rej_3_stg_binary . . . 169
one_arm_rej_simon_binary . . . 170
plot.ph2simon . . . 171
power_alsp_boundary_binary_diff . . . 172

power_alsp_boundary_binary_diff_NI . . . 173
power_alsp_boundary_neg_binomial . . . 174
power_alsp_boundary_neg_binomial_NI . . . 176
power_alsp_boundary_normal . . . 177
power_alsp_boundary_normal_NI . . . 179
power_alsp_boundary_poisson . . . 180
power_alsp_boundary_poisson_NI . . . 181
power_alsp_boundary_survival_Schoenfeld . . . 183
power_alsp_boundary_survival_Schoenfeld_NI . . . 184
power_binary_diff . . . 185
power_binary_diff_NI . . . 186
power_OF_boundary_binary_diff . . . 187
power_OF_boundary_binary_diff_NI . . . 188
power_OF_boundary_neg_binomial . . . 189
power_OF_boundary_neg_binomial_NI . . . 190
power_OF_boundary_normal . . . 192
power_OF_boundary_normal_NI . . . 193
power_OF_boundary_poisson . . . 195
power_OF_boundary_poisson_NI . . . 196
power_OF_boundary_survival_Schoenfeld . . . 197
power_OF_boundary_survival_Schoenfeld_NI . . . 198
power_pocock_boundary_binary_diff . . . 200
power_pocock_boundary_binary_diff_NI . . . 201
power_pocock_boundary_neg_binomial . . . 202
power_pocock_boundary_neg_binomial_NI . . . 204
power_pocock_boundary_normal . . . 205
power_pocock_boundary_normal_NI . . . 206
power_pocock_boundary_poisson . . . 208
power_pocock_boundary_poisson_NI . . . 209
power_pocock_boundary_survival_Schoenfeld . . . 210
power_pocock_boundary_survival_Schoenfeld_NI . . . 211
power_two_sample_neg_binomial . . . 213
power_two_sample_neg_binomial_NI . . . 214
power_two_sample_normal . . . 215
power_two_sample_normal_NI . . . 216
power_two_sample_Poisson . . . 217
power_two_sample_Poisson_NI . . . 217
power_two_sample_surv_Schoenfeld . . . 218
power_two_sample_surv_Schoenfeld_NI . . . 219
print.ph2simon . . . 220
Sample_size_alsp_boundary_binary_diff . . . 221
Sample_size_alsp_boundary_binary_diff_NI . . . 222
Sample_size_alsp_boundary_neg_binomial . . . 223
Sample_size_alsp_boundary_neg_binomial_NI . . . 225
Sample_size_alsp_boundary_normal . . . 226
Sample_size_alsp_boundary_normal_NI . . . 228
Sample_size_alsp_boundary_poisson . . . 229
Sample_size_alsp_boundary_poisson_NI . . . 231

Sample_size_alsp_boundary_survival_Schoenfeld . . . 232
Sample_size_alsp_boundary_survival_Schoenfeld_NI . . . 233
sample_size_binary_diff . . . 235
sample_size_binary_diff_NI . . . 235
sample_size_neg_binomial . . . 236
sample_size_neg_binomial_NI . . . 237
Sample_size_OF_boundary_binary_diff . . . 239
Sample_size_OF_boundary_binary_diff_NI . . . 240
Sample_size_OF_boundary_neg_binomial . . . 241
Sample_size_OF_boundary_neg_binomial_NI . . . 243
Sample_size_OF_boundary_normal . . . 244
Sample_size_OF_boundary_normal_NI . . . 246
Sample_size_OF_boundary_poisson . . . 247
Sample_size_OF_boundary_poisson_NI . . . 249
Sample_size_OF_boundary_survival_Schoenfeld . . . 250
Sample_size_OF_boundary_survival_Schoenfeld_NI . . . 251
Sample_size_pocock_boundary_binary_diff . . . 253
Sample_size_pocock_boundary_binary_diff_NI . . . 254
Sample_size_pocock_boundary_neg_binomial . . . 255
Sample_size_pocock_boundary_neg_binomial_NI . . . 257
Sample_size_pocock_boundary_normal . . . 258
Sample_size_pocock_boundary_normal_NI . . . 260
Sample_size_pocock_boundary_poisson . . . 261
Sample_size_pocock_boundary_poisson_NI . . . 263
Sample_size_pocock_boundary_survival_Schoenfeld . . . 264
Sample_size_pocock_boundary_survival_Schoenfeld_NI . . . 265
sample_size_two_sample_normal . . . 267
sample_size_two_sample_normal_NI . . . 268
sample_size_two_sample_Poisson . . . 269
sample_size_two_sample_Poisson_NI . . . 270
sample_size_two_sample_surv_Schoenfeld . . . 271
sample_size_two_sample_surv_Schoenfeld_NI . . . 271
simon_ph2_sz . . . 272
Two_stage_asd_simu_OC_binary . . . 274
Two_stage_asd_simu_OC_neg_binomial . . . 276
Two_stage_asd_simu_OC_normal . . . 278
Two_stage_asd_simu_OC_poisson . . . 281
Two_stage_asd_simu_OC_survival . . . 283
two_stage_ci_0 . . . 286
two_stage_ci_1 . . . 287
two_stage_est_back . . . 289
two_stage_power_alsp_boundary_binary_diff . . . 291
two_stage_power_alsp_boundary_neg_binomial . . . 293
two_stage_power_alsp_boundary_normal . . . 295
two_stage_power_alsp_boundary_poisson . . . 297
two_stage_power_alsp_boundary_survival_Schoenfeld . . . 299
two_stage_power_OF_boundary_binary_diff . . . 300
two_stage_power_OF_boundary_neg_binomial . . . 302

two_stage_power_OF_boundary_normal . . . 304
two_stage_power_OF_boundary_poisson . . . 306
two_stage_power_OF_boundary_survival_Schoenfeld . . . 307
two_stage_Sample_size_alsp_boundary_binary_diff . . . 309
two_stage_Sample_size_alsp_boundary_neg_binomial . . . 311
two_stage_Sample_size_alsp_boundary_normal . . . 313
two_stage_Sample_size_alsp_boundary_poisson . . . 315
two_stage_Sample_size_alsp_boundary_survival_Schoenfeld . . . 317
two_stage_Sample_size_OF_boundary_binary_diff . . . 319
two_stage_Sample_size_OF_boundary_neg_binomial . . . 321
two_stage_Sample_size_OF_boundary_normal . . . 323
two_stage_Sample_size_OF_boundary_poisson . . . 325
two_stage_Sample_size_OF_boundary_survival_Schoenfeld . . . 327
two_stg_adapt_power_simu_binary . . . 329
two_stg_adapt_power_simu_neg_binomial . . . 331
two_stg_adapt_power_simu_normal . . . 333
two_stg_adapt_power_simu_poisson . . . 335
two_stg_adapt_power_simu_survival . . . 337
two_stg_power_simu_binary . . . 339
two_stg_power_simu_neg_binomial . . . 340
two_stg_power_simu_normal . . . 342
two_stg_power_simu_poisson . . . 344
two_stg_power_simu_survival . . . 345

Index **348**

`asd_ci_est_back` *Group sequential designs / Adaptive sequential designs: Final analysis, With one sample size change*

Description

Group sequential designs / Adaptive sequential designs: Final analysis, With one sample size change

Usage

```
asd_ci_est_back(
  s,
  c_bry,
  snew,
  c_bry_new,
  theta_hat_inter,
  theta_hat_inter_sd,
  inter_vt,
  theta_hat_last_ad,
  theta_hat_last_ad_sd,
  last_vt_ad,
```

```
  alpha_2
)
```

Arguments

s	Vector of information fractions of the original design, e.g. c(0.3, 0.7, 1); the last element must be 1
c_bry	Vector of critical boundaries of the original design, one per analysis
snew	Vector of information fractions after the sample size is changed; the last element must be 1
c_bry_new	Vector of critical boundaries after the sample size is changed, one per remaining analysis
theta_hat_inter	Treatment effect estimate observed at the interim analysis at which the sample size was re-estimated
theta_hat_inter_sd	Standard error of theta_hat_inter
inter_vt	Index (1-based) of the interim analysis at which the sample size was re-estimated
theta_hat_last_ad	Treatment effect estimate observed at the last analysis after the sample size change
theta_hat_last_ad_sd	Standard error of theta_hat_last_ad
last_vt_ad	Index (1-based) of the last analysis after the sample size change
alpha_2	Type I error for the two-sided test; the confidence interval has coverage 1 - alpha_2

Value

A named list with the following components:

p-value Two-sided p-value for the null hypothesis of no treatment effect, obtained by inverting the adaptive sequential boundary under the Brownian motion approximation

confidence interval Numeric vector of length 3 giving the lower confidence limit, the point estimate and the upper confidence limit of the two-sided (1 - alpha_2) confidence interval

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_ci_est_back(s = c(0.3,0.7,1), c_bry = c(4.347011, 2.845787, 2.380956), snew = c(0.5,1),
c_bry_new = c(3.310743, 2.781890), theta_hat_inter = 1.2, theta_hat_inter_sd = 1, inter_vt = 1,
theta_hat_last_ad = 2.2, theta_hat_last_ad_sd = 1, last_vt_ad = 2, alpha_2 = 0.05)
```

---

asd_ci_est_one_arm_2_stage

Single arm phase 2 oncology trial: Final analysis: two stage design, with sample size change

---

Description

Single arm phase 2 oncology trial: Final analysis: two stage design, with sample size change

Usage

```
asd_ci_est_one_arm_2_stage(p_0, n_1, n_2, r_1_e, r_2, n_new, x_1, x_new, alpha)
```

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit
n_1	Number of patients at first look
n_2	Number of patients at second look in the original design
r_1_e	Superiority-stopping threshold at the first look: the trial would be stopped for superiority if at least r_1_e responses are observed at the first look. Enter NA when the design uses no efficacy boundary at the first look; the function then bases the final boundary on r_2 alone
r_2	If no more than r_2 responses are observed at the second look, then the null hypothesis will not be rejected
n_new	New sample size after the interim analysis, used as the final sample size
x_1	Number of responses at the first look
x_new	Number of responses at the final visit
alpha	Type I error for the one-sided test

Details

The results with continuity correction are not necessarily different from those without continuity correction. The need for continuity correction can be determined through simulations on the type I error (see Gao and Zhang, 2004).

Value

A named list whose components depend on whether a first-look efficacy boundary was supplied. When r_1_e is NA the list contains p_value and Confidence interval; otherwise it contains four components, reported without and with continuity correction:

p_value P-value of the test of the null hypothesis that the response rate equals p_0 at the final analysis; returned when r_1_e is NA

Confidence interval Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate; returned when r_1_e is NA

p_no_correction P-value at the final analysis computed without continuity correction

p_correction The same p-value computed with the 0.5 continuity correction

CI_withot_correction Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate, computed without continuity correction

CI_with_correction The same confidence interval computed with the 0.5 continuity correction

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_ci_est_one_arm_2_stage( p_0=0.2,n_1=100,n_2=105,r_1_e=33,r_2=29,n_new=115,
x_1=28,x_new=34,alpha=0.025)
```

---

asd_ci_est_one_arm_3_stage

Single arm phase 2 oncology trial: Final analysis: three stage design, with sample size change

---

Description

Single arm phase 2 oncology trial: Final analysis: three stage design, with sample size change

Usage

```
asd_ci_est_one_arm_3_stage(
  p_0,
  n_2,
  n_3,
  r_2_e,
  r_2,
  r_3,
  n_new,
  x_2,
  x_new,
  alpha
)
```

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit
n_2	Number of patients at second look
n_3	Number of patients at third look
r_2_e	Superiority-stopping threshold at the second look: the trial would be stopped for superiority if at least r_2_e responses are observed at the second look. If r_2_e was not used in the design, enter NA; the function then bases the final boundary on r_3 alone
r_2	If no more than r_2 responses are observed at the second look, then the trial would be stopped for futility; kept for consistency with the design of the trial and not used by this function, which conditions on the observed responses at the second look
r_3	If no more than r_3 responses are observed at the third look, then the null hypothesis will not be rejected
n_new	New sample size after the interim analysis, taken at the second look and used as the final sample size
x_2	Number of responses at the second look
x_new	Number of responses at the final visit
alpha	Type I error for the one-sided test

Details

The results with continuity correction are not necessarily different from those without continuity correction. The need for continuity correction can be determined through simulations on the type I error (see Gao and Zhang, 2004).

Value

A named list whose components depend on whether a second-look efficacy boundary was supplied. When r_2_e is NA the list contains p_value and Confidence interval; otherwise it contains four components, reported without and with continuity correction:

p_value P-value of the test of the null hypothesis that the response rate equals p_0 at the final analysis; returned when r_2_e is NA

Confidence interval Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate; returned when r_2_e is NA

p_no_correction P-value at the final analysis computed without continuity correction

p_correction The same p-value computed with the 0.5 continuity correction

CI_withot_correction Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate, computed without continuity correction

CI_with_correction The same confidence interval computed with the 0.5 continuity correction

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_ci_est_one_arm_3_stage( p_0=0.2,n_2=105,n_3=110,r_2_e=33,r_3=29,n_new=115,
x_2=28,x_new=34,alpha=0.025)
```

`asd_new_design` *Group sequential designs / Adaptive sequential designs: Interim analysis, Non-survival analysis, Use theta_interim*

Description

Group sequential designs / Adaptive sequential designs: Interim analysis, Non-survival analysis, Use theta_interim

Usage

```
asd_new_design(
  s,
  c_bry,
  inter_vt,
  snew,
  theta_hat_inter,
  theta_hat_inter_sd,
  n_control_inter,
  beta
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
theta_hat_inter	Treatment effect estimate observed at the interim analysis, e.g. the difference of the observed means or event rates between the test arm and the control arm
theta_hat_inter_sd	Standard error of 'theta_hat_inter'
n_control_inter	Sample size of the control arm at the interim analysis
beta	Type II error rate, i.e. 1 - power

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis

Wald statistics Wald statistic of the treatment effect observed at the interim analysis

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Estimated effect size: theta The effect size used for the conditional power calculation, taken to be the treatment effect estimate observed at the interim analysis

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0

c_power_theta Conditional power at the interim analysis using the estimated effect size theta

N_control_new New sample size for the control arm after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if the estimated effect size is < 0.001

new information fraction The new information fractions after the sample size change

New critical boundary New critical boundaries for the new interim analyses (O'Brien-Fleming type), or 'NA' if they were not calculated

Examples

```
asd_new_design(s = c(1/3, 2/3, 1), c_bry = c(3.984298, 3.961146, 2.349682), inter_vt = 1,
snew = c(0.5, 1), theta_hat_inter = 0.3, theta_hat_inter_sd = 0.5,
n_control_inter = 100, beta = 0.1)
```

asd_new_design_survival *Group sequential designs / Adaptive sequential designs: Interim analysis, Survival analysis, Use theta_interim*

Description

Group sequential designs / Adaptive sequential designs: Interim analysis, Survival analysis, Use theta_interim

Usage

```
asd_new_design_survival(
  s,
  c_bry,
  inter_vt,
  snew,
  theta_hat_inter,
  theta_hat_inter_sd,
  events_inter,
  beta
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
theta_hat_inter	Treatment effect estimate observed at the interim analysis, i.e. minus the log of the observed hazard ratio
theta_hat_inter_sd	Standard error of 'theta_hat_inter'
events_inter	Number of events observed at the interim analysis
beta	Type II error rate, i.e. 1 - power

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis

Wald statistics Wald statistic of the treatment effect observed at the interim analysis

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Estimated effect size: theta The effect size used for the conditional power calculation, taken to be the treatment effect estimate observed at the interim analysis

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0

c_power_theta Conditional power at the interim analysis using the estimated effect size theta

events_new New total number of events required after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if the estimated effect size is < 0.001

New information fraction The new information fractions after the sample size change

New critical boundary New critical boundaries for the new interim analyses (O'Brien-Fleming type), or 'NA' if they were not calculated

Examples

```
asd_new_design_survival(s = c(1/3, 2/3, 1), c_bry = c(3.984298, 3.961146, 2.349682),
inter_vt = 1, snew = c(0.5, 1), theta_hat_inter = 0.3, theta_hat_inter_sd = 0.5,
events_inter = 100, beta = 0.1)
```

`asd_new_design_theta` *Group sequential designs / Adaptive sequential designs: Interim analysis, Non-survival analysis, Input theta*

Description

Group sequential designs / Adaptive sequential designs: Interim analysis, Non-survival analysis, Input theta

Usage

```
asd_new_design_theta(
  theta,
  s,
  c_bry,
  inter_vt,
  snew,
  theta_hat_inter,
  theta_hat_inter_sd,
  n_control_inter,
  beta
)
```

Arguments

theta	Assumed effect size used for the conditional power calculation; different values of theta can be entered to check the sensitivity of the conditional power to the effect size; if theta < 0.001 the new sample size and the new critical boundary are returned as 'NA'
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
theta_hat_inter	Treatment effect estimate observed at the interim analysis, e.g. the difference of the observed means or event rates between the test arm and the control arm
theta_hat_inter_sd	Standard error of 'theta_hat_inter'
n_control_inter	Sample size of the control arm at the interim analysis
beta	Type II error rate, i.e. 1 - power

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis

Wald statistics Wald statistic of the treatment effect observed at the interim analysis

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Assumed effect size: theta The assumed effect size theta used for the conditional power calculation

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0

c_power_theta Conditional power at the interim analysis using the assumed effect size theta

N_control_new New sample size for the control arm after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if theta < 0.001

new information fraction The new information fractions after the sample size change

New critical boundary New critical boundaries for the new interim analyses (O'Brien-Fleming type), or 'NA' if they were not calculated

Examples

```
asd_new_design_theta(theta = 0.2, s = c(1/3, 2/3, 1), c_bry = c(3.984298, 3.961146, 2.349682),
inter_vt = 1, snew = c(0.5, 1), theta_hat_inter = 0.3, theta_hat_inter_sd = 0.5,
n_control_inter = 100, beta = 0.1)
```

`asd_new_design_theta_survival`

Group sequential designs / Adaptive sequential designs: Interim analysis, Survival analysis, Input theta

Description

Group sequential designs / Adaptive sequential designs: Interim analysis, Survival analysis, Input theta

Usage

```
asd_new_design_theta_survival(
  theta,
  s,
  c_bry,
  inter_vt,
  snew,
  theta_hat_inter,
  theta_hat_inter_sd,
  events_inter,
  beta
)
```

Arguments

`theta`	Assumed effect size used for the conditional power calculation, i.e. minus the log of the hazard ratio; different values of theta can be entered to check the sensitivity of the conditional power to the effect size; if theta < 0.001 the new number of events and the new critical boundary are returned as 'NA'
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`c_bry`	Vector of critical boundaries for each analysis
`inter_vt`	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
`snew`	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
`theta_hat_inter`	Treatment effect estimate observed at the interim analysis, i.e. minus the log of the observed hazard ratio
`theta_hat_inter_sd`	Standard error of 'theta_hat_inter'
`events_inter`	Number of events observed at the interim analysis
`beta`	Type II error rate, i.e. 1 - power

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis

Wald statistics Wald statistic of the treatment effect observed at the interim analysis

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Assumed effect size: theta The assumed effect size theta used for the conditional power calculation

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0

c_power_theta Conditional power at the interim analysis using the assumed effect size theta

events_new New total number of events required after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if theta < 0.001

New information fraction The new information fractions after the sample size change

New critical boundary New critical boundaries for the new interim analyses (O'Brien-Fleming type), or 'NA' if they were not calculated

Examples

```
asd_new_design_theta_survival(theta = 0.2, s = c(1/3, 2/3, 1),
c_bry = c(3.984298, 3.961146, 2.349682), inter_vt = 1, snew = c(0.5, 1), theta_hat_inter = 0.3,
theta_hat_inter_sd = 0.5, events_inter = 100, beta = 0.1)
```

`asd_power_simu_binary` *Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Operating characteristics*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Operating characteristics

Usage

```
asd_power_simu_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  N_max,
```

```
  theta_cut,
  beta,
  sim_num
)
```

Arguments

p_t	Event rate of the test arm; must be between 0 and 1
p_c	Event rate of the control arm; must be between 0 and 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm; the trial starts from this sample size and it is increased only if the conditional power at the interim analysis is below the target
N_max	Maximum sample size of the control arm allowed for the sample size change; the re-estimated sample size is truncated at N_max
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries, Sample size increase (the rate of sample size increase attributed to each look) and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_power_simu_binary(p_t = 0.4, p_c = 0.2, direction = 1, s = c(1/3,2/3,1), bry_type = 1,
alpha_2 = 0.05, samsz = 107, N_max = 500, theta_cut = 0.05, beta = 0.1, sim_num = 20)
```

`asd_power_simu_neg_binomial`

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Operating characteristics

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Operating characteristics

Usage

```
asd_power_simu_neg_binomial(
  r_t,
  r_c,
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  N_max,
  theta_cut,
  beta,
  sim_num
)
```

Arguments

r_t	Mean of the test arm; must be > 0
r_c	Mean of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm; the trial starts from this sample size and it is increased only if the conditional power at the interim analysis is below the target
N_max	Maximum sample size of the control arm allowed for the sample size change; the re-estimated sample size is truncated at N_max
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries, Sample size increase (the rate of sample size increase attributed to each look) and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_power_simu_neg_binomial(r_t = 0.3, r_c = 0.2, kappa = 1, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 112, N_max = 200, theta_cut = 0.01,
beta = 0.1, sim_num = 20)
```

---

asd_power_simu_normal *Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Operating characteristics*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Operating characteristics

Usage

```
asd_power_simu_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  N_max,
  theta_cut,
  beta,
  sim_num
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
sigma_t	Common standard deviation of the test arm and the control arm; must be > 0
sigma_c	Common standard deviation of the test arm and the control arm; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm; the trial starts from this sample size and it is increased only if the conditional power at the interim analysis is below the target
N_max	Maximum sample size of the control arm allowed for the sample size change; the re-estimated sample size is truncated at N_max
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries, Sample size increase (the rate of sample size increase attributed to each look) and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_power_simu_normal(mu_t = 0, mu_c = 0, sigma_t = 1, sigma_c = 1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, N_max = 500, theta_cut = 0.05,
beta = 0.1, sim_num = 20)
```

---

asd_power_simu_poisson

Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Operating characteristics

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Operating characteristics

Usage

```
asd_power_simu_poisson(
  lambda_t,
  lambda_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  N_max,
  theta_cut,
  beta,
  sim_num
)
```

Arguments

lambda_t	Mean event rate of the test arm; must be > 0
lambda_c	Mean event rate of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm; the trial starts from this sample size and it is increased only if the conditional power at the interim analysis is below the target

N_max	Maximum sample size of the control arm allowed for the sample size change; the re-estimated sample size is truncated at N_max
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries, Sample size increase (the rate of sample size increase attributed to each look) and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_power_simu_poisson(lambda_t = 1.1, lambda_c = 0.8, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 100, N_max = 200, theta_cut = 0.01,
beta = 0.1, sim_num = 20)
```

asd_power_simu_survival *Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Operating characteristics*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Operating characteristics

Usage

```
asd_power_simu_survival(
  HR,
  s,
  bry_type,
  alpha_2,
  evt_num,
  evt_max,
  HR_cut,
  surv_rate,
  beta,
  sim_num
)
```

Arguments

HR	Hazards ratio of the test arm vs. the control arm; HR < 1 favours the test arm
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
evt_num	Planned total number of events at the final analysis; the trial starts from this number of events and it is increased only if the conditional power at the interim analysis is below the target
evt_max	Maximum number of events allowed for the sample size change; the re-estimated number of events is truncated at evt_max
HR_cut	Lack of efficacy threshold on the hazards-ratio scale; the corresponding threshold on the log-hazards-ratio scale is theta_cut = -log(HR_cut). If the observed interim log-hazards-ratio is below theta_cut (i.e. the observed HR is greater than HR_cut), the trial continues to the planned number of events with no sample size increase and no early termination for futility
surv_rate	Survival rate at the end of the trial, used together with the number of events to derive the sample size; must be between 0 and 1

beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries, Sample size increase (the rate of sample size increase attributed to each look) and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size (the planned number of events), Maximum control sample size (the maximum number of events allowed), Mean control sample size (the mean simulated number of events) and mean control sample size conditional on increase

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_power_simu_survival(HR = 0.8, s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, evt_num = 845,
evt_max = 1500, HR_cut = 0.95, surv_rate = 0.5, beta = 0.1, sim_num = 20)
```

---

asd_simu_OC_binary *Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Optimizing adaptive sequential design*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Optimizing adaptive sequential design

Usage

```
asd_simu_OC_binary(
  p_t,
  p_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

p_t	Event rate of the test arm; must be between 0 and 1. The simulation grid varies p_t over the values supplied
p_c	Event rate of the control arm; must be between 0 and 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
alpha_2_alps_s1	Two-sided type I error spent at the interim analyses of schedule s1 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error spent at the interim analyses of schedule s2 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility

samsz_1	Planned sample size of the control arm for the first scenario of the simulation grid
samsz_2	Planned sample size of the control arm for the second scenario of the simulation grid
N_max_1	Maximum sample size of the control arm allowed for the sample size change in the first scenario of the simulation grid
N_max_2	Maximum sample size of the control arm allowed for the sample size change in the second scenario of the simulation grid
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with six components, one for each combination of critical boundary type (O'Brien-Fleming, Pocock, alpha-spending) and interim analysis schedule (s1, s2):

O'Brien-Fleming boundaries, interim analysis schedule=s1 Named list with the group sequential design (Looks, Information fractions, O'Brien-Fleming boundaries) and the simulation results for the four combinations of planned sample size (samsz_1, samsz_2) and maximum sample size (N_max_1, N_max_2), each a data frame with one row per test-arm event rate and the columns p_{t1},..., p_c, sample size for fixed design, Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

O'Brien-Fleming boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with the information fractions s2

Pocock boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s1

Pocock boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s2

Alpha-spending boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s1

Alpha-spending boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s2

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
set.seed(1)
asd_simu_OC_binary(p_t = c(0.3,0.35,0.4), p_c = 0.2, direction = 1, s1 = c(1/3,2/3,1),
s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01, samsz_1 = 100, samsz_2 = 150,
N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 20)
```

---

asd_simu_OC_neg_binomial

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

Usage

```
asd_simu_OC_neg_binomial(
  r_t,
  r_c,
  kappa,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

r_t	Mean of the test arm; must be > 0. The simulation grid varies r_t over the values supplied
r_c	Mean of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
alpha_2_alps_s1	Two-sided type I error spent at the interim analyses of schedule s1 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error spent at the interim analyses of schedule s2 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
samsz_1	Planned sample size of the control arm for the first scenario of the simulation grid
samsz_2	Planned sample size of the control arm for the second scenario of the simulation grid
N_max_1	Maximum sample size of the control arm allowed for the sample size change in the first scenario of the simulation grid
N_max_2	Maximum sample size of the control arm allowed for the sample size change in the second scenario of the simulation grid
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with six components, one for each combination of critical boundary type (O'Brien-Fleming, Pocock, alpha-spending) and interim analysis schedule (s1, s2):

O'Brien-Fleming boundaries, interim analysis schedule=s1 Named list with the group sequential design (Looks, Information fractions, O'Brien-Fleming boundaries) and the simulation results for the four combinations of planned sample size (samsz_1, samsz_2) and maximum sample size (N_max_1, N_max_2), each a data frame with one row per test-arm mean and

the columns r_{t1},..., r_c, sample size for fixed design, Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

O'Brien-Fleming boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with the information fractions s2

Pocock boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s1

Pocock boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s2

Alpha-spending boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s1

Alpha-spending boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s2

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
set.seed(1)
asd_simu_OC_neg_binomial(r_t = c(0.3,0.4,0.5), r_c = 0.2, kappa = 1, direction = 1,
s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01, samsz_1 = 100, samsz_2 = 150,
N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 20)
```

`asd_simu_OC_normal` *Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Optimizing adaptive sequential design*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Optimizing adaptive sequential design

Usage

```
asd_simu_OC_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`sigma_t`	Common standard deviation of the test arm and the control arm; must be > 0
`sigma_c`	Common standard deviation of the test arm and the control arm; must be > 0
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s1`	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
`s2`	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries

`alpha_2_alps_s1`
: Two-sided type I error spent at the interim analyses of schedule s1 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2

`alpha_2_alps_s2`
: Two-sided type I error spent at the interim analyses of schedule s2 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2

`theta_cut`
: Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility

`samsz_1`
: Planned sample size of the control arm for the first stage of the simulation grid

`samsz_2`
: Planned sample size of the control arm for the second stage of the simulation grid

`N_max_1`
: Maximum sample size of the control arm allowed for the sample size change in the first scenario of the simulation grid

`N_max_2`
: Maximum sample size of the control arm allowed for the sample size change in the second scenario of the simulation grid

`beta`
: Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1

`sim_num`
: Number of simulation replicates; must be > 0

Value

A named list with six components, one for each combination of critical boundary type (O'Brien-Fleming, Pocock, alpha-spending) and interim analysis schedule (s1, s2):

O'Brien-Fleming boundaries, interim analysis schedule=s1 Named list with the group sequential design (Looks, Information fractions, O'Brien-Fleming boundaries) and the simulation results for the four combinations of planned sample size (samsz_1, samsz_2) and maximum sample size (N_max_1, N_max_2), each a data frame with one row per test-arm mean and the columns mu_t1,..., mu_c, sample size for fixed design, Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size, mean control sample size conditional on increase and Ratio of adaptive sample size over fixed sample size

O'Brien-Fleming boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with the information fractions s2

Pocock boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s1

Pocock boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s2

Alpha-spending boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s1

Alpha-spending boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s2

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
set.seed(1)
asd_simu_OC_normal(mu_t = c(0.3,0.4,0.5), mu_c = 0.2, sigma_t = 1, sigma_c = 1, direction = 1,
s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01, samsz_1 = 100, samsz_2 = 150,
N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 20)
```

`asd_simu_OC_poisson` *Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Optimizing adaptive sequential design*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Optimizing adaptive sequential design

Usage

```
asd_simu_OC_poisson(
  lambda_t,
  lambda_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
```

```
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

lambda_t	Mean event rate of the test arm; must be > 0. The simulation grid varies lambda_t over the values supplied
lambda_c	Mean event rate of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
alpha_2_alps_s1	Two-sided type I error spent at the interim analyses of schedule s1 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error spent at the interim analyses of schedule s2 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
theta_cut	Lack of efficacy threshold on the effect-size scale: if the observed interim effect size is below theta_cut, the trial continues to the planned sample size with no sample size increase and no early termination for futility
samsz_1	Planned sample size of the control arm for the first scenario of the simulation grid
samsz_2	Planned sample size of the control arm for the second scenario of the simulation grid
N_max_1	Maximum sample size of the control arm allowed for the sample size change in the first scenario of the simulation grid
N_max_2	Maximum sample size of the control arm allowed for the sample size change in the second scenario of the simulation grid
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with six components, one for each combination of critical boundary type (O'Brien-Fleming, Pocock, alpha-spending) and interim analysis schedule (s1, s2):

O'Brien-Fleming boundaries, interim analysis schedule=s1 Named list with the group sequential design (Looks, Information fractions, O'Brien-Fleming boundaries) and the simulation results for the four combinations of planned sample size (samsz_1, samsz_2) and maximum sample size (N_max_1, N_max_2), each a data frame with one row per test-arm event rate and the columns lambda_t1,..., lambda_c, sample size for fixed design, Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned control sample size, Maximum control sample size, Mean control sample size and mean control sample size conditional on increase

O'Brien-Fleming boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with the information fractions s2

Pocock boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s1

Pocock boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s2

Alpha-spending boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s1

Alpha-spending boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s2

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
asd_simu_OC_poisson(lambda_t = c(0.3,0.4,0.5), lambda_c = 0.2, direction = 1, s1 = c(1/3,2/3,1),
s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01, samsz_1 = 50, samsz_2 = 80,
N_max_1 = 120, N_max_2 = 150, beta = 0.1, sim_num = 20)
```

`asd_simu_OC_survival` *Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Optimizing adaptive sequential design*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Optimizing adaptive sequential design

Usage

```
asd_simu_OC_survival(
  HR,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  surv_rate,
  evt_num_1,
  evt_num_2,
  evt_max_1,
  evt_max_2,
  HR_cut,
  beta,
  sim_num
)
```

Arguments

`HR`	Hazards ratio of the test arm vs. the control arm; HR < 1 favours the test arm. The simulation grid varies HR over the values supplied
`s1`	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
`s2`	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
`alpha_2_alps_s1`	Two-sided type I error spent at the interim analyses of schedule s1 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2
`alpha_2_alps_s2`	Two-sided type I error spent at the interim analyses of schedule s2 with the alpha-spending boundary; each element must be between 0 and 1 and the elements must sum to alpha_2

surv_rate	Survival rate at the end of the trial, used together with the number of events to derive the sample size; must be between 0 and 1
evt_num_1	Planned number of events for the first scenario of the simulation grid
evt_num_2	Planned number of events for the second scenario of the simulation grid
evt_max_1	Maximum number of events allowed for the sample size change in the first scenario of the simulation grid
evt_max_2	Maximum number of events allowed for the sample size change in the second scenario of the simulation grid
HR_cut	Lack of efficacy threshold on the hazards-ratio scale; the corresponding threshold on the log-hazards-ratio scale is theta_cut = -log(HR_cut). If the observed interim log-hazards-ratio is below theta_cut (i.e. the observed HR is greater than HR_cut), the trial continues to the planned number of events with no sample size increase and no early termination for futility
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; must be between 0 and 1
sim_num	Number of simulation replicates; must be > 0

Value

A named list with six components, one for each combination of critical boundary type (O'Brien-Fleming, Pocock, alpha-spending) and interim analysis schedule (s1, s2):

O'Brien-Fleming boundaries, interim analysis schedule=s1 Named list with the group sequential design (Looks, Information fractions, O'Brien-Fleming boundaries) and the simulation results for the four combinations of planned number of events (evt_num_1, evt_num_2) and maximum number of events (evt_max_1, evt_max_2), each a data frame with one row per hazards ratio and the columns HR₁,..., sample size for fixed design, Rejection rate without SSR, Rejection rate with SSR, Rate of sample size increase, Rejection rate without SSR/(meeting sample size incerase criteria), Rejection rate with SSR/(sample size incerase), Futility rate, Planned sample size (the planned number of events), Maximum sample size (the maximum number of events allowed), Mean sample size (the mean simulated number of events), mean sample size conditional on increase and Ratio of adaptive sample size over fixed sample size

O'Brien-Fleming boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with the information fractions s2

Pocock boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s1

Pocock boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with Pocock boundaries and the information fractions s2

Alpha-spending boundaries, interim analysis schedule=s1 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s1

Alpha-spending boundaries, interim analysis schedule=s2 The same group sequential design and simulation results computed with alpha-spending boundaries and the information fractions s2

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
set.seed(1)
asd_simu_OC_survival(HR = c(0.75,0.8,0.85), s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), surv_rate = 0.5,
evt_num_1 = 200, evt_num_2 = 300, evt_max_1 = 2000, evt_max_2 = 3000, HR_cut = 0.95, beta = 0.1,
sim_num = 20)
```

EXP_3_stg_sz *Single arm phase 2 oncology trial: Three-stage design*

Description

Single arm phase 2 oncology trial: Three-stage design

Usage

```
EXP_3_stg_sz(alpha, beta, p_0, p_low, p_1, d_23_cut)
```

Arguments

alpha	Type I error for the one-sided test
beta	Type II error rate, i.e. 1 - power
p_0	Response rate indicating low activity with insufficient clinical benefit
p_low	Minimally clinically beneficial response rate
p_1	Assumed response rate
d_23_cut	Sets the minimal difference between n_3 and n_2 for the design; min(n_3 - n_2)

Value

A named list with the following components:

Simon's design: p=p_1 A matrix with one row per design (minimax, optimal and average) for Simon's design using p_1 as the target response rate, with columns r1, n1, r_2, n_2, EN(p0) (expected sample size under p_0), PET(p0) (probability of early termination under p_0), t1_err, PET_p (PET under p_1), PET_p_low (PET under p_low), power_p (power under p_1) and power_p_low (power under p_low)

Simon's design: p=p_low The corresponding matrix for Simon's design using p_low as the target response rate

Expanded 3 stage design A matrix with one row per design (minimax, optimal and average) and columns r_1, r_2, r_3, n_1, n_2, n_3 (n_3 is also the total sample size), r_2_e (the trial is stopped for superiority if at least r_2_e responses are observed at the second look), t1_err, PET_p1, PET_plow, power (power under p_1), EN_p0 (expected sample size under p_0) and PW_p_low (power under p_low)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Examples

```
EXP_3_stg_sz( alpha = c(0.001,0.024), beta = 0.1, p_0 = 0.2, p_low = 0.4, p_1 = 0.55,
  d_23_cut = 0)
```

`fixed_rej_nbglm_simu` *Fixed sample designs: Negative binomial distribution, Simulations*

Description

Fixed sample designs: Negative binomial distribution, Simulations

Usage

```
fixed_rej_nbglm_simu(alpha_2, r_c, r_t, rand_ratio, kappa, samsz, sim_num)
```

Arguments

alpha_2	Type I error for the two-sided test
r_c	Event rate of the control arm; must be > 0
r_t	Event rate of the test arm; the null hypothesis is r_t >= r_c and the alternative hypothesis is r_t < r_c; must be > 0
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial distribution; the negative binomial size parameter used in the simulation is 1/kappa, so kappa must be > 0 and a larger kappa means more overdispersion
samsz	Sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate Simulated rejection rate of the two-sided Wald test from the negative binomial log-link GLM; this is the simulated power, and the type I error rate when r_t = r_c

mean size Mean over the simulation replicates of the estimated negative binomial size (dispersion) parameter theta of the fitted GLM

Examples

```
fixed_rej_nbglm_simu(alpha_2 = 0.05, r_c = 1, r_t = 1*0.6, rand_ratio = 1, kappa = 1,
samsz = 188, sim_num = 20)
```

---

fixed_rej_rate_binary *Fixed sample designs: Binary distribution, Simulations*

Description

Fixed sample designs: Binary distribution, Simulations

Usage

```
fixed_rej_rate_binary(p_t, p_c, rand_ratio, alpha_2, samsz, sim_num)
```

Arguments

p_t	Event rate (probability of an event) of the test arm; the null hypothesis is p_t <= p_c and the alternative hypothesis is p_t > p_c; 0 < p_t < 1
p_c	Event rate (probability of an event) of the control arm; 0 < p_c < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha_2	Type I error for the two-sided test
samsz	Sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named numeric value with the following component:

rejection rate Simulated rejection rate of the two-sided fixed-sample Wald test of p_t = p_c; this is the simulated power, and the type I error rate when p_t = p_c

Examples

```
fixed_rej_rate_binary(p_t = 0.4, p_c = 0.2, rand_ratio = 1, alpha_2 = 0.05,
samsz = 106, sim_num = 20)
```

---

fixed_rej_rate_normal *Fixed sample designs: Normal distribution, Simulations*

Description

Fixed sample designs: Normal distribution, Simulations

Usage

```
fixed_rej_rate_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  alpha_2,
  rand_ratio,
  samsz,
  sim_num
)
```

Arguments

mu_t	Mean of the test arm; the null hypothesis is mu_t <= mu_c and the alternative hypothesis is mu_t > mu_c
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arm
sigma_c	Standard deviation of the control arm
alpha_2	Type I error for the two-sided test
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
samsz	Sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named numeric value with the following component:

rejection rate Simulated rejection rate of the two-sided fixed-sample Wald test of mu_t = mu_c; this is the simulated power, and the type I error rate when mu_t = mu_c

Examples

```
fixed_rej_rate_normal(mu_t = 0, mu_c = 0, sigma_t = 1, sigma_c = 1, alpha_2 = 0.05,
rand_ratio = 1, samsz = 82, sim_num = 20)
```

---

fixed_rej_rate_poisson

Fixed sample designs: Poisson distribution, Simulations

Description

Fixed sample designs: Poisson distribution, Simulations

Usage

```
fixed_rej_rate_poisson(lambda_t, lambda_c, rand_ratio, alpha_2, samsz, sim_num)
```

Arguments

lambda_t	Event rate of the test arm; the null hypothesis is lambda_t <= lambda_c and the alternative hypothesis is lambda_t > lambda_c; must be > 0
lambda_c	Event rate of the control arm; must be > 0
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha_2	Type I error for the two-sided test
samsz	Sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named numeric value with the following component:

rejection rate Simulated rejection rate of the two-sided fixed-sample Wald test of lambda_t = lambda_c; this is the simulated power, and the type I error rate when lambda_t = lambda_c

Examples

```
fixed_rej_rate_poisson(lambda_t = 11, lambda_c = 10, rand_ratio = 2, alpha_2 = 0.05,
samsz = 163, sim_num = 20)
```

`fixed_rej_rate_surv_cox`

Fixed sample designs: Survival analysis, Simulations

Description

Fixed sample designs: Survival analysis, Simulations

Usage

```
fixed_rej_rate_surv_cox(HR, evt_num, alpha_2, sim_num)
```

Arguments

`HR`	Hazard ratio of the test arm vs. the control arm; the null hypothesis is HR >= 1 and the alternative hypothesis is HR < 1; must be > 0
`evt_num`	Total number of events at the final analysis; the simulated data are truncated at the first observation at which this number of events is reached
`alpha_2`	Type I error for the two-sided test
`sim_num`	Number of simulation replicates

Value

A named numeric value with the following component:

rejection CPH Simulated rejection rate of the two-sided Wald test from the Cox proportional hazards model; this is the simulated power, and the type I error rate when HR = 1

Examples

```
fixed_rej_rate_surv_cox(HR = 0.8, evt_num = 845, alpha_2 = 0.05, sim_num = 20)
```

gsd_ci_est *Group sequential designs / Adaptive sequential designs: Final analysis, Without sample size change*

Description

Group sequential designs / Adaptive sequential designs: Final analysis, Without sample size change

Usage

```
gsd_ci_est(s, c_bry, theta_hat_last, theta_hat_last_sd, last_vt, alpha_2)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
theta_hat_last	Treatment effect estimate observed at the final analysis, i.e. the naive point estimate of the parameter of interest at the analysis at which the trial terminated
theta_hat_last_sd	Standard error of 'theta_hat_last'
last_vt	Index of the analysis at which the trial stopped (1-based); this can be the final analysis, at which s = 1, or an interim analysis, and it must not exceed length(s)
alpha_2	Type I error for the two-sided test

Value

A named list with the following components:

p-value The p-value of the test of the null hypothesis that the treatment effect is 0

confidence interval Numeric vector of length 3 giving the lower confidence limit, the median-unbiased point estimate and the upper confidence limit of the two-sided (1 - alpha_2) confidence interval

Examples

```
gsd_ci_est(s = c(1/3,2/3,1), c_bry = c(3.471095, 2.454434,2.004037), theta_hat_last = 2.004,
theta_hat_last_sd = 1, last_vt = 3, alpha_2 = 0.05)
```

`gsd_ci_est_2_stage` *Single arm phase 2 oncology trial: Final analysis: two stage design, no sample size change*

Description

Single arm phase 2 oncology trial: Final analysis: two stage design, no sample size change

Usage

```
gsd_ci_est_2_stage(p_0, n_1, n_2, r_1_e, r_2, x_last, last_vt, alpha)
```

Arguments

`p_0`	Response rate indicating low activity with insufficient clinical benefit
`n_1`	Number of patients at first look
`n_2`	Number of patients at second look
`r_1_e`	Superiority-stopping threshold at the first look: the trial would be stopped for superiority if at least r_1_e responses are observed at the first look. Enter NA when the design uses no efficacy boundary at the first look; the function then substitutes a boundary that cannot be crossed
`r_2`	If no more than r_2 responses are observed at the second look, then the null hypothesis will not be rejected
`x_last`	Number of responses at the final visit
`last_vt`	Index of the analysis at which the trial stopped: 1 = first look, 2 = second (final) look
`alpha`	Type I error for the one-sided test

Details

The results with continuity correction are not necessarily different from those without continuity correction. The need for continuity correction can be determined through simulations on the type I error (see Gao and Zhang, 2004).

Value

A named list with the following components:

p_no_correction P-value of the test of the null hypothesis that the response rate equals p_0, calculated at the analysis at which the trial stopped without continuity correction

p_correction The same p-value calculated with the 0.5 continuity correction

CI_without_correction Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate, computed without continuity correction

CI_with_correction The same confidence interval computed with the 0.5 continuity correction

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_ci_est_2_stage(p_0=0.2,n_1=100,n_2=105,r_1_e=NA,r_2=29,x_last=31,last_vt=1,alpha=0.025)
```

`gsd_ci_est_3_stage` *Single arm phase 2 oncology trial: Final analysis: three stage design, no sample size change*

Description

Single arm phase 2 oncology trial: Final analysis: three stage design, no sample size change

Usage

```
gsd_ci_est_3_stage(p_0, n_2, n_3, r_2_e, r_3, x_last, last_vt, alpha)
```

Arguments

`p_0`	Response rate indicating low activity with insufficient clinical benefit
`n_2`	Number of patients at second look; because the trial has proceeded to the third look, n_1, r_1 and r_2 of the original design are not needed for the final analysis
`n_3`	Number of patients at third look
`r_2_e`	Superiority-stopping threshold at the second look: the trial would be stopped for superiority if at least r_2_e responses are observed at the second look. If r_2_e was not used in the design, enter NA; the function then substitutes a boundary that cannot be crossed
`r_3`	If no more than r_3 responses are observed at the third look, then the null hypothesis will not be rejected
`x_last`	Number of responses at the final visit
`last_vt`	Index of the analysis at which the trial stopped: 2 = second look, 3 = third (final) look
`alpha`	Type I error for the one-sided test

Details

The results with continuity correction are not necessarily different from those without continuity correction. The need for continuity correction can be determined through simulations on the type I error (see Gao and Zhang, 2004).

Value

A named list with the following components:

p_no_correction P-value of the test of the null hypothesis that the response rate equals p_0, calculated at the analysis at which the trial stopped without continuity correction

p_correction The same p-value calculated with the 0.5 continuity correction

CI_withot_correction Numeric vector of length 3 holding the lower limit, the point estimate and the upper limit of the two-sided (1 - 2*alpha) confidence interval for the response rate, computed without continuity correction

CI_with_correction The same confidence interval computed with the 0.5 continuity correction

References

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_ci_est_3_stage(p_0=0.2,n_2=100,n_3=105,r_2_e=31,r_3=29,x_last=31,last_vt=3,alpha=0.025)
```

`gsd_power_simu_binary` *Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Type I error and power*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Binary distribution, Type I error and power

Usage

```
gsd_power_simu_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

p_t	Event rate of the test arm; must be between 0 and 1
p_c	Event rate of the control arm; must be between 0 and 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Planned control sample size (the sample size used in the simulation), Rejection rate (the simulated power, i.e. the type I error rate when p_t = p_c) and Mean control sample size (the mean simulated sample size)

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_power_simu_binary(p_t = 0.4, p_c = 0.4, direction = 1, s = c(1/3,2/3,1), bry_type = 1,
alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

gsd_power_simu_negbinom

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Type I error and power

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Negative binomial distribution, Type I error and power

Usage

```
gsd_power_simu_negbinom(
  r_t,
  r_c,
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

r_t	Mean of the test arm; must be > 0
r_c	Mean of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries

samsz	Planned sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Planned control sample size (the sample size used in the simulation), Rejection rate (the simulated power, i.e. the type I error rate when r_t = r_c) and Mean control sample size (the mean simulated sample size)

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_power_simu_negbinom(r_t = 1.1, r_c = 1.1, kappa = 1, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

gsd_power_simu_normal *Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Type I error and power*

Description

Group sequential designs / Adaptive sequential designs: Simulations, Normal distribution, Type I error and power

Usage

```
gsd_power_simu_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
sigma_t	Common standard deviation of the test arm and the control arm; must be > 0
sigma_c	Common standard deviation of the test arm and the control arm; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate (the simulated power, i.e. the type I error rate when mu_t = mu_c), Planned control sample size (the sample size used in the simulation) and Mean control sample size (the mean simulated sample size)

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_power_simu_normal(mu_t = 0.4, mu_c = 0, sigma_t = 1, sigma_c = 1, direction = 1,
s = c(1/4,1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

gsd_power_simu_poisson

Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Type I error and power

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Poisson distribution, Type I error and power

Usage

```
gsd_power_simu_poisson(
  lambda_c,
  lambda_t,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

lambda_c	Mean event rate of the control arm; must be > 0
lambda_t	Mean event rate of the test arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1

bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
samsz	Planned sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Planned control sample size (the sample size used in the simulation), Rejection rate (the simulated power, i.e. the type I error rate when lambda_t = lambda_c) and Mean control sample size (the mean simulated sample size)

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_power_simu_poisson(lambda_c = 0.5, lambda_t = 0.8, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

gsd_power_simu_survival

Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Type I error and power

---

Description

Group sequential designs / Adaptive sequential designs: Simulations, Survival analysis, Type I error and power

Usage

```
gsd_power_simu_survival(HR, s, bry_type, alpha_2, surv_rate, evt_num, sim_num)
```

Arguments

HR	Hazards ratio of the test arm vs. the control arm; HR < 1 favours the test arm
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock, 3 = alpha-spending
alpha_2	Type I error for the two-sided test; must be between 0 and 1, and alpha_2/2 is the one-sided type I error used for the critical boundaries
surv_rate	Survival rate at the end of the trial, used together with the number of events to derive the sample size; must be between 0 and 1
evt_num	Planned total number of events at the final analysis; must be > 0
sim_num	Number of simulation replicates; must be > 0

Value

A named list with the following components:

Sequential design and rejection by look Data frame with one row per analysis and the columns Looks, Information fraction, Critical boundaries and Rejection by look (the rejection rate at each interim analysis)

Power and sample size Named vector with the components Rejection rate (the simulated power, i.e. the type I error rate when HR = 1), Planned sample size (the planned number of events) and Mean sample size (the mean simulated number of events)

References

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Gao, P., L. Liu, and C. Mehta. 2013 Oct 15. Exact inference for adaptive group sequential designs. Statistics in Medicine 32(23):3991–4005. doi:10.1002/sim.5847.

Examples

```
gsd_power_simu_survival(HR = 0.8, s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05,
surv_rate = 0.5, evt_num = 845, sim_num = 20)
```

`hybrid_fixed_prior_rej_binary_simu` *Hybrid: Simulations, Binary distribution, Using given estimates of informative prior*

Description

Hybrid: Simulations, Binary distribution, Using given estimates of informative prior

Usage

```
hybrid_fixed_prior_rej_binary_simu(
  t_prior,
  theta_prior,
  p_t,
  p_c,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

`t_prior`	Prior information time: the prior distribution of theta = p_t - p_c is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
`theta_prior`	Mean effect size of prior: the mean of the normal prior distribution of theta = p_t - p_c; set theta_prior = 0 for a non-informative prior
`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1. The effect size is theta = p_t - p_c. Enter p_t = p_c to verify type I error control and p_t > p_c for the power simulation
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1. The effect size is theta = p_t - p_c
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`sampsz`	Planned sample size: the planned sample size at the final analysis
`N_max`	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification

theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_fixed_prior_rej_binary_simu(t_prior = 5, theta_prior = 0.2, p_t = 0.3, p_c = 0.3,
s = c(0.5,1), sampsz = 100, N_max = 150, theta_cut = 0.001, cp_min = 0.27, gamma = 0.5,
alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

`hybrid_fixed_prior_rej_negbinom_simu` *Hybrid: Simulations, Negative binomial distribution, Using given estimates of informative prior*

Description

Hybrid: Simulations, Negative binomial distribution, Using given estimates of informative prior

Usage

```
hybrid_fixed_prior_rej_negbinom_simu(
  t_prior,
  theta_prior,
  r_t,
  r_c,
  kappa,
  nu_t,
  rand_ratio,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

t_prior	Prior information time: the prior distribution of theta = -log(r_t/r_c) is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
theta_prior	Mean effect size of prior: the mean of the normal prior distribution of theta = -log(r_t/r_c); set theta_prior = 0 for a non-informative prior
r_t	Event rate in the test arm; the effect size is theta = -log(r_t/r_c) and a smaller event rate is assumed to be associated with better efficacy. Enter r_t = r_c to verify type I error control and r_t < r_c for the power simulation
r_c	Event rate in the control arm; the effect size is theta = -log(r_t/r_c)
kappa	Dispersion parameter of the negative binomial distribution; must be > 0
nu_t	Exposure time for the negative binomial distribution; must be > 0

rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_fixed_prior_rej_negbinom_simu(t_prior = 5, theta_prior = 0.2, r_t = 1, r_c = 1,
kappa = 1, nu_t = 1, rand_ratio = 1, s = c(0.5,1), sampsz = 100, N_max = 150,
theta_cut = 0.001, cp_min = 0.27, gamma = 0.5, alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_fixed_prior_rej_normal_simu

Hybrid: Simulations, Normal distribution, Using given estimates of informative prior

---

Description

Hybrid: Simulations, Normal distribution, Using given estimates of informative prior

Usage

```
hybrid_fixed_prior_rej_normal_simu(
  t_prior,
  theta_prior,
  mu,
  sigma,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

t_prior	Prior information time: the prior distribution of theta = mu_t - mu_c is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
theta_prior	Mean effect size of prior: the mean of the normal prior distribution of theta = mu_t - mu_c; set theta_prior = 0 for a non-informative prior

mu	Effect size (difference in means) of the current trial: theta = mu_t - mu_c, where mu_t is the mean of the treatment arm and mu_c is the mean of the control arm. In the simulations the test arm is generated from a normal distribution with mean mu and the control arm from a normal distribution with mean 0, both with standard deviation sigma. Enter mu = 0 to verify type I error control and mu > 0 for the power simulation
sigma	Common standard deviation shared by the test and control arms; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_fixed_prior_rej_normal_simu(t_prior = 5, theta_prior = 0.2, mu = 0, sigma = 1,
s = c(0.5,1), sampsz = 100, N_max = 150, theta_cut = 0.001, cp_min = 0.27, gamma = 0.5,
alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_fixed_prior_rej_poisson_simu

Hybrid: Simulations, Poisson distribution, Using given estimates of informative prior

---

Description

Hybrid: Simulations, Poisson distribution, Using given estimates of informative prior

Usage

```
hybrid_fixed_prior_rej_poisson_simu(
  t_prior,
  theta_prior,
  lambda_t,
  lambda_c,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

t_prior	Prior information time: the prior distribution of theta = lambda_t - lambda_c is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
theta_prior	Mean effect size of prior: the mean of the normal prior distribution of theta = lambda_t - lambda_c; set theta_prior = 0 for a non-informative prior
lambda_t	Event rate in the test arm of the current trial: the number of events per subject, generated as rpois(lambda_t). The effect size is theta = lambda_t - lambda_c. Enter lambda_t = lambda_c to verify type I error control and lambda_t > lambda_c for the power simulation
lambda_c	Event rate in the control arm of the current trial, generated as rpois(lambda_c); the effect size is theta = lambda_t - lambda_c
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_fixed_prior_rej_poisson_simu(t_prior = 5, theta_prior = 0.2, lambda_t = 0.5,
lambda_c = 0.5, s = c(0.5,1), sampsz = 100, N_max = 150, theta_cut = 0.001, cp_min = 0.27,
gamma = 0.5, alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_fixed_prior_rej_survival_simu

Hybrid: Simulations, Survival analysis, Using given estimates of informative prior

---

Description

Hybrid: Simulations, Survival analysis, Using given estimates of informative prior

Usage

```
hybrid_fixed_prior_rej_survival_simu(
  t_prior,
  theta_prior,
  HR,
  lambda,
  s,
  alpha_2,
  surv_rate,
  evt_num,
  evt_max,
  HR_cut,
  cp_min,
  gamma,
  samp_multip,
  sim_num,
  beta
)
```

Arguments

t_prior	Prior information time: the prior distribution of theta = -log(HR) is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
theta_prior	Mean effect size of prior: the mean of the normal prior distribution of theta = -log(HR); set theta_prior = 0 for a non-informative prior
HR	Hazards ratio of test arm vs. the control arm. The effect size is theta = -log(HR) and a smaller HR indicates better efficacy. Enter HR = 1 to verify type I error control and HR < 1 for the power simulation
lambda	Baseline hazard rate of the control arm for the exponential survival times: the control arm is generated as rexp(lambda) and the test arm as rexp(HR * lambda), so lambda is a rate (not a log-hazard) and must be > 0. It also sets the censoring time T = -log(surv_rate)/lambda
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test
surv_rate	Survival rate used to translate the number of events into a sample size; it is the survival probability at the (administrative) censoring time T = -log(surv_rate)/lambda, 0 < surv_rate < 1
evt_num	Planned number of events: the planned number of events at the final analysis
evt_max	Maximum number of events: a user chosen, maximum allowable number of events for sample size modification
HR_cut	Futility hazards ratio threshold: a cut-off for HR_hat. In the simulations, if the estimated hazards ratio at the interim analysis is at or above HR_cut the trial is considered futile and proceeds to the planned number of events without any change; it is converted internally to theta_cut = -log(HR_cut)
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
samp_multip	Multiplication factor applied when translating the maximum number of events into the sample size used in the simulations, sampsz = ceiling(samp_multip * evt_max / surv_rate); it must be large enough for the required number of events to be observed
sim_num	Number of simulation replicates
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods. For this survival design the mean sample size is the mean number of events

futility rate The rate at which the estimated hazards ratio at the interim analysis is at or above HR_cut, so that the trial proceeds without any change to the number of events

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_fixed_prior_rej_survival_simu(t_prior = 10, theta_prior = 0.8, HR = 1, lambda = 1,
s = c(0.5,1), alpha_2 = 0.05, surv_rate = 0.5, evt_num = 88, evt_max = 331, HR_cut = 0.95,
cp_min = 0.27, gamma = 0.5, samp_multip = 5, beta = 0.1, sim_num = 20)
```

---

hybrid_random_prior_rej_binary_simu

Hybrid: Simulations, Binary distribution, Using random informative prior from previous trial

---

Description

Hybrid: Simulations, Binary distribution, Using random informative prior from previous trial

Usage

```
hybrid_random_prior_rej_binary_simu(
  p_t_0,
  p_c_0,
  sampsz_0,
```

```
  p_t,
  p_c,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

p_t_0	Response rate (probability of response) in the test arm of the previous trial, p_t0; the previous-trial effect size is theta_0 = p_t_0 - p_c_0
p_c_0	Response rate (probability of response) in the control arm of the previous trial
sampsz_0	Sample size per arm from the previous trial, N_0; random samples of this size are drawn from the previous trial to form the random prior
p_t	Response rate (probability of response) in the test arm of the current trial; 0 < p_t < 1. The effect size is theta = p_t - p_c. Enter p_t = p_c to verify type I error control and p_t > p_c for the power simulation
p_c	Response rate (probability of response) in the control arm of the current trial; 0 < p_c < 1. The effect size is theta = p_t - p_c
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_random_prior_rej_binary_simu(p_t_0 = 0.4, p_c_0 = 0.3, sampsz_0 = 60, p_t = 0.3,
p_c = 0.3, s = c(0.5,1), sampsz = 100, N_max = 150, theta_cut = 0.001, cp_min = 0.27,
gamma = 0.5, alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_random_prior_rej_negbinom_simu

Hybrid: Simulations, Negative binomial distribution, Using random informative prior from previous trial

---

Description

Hybrid: Simulations, Negative binomial distribution, Using random informative prior from previous trial

Usage

```
hybrid_random_prior_rej_negbinom_simu(
  r_t_0,
  r_c_0,
  sampsz_0,
  r_t,
  r_c,
  kappa,
  nu_t,
  rand_ratio,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

r_t_0	Event rate in the test arm of the previous trial, r_t0; the previous-trial effect size is theta_0 = -log(r_t_0/r_c_0)
r_c_0	Event rate in the control arm of the previous trial, r_c0
sampsz_0	Sample size per arm from the previous trial, N_0; random samples of this size are drawn from the previous trial to form the random prior
r_t	Event rate in the test arm of the current trial; the effect size is theta = -log(r_t/r_c) and a smaller event rate is assumed to be associated with better efficacy. Enter r_t = r_c to verify type I error control and r_t < r_c for the power simulation
r_c	Event rate in the control arm of the current trial; the effect size is theta = -log(r_t/r_c)
kappa	Dispersion parameter of the negative binomial distribution; must be > 0
nu_t	Exposure time for the negative binomial distribution; must be > 0
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change

cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_random_prior_rej_negbinom_simu(r_t_0 = 1.2, r_c_0 = 1, sampsz_0 = 50, r_t = 1, r_c = 1,
kappa = 1, nu_t = 1, rand_ratio = 1, s = c(0.5,1), sampsz = 100, N_max = 150,
theta_cut = 0.001, cp_min = 0.27, gamma = 0.5, alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

hybrid_random_prior_rej_normal_simu *Hybrid: Simulations, Normal distribution, Using random informative prior from previous trial*

Description

Hybrid: Simulations, Normal distribution, Using random informative prior from previous trial

Usage

```
hybrid_random_prior_rej_normal_simu(
  mu_0,
  sigma_0,
  sampsz_0,
  mu,
  sigma,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

mu_0	Effect size (difference in means) of the previous trial: theta_0 = mu_t0 - mu_c0; in the simulations the previous-trial test arm is generated from a normal distribution with mean mu_0 and the previous-trial control arm from a normal distribution with mean 0, both with standard deviation sigma_0
sigma_0	Common standard deviation of the test and control arms in the previous trial; must be > 0
sampsz_0	Sample size per arm from the previous trial, N_0; random samples of this size are drawn from the previous trial to form the random prior
mu	Effect size (difference in means) of the current trial: theta = mu_t - mu_c, where mu_t is the mean of the treatment arm and mu_c is the mean of the control arm. In the simulations the test arm is generated from a normal distribution with mean mu and the control arm from a normal distribution with mean 0, both with standard deviation sigma. Enter mu = 0 to verify type I error control and mu > 0 for the power simulation
sigma	Common standard deviation shared by the test and control arms; must be > 0

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_random_prior_rej_normal_simu(mu_0 = 0.3, sigma_0 = 1, sampsz_0 = 60, mu = 0, sigma = 1,
s = c(0.5,1), sampsz = 100, N_max = 250, theta_cut = 0.01, cp_min = 0.27, gamma = 0.5,
alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_random_prior_rej_poisson_simu

Hybrid: Simulations, Poisson distribution, Using random informative prior from previous trial

---

Description

Hybrid: Simulations, Poisson distribution, Using random informative prior from previous trial

Usage

```
hybrid_random_prior_rej_poisson_simu(
  lambda_t_0,
  lambda_c_0,
  sampsz_0,
  lambda_t,
  lambda_c,
  s,
  sampsz,
  N_max,
  theta_cut,
  cp_min,
  gamma,
  alpha_2,
  beta,
  sim_num
)
```

Arguments

lambda_t_0	Event rate in the test arm of the previous trial, generated as rpois(lambda_t_0); the previous-trial effect size is theta_0 = lambda_t_0 - lambda_c_0
lambda_c_0	Event rate in the control arm of the previous trial, generated as rpois(lambda_c_0)
sampsz_0	Sample size per arm from the previous trial, N_0; random samples of this size are drawn from the previous trial to form the random prior
lambda_t	Event rate in the test arm of the current trial: the number of events per subject, generated as rpois(lambda_t). The effect size is theta = lambda_t - lambda_c. Enter lambda_t = lambda_c to verify type I error control and lambda_t > lambda_c for the power simulation

lambda_c	Event rate in the control arm of the current trial, generated as rpois(lambda_c); the effect size is theta = lambda_t - lambda_c
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz	Planned sample size: the planned sample size at the final analysis
N_max	Maximum sample size: a user chosen, maximum allowable sample size for sample size modification
theta_cut	Futility threshold: a cut-off for theta_hat. In the simulations, if theta_hat at the interim analysis is at or below theta_cut the trial is considered futile and proceeds to the planned sample size without any change
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
alpha_2	Type I error for the two-sided test
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation
sim_num	Number of simulation replicates

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods

futility rate The rate at which the observed theta_hat at the interim analysis is at or below theta_cut, so that the trial proceeds without any sample size change

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_random_prior_rej_poisson_simu(lambda_t_0 = 0.5, lambda_c_0 = 0.3, sampsz_0 = 60,
lambda_t = 0.5, lambda_c = 0.5, s = c(0.5,1), sampsz = 100, N_max = 150, theta_cut = 0.001,
cp_min = 0.27, gamma = 0.5, alpha_2 = 0.05, beta = 0.1, sim_num = 20)
```

---

hybrid_random_prior_rej_survival_simu

Hybrid: Simulations, Survival analysis, Using random informative prior from previous trial

---

Description

Hybrid: Simulations, Survival analysis, Using random informative prior from previous trial

Usage

```
hybrid_random_prior_rej_survival_simu(
  HR_0,
  evt_num_0,
  HR,
  lambda,
  s,
  alpha_2,
  surv_rate,
  evt_num,
  evt_max,
  HR_cut,
  cp_min,
  gamma,
  samp_multip,
  sim_num,
  beta
)
```

Arguments

HR_0	Hazards ratio of test vs. control in the previous trial, HR_0; the previous-trial effect size is theta_0 = -log(HR_0)
evt_num_0	Number of events from the previous trial, N_0; random samples are drawn from the previous trial up to this number of events to form the random prior

HR	Hazards ratio of test arm vs. the control arm for the current trial. The effect size is theta = -log(HR) and a smaller HR indicates better efficacy. Enter HR = 1 to verify type I error control and HR < 1 for the power simulation
lambda	Baseline hazard rate of the control arm for the exponential survival times: the control arm is generated as rexp(lambda) and the test arm as rexp(HR * lambda), so lambda is a rate (not a log-hazard) and must be > 0. It also sets the censoring time T = -log(surv_rate)/lambda for both the previous and the current trial
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test
surv_rate	Survival rate used to translate the number of events into a sample size; it is the survival probability at the (administrative) censoring time T = -log(surv_rate)/lambda, 0 < surv_rate < 1
evt_num	Planned number of events: the planned number of events at the final analysis of the current trial
evt_max	Maximum number of events: a user chosen, maximum allowable number of events for sample size modification
HR_cut	Futility hazards ratio threshold: a cut-off for HR_hat. In the simulations, if the estimated hazards ratio at the interim analysis is at or above HR_cut the trial is considered futile and proceeds to the planned number of events without any change; it is converted internally to theta_cut = -log(HR_cut)
cp_min	Promising zone cp_min: CP_min in the promising zone sample size re-estimation; a conditional power below cp_min is the unfavorable zone. The user should select this value from Mehta, Pocock (2011)
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
samp_multip	Multiplication factor applied when translating the number of events of the previous and the current trial into sample sizes, for example sampsz = ceiling(samp_multip * evt_max / surv_rate); it must be large enough for the required number of events to be observed
sim_num	Number of simulation replicates
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation

Value

A named list with the following components:

rejection rate and mean sample size A data frame with the columns "Prior type", "SSR method", "Rejection rate" and "Mean sample size", with one row per sample size re-estimation (SSR) method. The methods compared are the planned sample size with no SSR, the promising zone SSR, the SSR using the true effect size with conditional power, and, for both the non-informative prior and the informative prior, the cp SSR, pp SSR, mpp SSR and ci_mpp SSR methods. For this survival design the mean sample size is the mean number of events

futility rate The rate at which the estimated hazards ratio at the interim analysis is at or above HR_cut, so that the trial proceeds without any change to the number of events

References A data frame of the references for the methods compared

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
hybrid_random_prior_rej_survival_simu(HR_0 = 0.63, evt_num_0 = 40, HR = 1, lambda = 1,
s = c(0.5,1), alpha_2 = 0.05, surv_rate = 0.5, evt_num = 88, evt_max = 331, HR_cut = 0.95,
cp_min = 0.27, gamma = 0.5, samp_multip = 5, beta = 0.1, sim_num = 20)
```

---

hybrid_sz *Single arm phase 2 oncology trial: Two-stage design, the hybrid design*

Description

Single arm phase 2 oncology trial: Two-stage design, the hybrid design

Usage

```
hybrid_sz(alpha, beta, p_0, p_low, p_1, d_12_cut)
```

Arguments

alpha	Type I error for the one-sided test
beta	Type II error rate, i.e. 1 - power
p_0	Response rate indicating low activity with insufficient clinical benefit
p_low	Minimally clinically beneficial response rate
p_1	Assumed response rate
d_12_cut	Sets the minimal difference between n_2 and n_1 for the design; min(n_2 - n_1)

Value

A named list with the following components:

Simon's design: p=p_1 A matrix with one row per design (minimax, optimal and average) for Simon's design using p_1 as the target response rate, with columns r1, n1, r_2, n_2, EN(p0) (expected sample size under p_0), PET(p0) (probability of early termination under p_0), t1_err, PET_p (PET under p_1), PET_p_low (PET under p_low), power_p (power under p_1) and power_p_low (power under p_low)

Simon's design: p=p_low The corresponding matrix for Simon's design using p_low as the target response rate

Hybrid design A matrix with one row per design (minimax, optimal and average) and columns n_1, r_1, r_1_e (the trial is stopped for superiority if at least r_1_e responses are observed at the first look), r_2, n_2, t1_err, power (power under p_1), PET_p1, PET_p_low, PET_p0, En_p0 (expected sample size under p_0) and PW_p_low (power under p_low)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Examples

```
hybrid_sz(alpha=c(0.001,0.024),beta=0.1,p_0=0.2,p_low=0.4,p_1=0.55,d_12_cut=0)
```

---

interim_analysis *Single arm phase 2 oncology trial: The interim analysis can be conducted for both two-stage and three-stage designs*

Description

Single arm phase 2 oncology trial: The interim analysis can be conducted for both two-stage and three-stage designs

Usage

```
interim_analysis(p_0, r_final, n_inter, n_final, x_inter, beta, N_max)
```

Arguments

p_0	Response rate indicating low activity with insufficient clinical benefit
r_final	Rejection threshold of the original design in terms of the number of responses: r_final = r_2 for a two-stage design and r_final = r_3 for a three-stage design
n_inter	Number of patients at the interim look: n_inter = n_1 for a two-stage design and n_inter = n_2 for a three-stage design
n_final	Number of patients at the final look: n_final = n_2 for a two-stage design and n_final = n_3 for a three-stage design; must be greater than n_inter
x_inter	Number of responses observed at the interim look
beta	Conditional type II error rate: 1 - beta is the desired conditional power, which drives the re-estimated sample size
N_max	Pre-selected maximum sample size for the trial; the new sample size is truncated at N_max

Value

A named list with the following components:

new sample size Re-estimated total sample size N_new, obtained by converting the required information time into a number of patients and truncating at N_max

new discrete rejection boundary without continuity correction Threshold r_new such that the null hypothesis is rejected at the new sample size if at least r_new responses are observed; no continuity correction

new discrete rejection boundary with continuity correction The same rejection threshold computed with the 0.5 continuity correction applied to the response count

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
interim_analysis(p_0=0.2,r_final=17,n_inter=22,n_final=56,x_inter=7,beta=0.1,N_max=120)
```

masd_est_back_no_drop *Multiple comparisons Group sequential design: Final analysis, With one sample size change, orgin_comp==comp2*

Description

Multiple comparisons Group sequential design: Final analysis, With one sample size change, orgin_comp==comp2

Usage

```
masd_est_back_no_drop(
  s,
  c_bry,
  snew,
  c_bry_new,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  inter_vt,
  theta_hat_last_ad_m1,
  theta_hat_last_ad_m1_sd,
  last_vt_ad,
  alpha_2,
  dist
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
c_bry_new	Vector of new critical boundaries after the sample size is changed, one per element of 'snew'
theta_hat_inter_m1	Numeric vector of treatment effect estimates observed at the interim analysis at which the sample size was changed, one per original comparison (dose), e.g. the difference of the observed means or event rates between a test arm and the common control arm
theta_hat_inter_m1_sd	Standard error of 'theta_hat_inter_m1'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0
inter_vt	Index of the interim analysis at which the sample size was changed (1-based); must be less than length(s)

`theta_hat_last_ad_m1`
: Numeric vector of treatment effect estimates observed at the analysis after the sample size change at which the trial was terminated, one per original comparison (dose), so that no doses were dropped; the comparison with the largest estimate is the one for which the point estimate and confidence interval are returned

`theta_hat_last_ad_m1_sd`
: Standard error of 'theta_hat_last_ad_m1'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0

`last_vt_ad`
: Index of the interim or final analysis after the sample size change at which the trial was terminated (1-based); it indexes 'snew'

`alpha_2`
: Type I error for the two-sided test

`dist`
: Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

p-value The p-value of the test of the null hypothesis that the treatment effect of the comparison (dose) with the best efficacy is 0

confidence interval Numeric vector of length 3 giving the lower confidence limit, the conservatively median unbiased point estimate and the upper confidence limit for the comparison (dose) with the best efficacy; this is the two-sided (1 - alpha_2) * 100 percent confidence interval, and its lower limit is consistent with the p-value, in the sense that the p-value < alpha_2/2 if and only if the lower limit is greater than 0

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_est_back_no_drop(s = c(0.3,0.7,1), c_bry = c(4.347011, 2.845787, 2.380956), snew = c(0.5,1),
c_bry_new = c(3.310743,2.781890), theta_hat_inter_m1 = c(1.2,1.3,1.5), theta_hat_inter_m1_sd = 1,
inter_vt = 1, theta_hat_last_ad_m1 = c(2.2,1.4,1.8), theta_hat_last_ad_m1_sd = 1,
last_vt_ad = 2, alpha_2 = 0.05, dist = 1)
```

`masd_est_back_with_drop` *Multiple comparisons Group sequential design: Final analysis, With one sample size change, orgin_comp>comp2*

Description

Multiple comparisons Group sequential design: Final analysis, With one sample size change, orgin_comp>comp2

Usage

```
masd_est_back_with_drop(
  s,
  c_bry,
  snew,
  c_bry_new,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  theta_hat_inter_m2,
  theta_hat_inter_m2_sd,
  inter_vt,
  theta_hat_last_ad_m2,
  theta_hat_last_ad_m2_sd,
  last_vt_ad,
  alpha_2,
  dist
)
```

Arguments

`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`c_bry`	Vector of critical boundaries for each analysis
`snew`	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
`c_bry_new`	Vector of new critical boundaries after the sample size is changed, one per element of 'snew'

`theta_hat_inter_m1`
: Numeric vector of treatment effect estimates observed at the interim analysis at which the sample size was changed, one per original comparison (dose), e.g. the difference of the observed means or event rates between a test arm and the common control arm

`theta_hat_inter_m1_sd`
: Standard error of 'theta_hat_inter_m1'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0

`theta_hat_inter_m2`
: Numeric vector of treatment effect estimates at the interim analysis for the M^(2) comparisons that remain after the doses (comparisons) dropped for lack of efficacy are removed; each element must appear in 'theta_hat_inter_m1', which is used to map the remaining comparisons back onto the original ones

`theta_hat_inter_m2_sd`
: Standard error of 'theta_hat_inter_m2'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0

`inter_vt`
: Index of the interim analysis at which the sample size was changed (1-based); must be less than length(s)

`theta_hat_last_ad_m2`
: Numeric vector of treatment effect estimates observed at the analysis after the sample size change at which the trial was terminated, one per remaining comparison (dose); the remaining comparison with the largest estimate is the one for which the point estimate and confidence interval are returned

`theta_hat_last_ad_m2_sd`
: Standard error of 'theta_hat_last_ad_m2'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0

`last_vt_ad`
: Index of the interim or final analysis after the sample size change at which the trial was terminated (1-based); it indexes 'snew'

`alpha_2`
: Type I error for the two-sided test

`dist`
: Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

p-value The p-value of the test of the null hypothesis that the treatment effect of the remaining comparison (dose) with the best efficacy is 0

confidence interval Numeric vector of length 3 giving the lower confidence limit, the conservatively median unbiased point estimate and the upper confidence limit for the remaining comparison (dose) with the best efficacy; this is the two-sided (1 - alpha_2) * 100 percent confidence interval, and its lower limit is consistent with the p-value, in the sense that the p-value < alpha_2/2 if and only if the lower limit is greater than 0

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_est_back_with_drop(s = c(0.3,0.7,1), c_bry = c(4.347011,2.845787,2.380956), snew = c(0.5,1),
c_bry_new = c(3.310743,2.781890), theta_hat_inter_m1 = c(1.2,1.3,1.5), theta_hat_inter_m1_sd = 1,
theta_hat_inter_m2 = c(1.3,1.5), theta_hat_inter_m2_sd = 1, inter_vt = 1,
theta_hat_last_ad_m2 = c(2.2,1.4), theta_hat_last_ad_m2_sd = 1, last_vt_ad = 2,
alpha_2 = 0.05, dist = 1)
```

`masd_est_ci` *Multiple comparisons Group sequential design: Final analysis, Without sample size change*

Description

Multiple comparisons Group sequential design: Final analysis, Without sample size change

Usage

```
masd_est_ci(
  s,
  c_bry,
  theta_hat_last_m1,
  theta_hat_last_m1_sd,
  last_vt,
  alpha_2,
  dist
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
theta_hat_last_m1	Numeric vector of treatment effect estimates observed at the analysis at which the trial stopped, one per comparison (dose), e.g. the difference of the observed means or event rates between a test arm and the common control arm, or minus the log of the observed hazard ratio; its length gives the number of comparisons
theta_hat_last_m1_sd	Standard error of 'theta_hat_last_m1'; either a single value shared by all comparisons or a vector with one value per comparison; must be > 0
last_vt	Index of the analysis at which the trial stopped (1-based); this can be the final analysis, at which s = 1, or an interim analysis, and it must not exceed length(s)
alpha_2	Type I error for the two-sided test
dist	Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

p-value The p-value of the test of the null hypothesis that the treatment effect of the dose (comparison) with the best efficacy is 0

confidence interval Numeric vector of length 3 giving the lower confidence limit, the conservatively median unbiased point estimate and the upper confidence limit for the dose (comparison) with the best efficacy; the lower limit is consistent with the p-value, in the sense that the p-value < alpha_2/2 if and only if the lower limit is greater than 0

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_est_ci(s = c(1/3, 2/3, 1), c_bry = c(3.984298, 3.961146, 2.349682),
theta_hat_last_m1 = 0.35, theta_hat_last_m1_sd = 0.6,
last_vt = 1, alpha_2 = 0.05, dist = 1)
```

`masd_new_samsz` *Multiple comparisons Group sequential design: Interim analysis, Non-survival analysis, Use theta_interim*

Description

Multiple comparisons Group sequential design: Interim analysis, Non-survival analysis, Use theta_interim

Usage

```
masd_new_samsz(
  s,
  c_bry,
  snew,
  inter_vt,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  theta_hat_inter_m2,
  theta_hat_inter_m2_sd,
  beta,
  n_control_inter,
  dist
)
```

Arguments

`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`c_bry`	Vector of critical boundaries for each analysis
`snew`	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
`inter_vt`	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
`theta_hat_inter_m1`	Numeric vector of treatment effect estimates observed at the interim analysis for all M^(1) comparisons, e.g. the difference of the observed means or event rates between a test arm and the common control arm, or minus the log of the observed hazard ratio; it is also used as the estimated effect size for the conditional power calculation

`theta_hat_inter_m1_sd`
: Standard error of 'theta_hat_inter_m1'; must be > 0

`theta_hat_inter_m2`
: Numeric vector of treatment effect estimates at the interim analysis for the M^(2) comparisons that remain after the comparisons (doses) dropped for lack of efficacy are removed; each element must appear in 'theta_hat_inter_m1', which is used to map the remaining comparisons back onto the original ones

`theta_hat_inter_m2_sd`
: Standard error of 'theta_hat_inter_m2'; must be > 0

`beta`
: Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation

`n_control_inter`
: Sample size of the control arm at the interim analysis

`dist`
: Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis, which is the case if the largest Wald statistic reaches the planned critical boundary

Wald statistics Numeric vector of the Wald statistics of the treatment effects observed at the interim analysis, one per original (M^(1)) comparison

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Estimated effect size: theta The effect size used for the conditional power calculation, taken to be the treatment effect estimates observed at the interim analysis, one value per original (M^(1)) comparison

remaining effect size The elements of the estimated effect size belonging to the M^(2) comparisons that remain after the doses (comparisons) are dropped

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0 for all comparisons

c_power_m1 Conditional power at the interim analysis using all M^(1) comparisons, the estimated effect size and the original critical boundaries

c_power_m2 Conditional power for the remaining M^(2) comparisons using the new critical boundary evaluated at the planned sample size (ratio of new to original sample size 1), or 'NA' if the null hypothesis was rejected at the interim analysis or if the largest observed effect estimate is < 0.001

N_control_new New sample size for the control arm after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if the largest observed effect estimate is < 0.001

new information fraction The new information fractions after the sample size change, i.e. 'snew'

New critical boundary Numeric vector of the new critical boundaries for the new interim analyses (O'Brien-Fleming type), one per element of 'snew', or 'NA' if they were not calculated

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_new_samsz( s = c(1/3,2/3,1), c_bry = c(3.984298, 3.961146, 2.349682), snew = 1,
  inter_vt = 2, theta_hat_inter_m1 = c(0.2,0.5,0.8), theta_hat_inter_m1_sd = 0.5,
  theta_hat_inter_m2 = c(0.5,0.8), theta_hat_inter_m2_sd = 0.2, beta = 0.1,
  n_control_inter = 65, dist = 1)
```

---

masd_new_samsz_survival

Multiple comparisons Group sequential design: Interim analysis, Survival analysis, Use theta_interim

---

Description

Multiple comparisons Group sequential design: Interim analysis, Survival analysis, Use theta_interim

Usage

```
masd_new_samsz_survival(
  s,
  c_bry,
  snew,
  inter_vt,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  theta_hat_inter_m2,
```

```
  theta_hat_inter_m2_sd,
  beta,
  tot_events_inter_m1,
  dist
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
theta_hat_inter_m1	Numeric vector of treatment effect estimates observed at the interim analysis for all M^(1) comparisons, i.e. minus the log of the observed hazard ratio for each comparison; it is also used as the estimated effect size for the conditional power calculation
theta_hat_inter_m1_sd	Standard error of 'theta_hat_inter_m1'; must be > 0
theta_hat_inter_m2	Numeric vector of treatment effect estimates at the interim analysis for the M^(2) comparisons that remain after the comparisons (doses) dropped for lack of efficacy are removed; each element must appear in 'theta_hat_inter_m1', which is used to map the remaining comparisons back onto the original ones
theta_hat_inter_m2_sd	Standard error of 'theta_hat_inter_m2'; must be > 0
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation
tot_events_inter_m1	Total number of events observed at the interim analysis across all M^(1) test arms and the common control arm
dist	Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis, which is the case if the largest Wald statistic reaches the planned critical boundary

Wald statistics Numeric vector of the Wald statistics of the treatment effects observed at the interim analysis, one per original (M^(1)) comparison

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Assumed effect size: theta The effect size used for the conditional power calculation, taken to be the treatment effect estimates observed at the interim analysis (minus the log of the observed hazard ratio), one value per original (M^(1)) comparison

remaining effect size The elements of the effect size belonging to the M^(2) comparisons that remain after the doses (comparisons) are dropped

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0 for all comparisons

c_power_m1 Conditional power at the interim analysis using all M^(1) comparisons, the observed effect size and the original critical boundaries

c_power_m2 Conditional power for the remaining M^(2) comparisons using the new critical boundary evaluated at the planned sample size (ratio of new to original sample size 1), or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new events between a test arm and control Number of events between one test arm and the common control arm required after the sample size re-estimation, derived from the interim total events and the ratio of the new to the planned information, or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new total events New total number of events after the sample size re-estimation, across the M^(2) remaining test arms and the common control arm, or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new information fraction The new information fractions after the sample size change, i.e. 'snew'

New critical boundary Numeric vector of the new critical boundaries for the new interim analyses (O'Brien-Fleming type), one per element of 'snew', or 'NA' if they were not calculated

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_new_samsz_survival(s = c(1/3,2/3,1), c_bry = c(3.984298, 3.961146, 2.349682), snew = 1,
inter_vt = 2, theta_hat_inter_m1 = c(1.2,1.5,1.1),
theta_hat_inter_m1_sd = 1.2, theta_hat_inter_m2 = c(1.2,1.5),
theta_hat_inter_m2_sd = 1.2, beta = 0.1, tot_events_inter_m1 = 65, dist = 1)
```

`masd_new_samsz_theta` *Multiple comparisons Group sequential design: Interim analysis, Non-survival analysis, Input theta*

Description

Multiple comparisons Group sequential design: Interim analysis, Non-survival analysis, Input theta

Usage

```
masd_new_samsz_theta(
  theta,
  s,
  c_bry,
  snew,
  inter_vt,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  theta_hat_inter_m2,
  theta_hat_inter_m2_sd,
  beta,
  n_control_inter,
  dist
)
```

Arguments

`theta`	Assumed effect size for each of the M^(1) comparisons, i.e. a vector with length(theta) = length(theta_hat_inter_m1); different values can be entered to check the sensitivity of the conditional power to the effect size
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`c_bry`	Vector of critical boundaries for each analysis
`snew`	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
`inter_vt`	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)

`theta_hat_inter_m1`
: Numeric vector of treatment effect estimates observed at the interim analysis for all M^(1) comparisons, e.g. the difference of the observed means or event rates between a test arm and the common control arm, or minus the log of the observed hazard ratio

`theta_hat_inter_m1_sd`
: Standard error of 'theta_hat_inter_m1'; must be > 0

`theta_hat_inter_m2`
: Numeric vector of treatment effect estimates at the interim analysis for the M^(2) comparisons that remain after the comparisons (doses) dropped for lack of efficacy are removed; each element must appear in 'theta_hat_inter_m1', which is used to map the remaining comparisons back onto the original ones

`theta_hat_inter_m2_sd`
: Standard error of 'theta_hat_inter_m2'; must be > 0

`beta`
: Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation

`n_control_inter`
: Sample size of the control arm at the interim analysis

`dist`
: Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis, which is the case if the largest Wald statistic reaches the planned critical boundary

Wald statistics Numeric vector of the Wald statistics of the treatment effects observed at the interim analysis, one per original (M^(1)) comparison

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Assumed effect size: theta The assumed effect size theta entered by the user, one value per original (M^(1)) comparison

remaining effect size The elements of the assumed effect size belonging to the M^(2) comparisons that remain after the doses (comparisons) are dropped

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0 for all comparisons

c_power_m1 Conditional power at the interim analysis using all M^(1) comparisons, the assumed effect size theta and the original critical boundaries

c_power_m2 Conditional power for the remaining M^(2) comparisons using the new critical boundary evaluated at the planned sample size (ratio of new to original sample size 1), or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

N_control_new New sample size for the control arm after the sample size re-estimation, or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new information fraction The new information fractions after the sample size change, i.e. 'snew'

New critical boundary Numeric vector of the new critical boundaries for the new interim analyses (O'Brien-Fleming type), one per element of 'snew', or 'NA' if they were not calculated

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_new_samsz_theta( theta = c(0,0.2,0), s = c(1/3,2/3,1),
  c_bry = c(3.984298, 3.961146, 2.349682), snew = 1, inter_vt = 2,
  theta_hat_inter_m1 = c(0.2,0.5,0.8), theta_hat_inter_m1_sd = 0.5,
  theta_hat_inter_m2 = c(0.5,0.8), theta_hat_inter_m2_sd = 0.2, beta = 0.1,
  n_control_inter = 65, dist = 1)
```

---

masd_new_samsz_theta_survival

Multiple comparisons Group sequential design: Interim analysis, Survival analysis, Input theta

---

Description

Multiple comparisons Group sequential design: Interim analysis, Survival analysis, Input theta

Usage

```
masd_new_samsz_theta_survival(
  theta,
  s,
  c_bry,
  snew,
  inter_vt,
  theta_hat_inter_m1,
  theta_hat_inter_m1_sd,
  theta_hat_inter_m2,
  theta_hat_inter_m2_sd,
  beta,
  tot_events_inter_m1,
  dist
)
```

Arguments

theta	Assumed effect size (minus the log of the hazard ratio) for each of the M^(1) comparisons, i.e. a vector with length(theta) = length(theta_hat_inter_m1); different values can be entered to check the sensitivity of the conditional power to the effect size
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry	Vector of critical boundaries for each analysis
snew	Vector of new information fractions after the sample size is changed, e.g. c(0.5, 1); the fractions are relative to the new total information and the last element must be 1
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than length(s)
theta_hat_inter_m1	Numeric vector of treatment effect estimates observed at the interim analysis for all M^(1) comparisons, i.e. minus the log of the observed hazard ratio for each comparison
theta_hat_inter_m1_sd	Standard error of 'theta_hat_inter_m1'; must be > 0
theta_hat_inter_m2	Numeric vector of treatment effect estimates at the interim analysis for the M^(2) comparisons that remain after the comparisons (doses) dropped for lack of efficacy are removed; each element must appear in 'theta_hat_inter_m1', which is used to map the remaining comparisons back onto the original ones
theta_hat_inter_m2_sd	Standard error of 'theta_hat_inter_m2'; must be > 0
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation

`tot_events_inter_m1`
: Total number of events observed at the interim analysis across all M^(1) test arms and the common control arm

`dist`
: Distribution indicator: 1 = the comparisons (doses) share one common control arm and the endpoint is normally distributed, so that the treatment effect estimates are correlated with correlation 1/2; otherwise the comparisons are treated as independent

Value

A named list with the following components:

Interim analysis hypothesis test Character string giving the outcome of the interim hypothesis test: whether the null hypothesis was rejected at the interim analysis, which is the case if the largest Wald statistic reaches the planned critical boundary

Wald statistics Numeric vector of the Wald statistics of the treatment effects observed at the interim analysis, one per original (M^(1)) comparison

Critical boundary Planned critical boundary at the interim analysis at which the sample size is re-estimated

Assumed effect size: theta The assumed effect size theta entered by the user, one value per original (M^(1)) comparison

remaining effect size The elements of the assumed effect size belonging to the M^(2) comparisons that remain after the doses (comparisons) are dropped

c_alpha Conditional type I error at the interim analysis, calculated by setting theta = 0 for all comparisons

c_power_m1 Conditional power at the interim analysis using all M^(1) comparisons, the assumed effect size theta and the original critical boundaries

c_power_m2 Conditional power for the remaining M^(2) comparisons using the new critical boundary evaluated at the planned sample size (ratio of new to original sample size 1), or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new events between a test arm and control Number of events between one test arm and the common control arm available for the re-estimation, calculated from the interim total events as 2 * tot_events_inter_m1 / (M^(1) + 1), or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new total events New total number of events after the sample size re-estimation, across the M^(2) remaining test arms and the common control arm, or 'NA' if the null hypothesis was rejected at the interim analysis or if max(theta) < 0.001

new information fraction The new information fractions after the sample size change, i.e. 'snew'

New critical boundary Numeric vector of the new critical boundaries for the new interim analyses (O'Brien-Fleming type), one per element of 'snew', or 'NA' if they were not calculated

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590.

To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_new_samsz_theta_survival( theta = c(0,0.2,0), s = c(1/3,2/3,1),
  c_bry = c(3.984298, 3.961146, 2.349682), snew = 1, inter_vt = 2,
  theta_hat_inter_m1 = c(1.2,1.5,1.1), theta_hat_inter_m1_sd = 1.2,
  theta_hat_inter_m2 = c(1.2,1.5), theta_hat_inter_m2_sd = 1.2, beta = 0.1,
  tot_events_inter_m1 = 65, dist = 1)
```

---

masd_power_simu_adapt_binary

Multiple comparisons Group sequential design: Simulations, Binary distribution, Operating characteristics

---

Description

Multiple comparisons Group sequential design: Simulations, Binary distribution, Operating characteristics

Usage

```
masd_power_simu_adapt_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  theta_cut,
  beta,
  samsz,
  N_max,
  sim_num
)
```

Arguments

p_t	Vector of true event rates of the test arms, one per dose; 0 < p_t < 1
p_c	Event rate of the control arm; 0 < p_c < 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
samsz	Sample size of the control arm used in the simulation; must be > 0
N_max	Maximum sample size for the control arm allowed by the sample size re-estimation; must be >= samsz
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary, the rejection rate by look and the rate of sample size increase

Summary by arm Matrix with one row per test arm giving the test-arm event rate, the control-arm event rate, the drop rate by arm and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate without and with sample size re-estimation, the rate of sample size increase, the rejection rates conditional on meeting the sample size increase criteria, the simulated type I error rate, the non-type I error rejection rate, the futility rate, the planned and maximum control sample sizes, the mean simulated control sample size and the mean simulated control sample size conditional on an increase

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_power_simu_adapt_binary(p_t = c(0.4,0.4,0.4), p_c = 0.4, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, theta_cut = 0.01, beta = 0.1, samsz = 100,
N_max = 200, sim_num = 20)
```

`masd_power_simu_adapt_neg_binomial`

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Operating characteristics

---

Description

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Operating characteristics

Usage

```
masd_power_simu_adapt_neg_binomial(
  r_t,
  r_c,
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  beta,
  theta_cut,
  samsz,
  N_max,
  sim_num
)
```

Arguments

`r_t`	Vector of true mean rates of the test arms, one per dose; must be > 0
`r_c`	Mean rate of the control arm; must be > 0
`kappa`	Dispersion parameter of the negative binomial model; must be > 0
`direction`	Test direction: 1 = larger r is better, otherwise smaller r is better

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz	Sample size of the control arm used in the simulation; must be > 0
N_max	Maximum sample size for the control arm allowed by the sample size re-estimation; must be >= samsz
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary, the rejection rate by look and the rate of sample size increase

Summary by arm Matrix with one row per test arm giving the test-arm mean rate, the control-arm mean rate, the drop rate by arm and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate without and with sample size re-estimation, the rate of sample size increase, the rejection rates conditional on meeting the sample size increase criteria, the simulated type I error rate, the non-type I error rejection rate, the futility rate, the planned and maximum control sample sizes, the mean simulated control sample size and the mean simulated control sample size conditional on an increase

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_power_simu_adapt_neg_binomial(r_t = c(1.1,1.1,1.1), r_c = 1.1, kappa = 1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, beta = 0.1, theta_cut = 0.01, samsz = 100,
N_max = 500, sim_num = 20)
```

`masd_power_simu_adapt_normal`

Multiple comparisons Group sequential design: Simulations, Normal distribution, Operating characteristics

---

Description

Multiple comparisons Group sequential design: Simulations, Normal distribution, Operating characteristics

Usage

```
masd_power_simu_adapt_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  beta,
  theta_cut,
  samsz,
  N_max,
  sim_num
)
```

Arguments

`mu_t`	Vector of true means of the test arms, one per dose; setting mu_t = mu_c gives the simulated type I error rate
`mu_c`	Mean of the control arm
`sigma_t`	Standard deviation of the test arm; must be > 0
`sigma_c`	Standard deviation of the control arm; must be > 0
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1

bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz	Sample size of the control arm used in the simulation; must be > 0
N_max	Maximum sample size for the control arm allowed by the sample size re-estimation; must be >= samsz
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary, the rejection rate by look and the rate of sample size increase

Summary by arm Matrix with one row per test arm giving the test-arm mean, the control-arm mean, the drop rate by arm and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate without and with sample size re-estimation, the rate of sample size increase, the rejection rates conditional on meeting the sample size increase criteria, the simulated type I error rate, the non-type I error rejection rate, the futility rate, the planned and maximum control sample sizes, the mean simulated control sample size and the mean simulated control sample size conditional on an increase

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_power_simu_adapt_normal(mu_t = c(0,0,0), mu_c = 0, sigma_t = 1, sigma_c = 1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, beta = 0.1, theta_cut = 0.01, samsz = 100,
N_max = 500, sim_num = 20)
```

`masd_power_simu_adapt_poisson` *Multiple comparisons Group sequential design: Simulations, Poisson distribution, Operating characteristics*

Description

Multiple comparisons Group sequential design: Simulations, Poisson distribution, Operating characteristics

Usage

```
masd_power_simu_adapt_poisson(
  lambda_t,
  lambda_c,
  direction,
  s,
  bry_type,
  alpha_2,
  beta,
  theta_cut,
  samsz,
  N_max,
  sim_num
)
```

Arguments

`lambda_t`	Vector of true mean event counts of the test arms, one per dose; must be > 0
`lambda_c`	Mean event count of the control arm; must be > 0
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`bry_type`	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
`alpha_2`	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error

beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz	Sample size of the control arm used in the simulation; must be > 0
N_max	Maximum sample size for the control arm allowed by the sample size re-estimation; must be >= samsz
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary, the rejection rate by look and the rate of sample size increase

Summary by arm Matrix with one row per test arm giving the test-arm mean, the control-arm mean, the drop rate by arm and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate without and with sample size re-estimation, the rate of sample size increase, the rejection rates conditional on meeting the sample size increase criteria, the simulated type I error rate, the non-type I error rejection rate, the futility rate, the planned and maximum control sample sizes, the mean simulated control sample size and the mean simulated control sample size conditional on an increase

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
masd_power_simu_adapt_poisson(lambda_t = c(1.1,1.1,1.1), lambda_c = 1.1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, beta = 0.1, theta_cut = 0.01, samsz = 100,
N_max = 500, sim_num = 20)
```

`masd_power_simu_adapt_survival` *Multiple comparisons Group sequential design: Simulations, Survival analysis, Operating characteristics*

Description

Multiple comparisons Group sequential design: Simulations, Survival analysis, Operating characteristics

Usage

```
masd_power_simu_adapt_survival(
  HR,
  s,
  bry_type,
  alpha_2,
  surv_rate,
  HR_cut,
  evt_num,
  evt_max,
  beta,
  sim_num
)
```

Arguments

`HR`	Vector of hazard ratios of each test arm vs. the control arm; HR < 1 favours the test arm; must be > 0
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`bry_type`	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
`alpha_2`	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
`surv_rate`	Survival rate at the end of follow-up; 0 < surv_rate < 1
`HR_cut`	Hazard-ratio cut-off for the lack-of-efficacy rule at the interim analysis: a test arm is dropped when its observed hazard ratio is greater than HR_cut
`evt_num`	Planned number of events between one test arm and the control arm by the final analysis; must be > 0
`evt_max`	Maximum number of events between one test arm and the control arm allowed by the sample size re-estimation; must be >= evt_num
`beta`	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
`sim_num`	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary, the rejection rate by look and the rate of sample size increase

Summary by arm Matrix with one row per test arm giving the hazard ratio, the drop rate by arm and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate without and with sample size re-estimation, the rate of sample size increase, the rejection rates conditional on meeting the sample size increase criteria, the simulated type I error rate, the non-type I error rejection rate, the futility rate, the planned and maximum two-arm event numbers and the mean simulated two-arm event numbers with and without conditioning on an increase

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_power_simu_adapt_survival(HR = c(0.63, 0.65, 0.7), s = c(1/3,2/3,1), bry_type = 1,
alpha_2 = 0.05, surv_rate = 0.5, HR_cut = 0.95, evt_num = 200, evt_max = 500, beta = 0.1,
sim_num = 2)
```

---

masd_simu_OC_binary *Multiple comparisons Group sequential design: Simulations, Binary distribution, Optimizing adaptive sequential design*

Description

Multiple comparisons Group sequential design: Simulations, Binary distribution, Optimizing adaptive sequential design

Usage

```
masd_simu_OC_binary(
  groups,
  p_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of true event rates of the test arms: each row is one simulation scenario and each column one test arm/dose; 0 < groups < 1
p_c	Event rate of the control arm; 0 < p_c < 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Two-sided type I error levels spent at each look of the schedule s1; must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error levels spent at each look of the schedule s2; must sum to alpha_2
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz_1	Sample size of the control arm used in the simulation for the first sample size scenario; must be > 0
samsz_2	Sample size of the control arm used in the simulation for the second sample size scenario; must be > 0
N_max_1	Maximum sample size for the control arm allowed by the sample size re-estimation in the first N_max scenario; must be >= samsz_1

N_max_2	Maximum sample size for the control arm allowed by the sample size re-estimation in the second N_max scenario; must be >= samsz_2
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the O'Brien-Fleming group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the O'Brien-Fleming group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s1 List holding the alpha-spending group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s2 List holding the alpha-spending group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_simu_OC_binary(groups = rbind(c(0.35,0.4,0.45),c(0.4,0.45,0.5),c(0.35,0.45,0.55),
c(0.45,0.5,0.55)), p_c = 0.3, direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1),
alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01, samsz_1 = 50, samsz_2 = 75,
```

```
N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

`masd_simu_OC_neg_binomial`

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

---

Description

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

Usage

```
masd_simu_OC_neg_binomial(
  groups,
  r_c,
  kappa,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

`groups`	Matrix of true mean rates of the test arms: each row is one simulation scenario and each column one test arm/dose; must be > 0
`r_c`	Mean rate of the control arm; must be > 0
`kappa`	Dispersion parameter of the negative binomial model; must be > 0
`direction`	Test direction: 1 = larger r is better, otherwise smaller r is better
`s1`	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
`s2`	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1

alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Two-sided type I error levels spent at each look of the schedule s1; must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error levels spent at each look of the schedule s2; must sum to alpha_2
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz_1	Sample size of the control arm used in the simulation for the first sample size scenario; must be > 0
samsz_2	Sample size of the control arm used in the simulation for the second sample size scenario; must be > 0
N_max_1	Maximum sample size for the control arm allowed by the sample size re-estimation in the first N_max scenario; must be >= samsz_1
N_max_2	Maximum sample size for the control arm allowed by the sample size re-estimation in the second N_max scenario; must be >= samsz_2
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the O'Brien-Fleming group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the O'Brien-Fleming group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s1 List holding the alpha-spending group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s2 List holding the alpha-spending group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_simu_OC_neg_binomial(
groups = rbind(c(0.2,0.3,0.4),c(0.3,0.4,0.5),c(0.4,0.5,0.6),c(0.5,0.6,0.7)), r_c = 0.35,
kappa = 1, direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
samsz_1 = 50, samsz_2 = 75, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

---

masd_simu_OC_normal *Multiple comparisons Group sequential design: Simulations, Normal distribution, Optimizing adaptive sequential design*

Description

Multiple comparisons Group sequential design: Simulations, Normal distribution, Optimizing adaptive sequential design

Usage

```
masd_simu_OC_normal(
  groups,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
```

```
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of true means of the test arms: each row is one simulation scenario and each column one test arm/dose
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arm; must be > 0
sigma_c	Standard deviation of the control arm; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Two-sided type I error levels spent at each look of the schedule s1; must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error levels spent at each look of the schedule s2; must sum to alpha_2
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz_1	Sample size of the control arm used in the simulation for the first sample size scenario; must be > 0
samsz_2	Sample size of the control arm used in the simulation for the second sample size scenario; must be > 0
N_max_1	Maximum sample size for the control arm allowed by the sample size re-estimation in the first N_max scenario; must be >= samsz_1
N_max_2	Maximum sample size for the control arm allowed by the sample size re-estimation in the second N_max scenario; must be >= samsz_2
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the O'Brien-Fleming group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the O'Brien-Fleming group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s1 List holding the alpha-spending group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s2 List holding the alpha-spending group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_simu_OC_normal(groups = rbind(c(0.3,0.4,0.5),c(0.1,0.2,0.3),c(0.3,0.4,0.5),c(0.1,0.2,0.3)),
mu_c = 0.15, sigma_t = 1, sigma_c = 1, direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1),
alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049),
theta_cut = 0.01, samsz_1 = 50, samsz_2 = 75, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1,
sim_num = 2)
```

---

masd_simu_OC_poisson *Multiple comparisons Group sequential design: Simulations, Poisson distribution, Optimizing adaptive sequential design*

Description

Multiple comparisons Group sequential design: Simulations, Poisson distribution, Optimizing adaptive sequential design

Usage

```
masd_simu_OC_poisson(
  groups,
  lambda_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of true mean event counts of the test arms: each row is one simulation scenario and each column one test arm/dose; must be > 0
lambda_c	Mean event count of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s1	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Two-sided type I error levels spent at each look of the schedule s1; must sum to alpha_2
alpha_2_alps_s2	Two-sided type I error levels spent at each look of the schedule s2; must sum to alpha_2
theta_cut	Lack-of-efficacy threshold on the effect-size scale: a test arm is dropped at the interim analysis when its observed effect size is below this value
samsz_1	Sample size of the control arm used in the simulation for the first sample size scenario; must be > 0
samsz_2	Sample size of the control arm used in the simulation for the second sample size scenario; must be > 0
N_max_1	Maximum sample size for the control arm allowed by the sample size re-estimation in the first N_max scenario; must be >= samsz_1

N_max_2	Maximum sample size for the control arm allowed by the sample size re-estimation in the second N_max scenario; must be >= samsz_2
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the O'Brien-Fleming group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the O'Brien-Fleming group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s1 List holding the alpha-spending group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

Alpha-spending boundaries, interim analysis schedule=s2 List holding the alpha-spending group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned control sample sizes and the two maximum control sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_simu_OC_poisson(
groups = rbind(c(0.2,0.3,0.4),c(0.3,0.4,0.5),c(0.4,0.5,0.6),c(0.5,0.6,0.7)), lambda_c = 0.3,
direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
```

```
samsz_1 = 50, samsz_2 = 75, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

`masd_simu_OC_survival` *Multiple comparisons Group sequential design: Simulations, Survival analysis, Optimizing adaptive sequential design*

Description

Multiple comparisons Group sequential design: Simulations, Survival analysis, Optimizing adaptive sequential design

Usage

```
masd_simu_OC_survival(
  groups,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  surv_rate,
  evt_num_1,
  evt_num_2,
  evt_max_1,
  evt_max_2,
  HR_cut,
  beta,
  sim_num
)
```

Arguments

`groups`	Matrix of true hazard ratios of each test arm vs. the control arm: each row is one simulation scenario and each column one test arm; must be > 0
`s1`	Vector of information fractions of the first interim analysis schedule, e.g. c(1/3, 2/3, 1); the last element must be 1
`s2`	Vector of information fractions of the second interim analysis schedule, e.g. c(0.5, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1
`alpha_2_alps_s1`	Two-sided type I error levels spent at each look of the schedule s1; must sum to alpha_2
`alpha_2_alps_s2`	Two-sided type I error levels spent at each look of the schedule s2; must sum to alpha_2

surv_rate	Survival rate at the end of follow-up; 0 < surv_rate < 1
evt_num_1	Planned number of events between one test arm and the control arm by the final analysis in the first event number scenario; must be > 0
evt_num_2	Planned number of events between one test arm and the control arm by the final analysis in the second event number scenario; must be > 0
evt_max_1	Maximum number of events between one test arm and the control arm in the first maximum-event-number scenario; must be >= evt_num_1
evt_max_2	Maximum number of events between one test arm and the control arm in the second maximum-event-number scenario; must be >= evt_num_2
HR_cut	Hazard-ratio cut-off for the lack-of-efficacy rule at the interim analysis: a test arm is dropped when its observed hazard ratio is greater than HR_cut
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the O'Brien-Fleming group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned event numbers and the two maximum event numbers

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the O'Brien-Fleming group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned event numbers and the two maximum event numbers

Alpha-spending boundaries, interim analysis schedule=s1 List holding the alpha-spending group sequential design for the schedule s1 and the simulation results for the four combinations of the two planned event numbers and the two maximum event numbers

Alpha-spending boundaries, interim analysis schedule=s2 List holding the alpha-spending group sequential design for the schedule s2 and the simulation results for the four combinations of the two planned event numbers and the two maximum event numbers

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
masd_simu_OC_survival(
groups = rbind(c(0.85, 0.87, 0.9), c(0.8, 0.82, 0.85), c(0.75, 0.78, 0.8), c(0.7, 0.75, 0.8)),
s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.001,0.049), surv_rate = 0.5, evt_num_1 = 200, evt_num_2 = 300,
evt_max_1 = 2000, evt_max_2 = 3000, HR_cut = 0.95, beta = 0.1, sim_num = 2)
```

---

midpnt_sz *Single arm phase 2 oncology trial: Two-stage design, the midpoint design*

Description

Single arm phase 2 oncology trial: Two-stage design, the midpoint design

Usage

```
midpnt_sz(alpha, beta, p_0, p_low, p_1, q, d_12_cut)
```

Arguments

alpha	Type I error for the one-sided test
beta	Type II error rate, i.e. 1 - power
p_0	Response rate indicating low activity with insufficient clinical benefit
p_low	Minimally clinically beneficial response rate
p_1	Assumed response rate
q	Weight between 0 and 1 used to interpolate the first-look sample size of the mid-point design from the two Simon's designs: n_1 = q * n_1(p_1) + (1 - q) * n_1(p_low), where n_1(p_1) and n_1(p_low) are the first-look sample sizes of Simon's designs with target response rates p_1 and p_low; 0 < q < 1
d_12_cut	Sets the minimal difference between n_2 and n_1 for the design; min(n_2 - n_1)

Value

A named list with the following components:

Simon's design: p=p_1 A matrix with one row per design (minimax, optimal and average) for Simon's design using p_1 as the target response rate, with columns r1, n1, r_2, n_2, EN(p0) (expected sample size under p_0), PET(p0) (probability of early termination under p_0), t1_err, PET_p (PET under p_1), PET_p_low (PET under p_low), power_p (power under p_1) and power_p_low (power under p_low)

Simon's design: p=p_low The corresponding matrix for Simon's design using p_low as the target response rate

The mid-point design: p=p_1 A matrix with one row per design (minimax, optimal and average) and columns r_1, r_2, n_1, n_2, r_1_e (the trial is stopped for superiority if at least r_1_e responses are observed at the first look), t1_err, PET_p_low, power_p (power under p_1), PET_p0, EN_p0 (expected sample size under p_0), PW_p_low (power under p_low) and q. If q is too large for the probability of early termination under p_low to be below beta, a character string with a warning message is returned instead

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Examples

```
midpnt_sz(alpha = c(0.001,0.024), beta = 0.1, p_0 = 0.2, p_low = 0.33, p_1 = 0.5, q = 0,
d_12_cut = 5)
```

MSD_power_alsp_boundary_binary_diff

Multiple comparisons Group sequential design: Binary distribution, Power calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Binary distribution, Power calculation, Alpha-spending boundary

Usage

```
MSD_power_alsp_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Vector of event rates of the test arms, one entry per dose or endpoint; 0 < p_t < 1
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_alsp_boundary_binary_diff(p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0.1,
direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.048), sampsz_control = 68,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`MSD_power_alsp_boundary_neg_binomial`

Multiple comparisons Group sequential design: Negative binomial distribution, Power calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Negative binomial distribution, Power calculation, Alpha-spending boundary

Usage

```
MSD_power_alsp_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa,
  dist
)
```

Arguments

`r_t`	Vector of mean rates of the test arms, one entry per dose or endpoint
`r_c`	Mean rate of the common control arm
`margin`	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
`direction`	Test direction: 1 = larger r is better, otherwise smaller r is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
`sampsz_control`	Sample size of the control arm

rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist	Distribution indicator kept for consistency with the sibling functions; it is not used here, because the function always sets dist1 = 2 for the boundary calculation and dist2 = 1 for the information time calculation

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

Reference Reference for the negative binomial sample size formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_alsp_boundary_neg_binomial(r_t=c(0.2,0.3,0.4), r_c=0.6, margin=0.1, direction=1,
s=c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), sampsz_control = 90, rand_ratio = 1,
nu_t = 1, kappa = 1, dist = 1)
```

`MSD_power_alsp_boundary_normal` *Multiple comparisons Group sequential design: Normal distribution, Power calculation, Alpha-spending boundary*

Description

Multiple comparisons Group sequential design: Normal distribution, Power calculation, Alpha-spending boundary

Usage

```
MSD_power_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

`mu_t`	Vector of means of the test arms, one entry per dose or endpoint
`mu_c`	Mean of the common control arm
`std_t`	Common standard deviation of the test arms; must be > 0
`std_c`	Standard deviation of the control arm; must be > 0
`margin`	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

`dist1` Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

`dist2` Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_alsp_boundary_normal(mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1, std_c = 1,
margin = 0, direction = 1, s = c(1/3,2/3,1),
alpha = c(0.001,0.001,0.023), sampsz_control = 148, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`MSD_power_alsp_boundary_poisson`

Multiple comparisons Group sequential design: Poisson distribution, Power calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Poisson distribution, Power calculation, Alpha-spending boundary

Usage

```
MSD_power_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Vector of means (rates) of the test arms, one entry per dose or endpoint
lambda_c	Mean (rate) of the common control arm
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_alsp_boundary_poisson(lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5, margin = 0.1,
direction = 2, s = c(1/3,2/3,1),
alpha = c(0.001,0.001,0.023), sampsz_control = 67, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

MSD_power_alsp_boundary_survival_Schoenfeld

Multiple comparisons Group sequential design: Survival analysis, Power calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Survival analysis, Power calculation, Alpha-spending boundary

Usage

```
MSD_power_alsp_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
```

```
  events_tot,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Vector of hazard ratios of the test arms vs. the control arm, one entry per dose or endpoint
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial (0 < margin < 1 if larger HR is better, margin > 1 if smaller HR is better)
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
events_tot	Total number of events for the trial, used in place of the control arm sample size
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage; dist1 = 2 is the conservative choice
dist2	Distribution indicator for the second stage; dist2 = 1 is the conservative choice

Value

A named list with the following components:

power Power of the trial for the given total number of events

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

reference Reference for the Schoenfeld event number formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_alsp_boundary_survival_Schoenfeld(HR = c(0.2,0.3,0.4), margin = 1.1, direction = 2,
s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023),
events_tot = 17, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`MSD_power_OF_boundary_binary_diff`

Multiple comparisons Group sequential design: Binary distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Binary distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
MSD_power_OF_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

`p_t`	Vector of event rates of the test arms, one entry per dose or endpoint; 0 < p_t < 1
`p_c`	Event rate of the common control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial

direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_OF_boundary_binary_diff(p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`MSD_power_OF_boundary_neg_binomial` *Multiple comparisons Group sequential design: Negative binomial distribution, Power calculation, O'Brien-Fleming boundary*

Description

Multiple comparisons Group sequential design: Negative binomial distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
MSD_power_OF_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
  dist2
)
```

Arguments

`r_t`	Vector of mean rates of the test arms, one entry per dose or endpoint
`r_c`	Mean rate of the common control arm
`margin`	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
`direction`	Test direction: 1 = larger r is better, otherwise smaller r is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
`nu_t`	Exposure time; must be > 0
`kappa`	Dispersion parameter of the negative binomial model; must be > 0
`dist1`	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control; 2 = otherwise. It has no effect here: the boundary calculation always uses dist1 = 2

`dist2` Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control; 2 = otherwise. It has no effect here: the information time calculation always uses dist2 = 1

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

Reference Reference for the negative binomial sample size formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_OF_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1,
nu_t = 6, kappa = 1, dist1 = 1, dist2 = 1)
```

`MSD_power_OF_boundary_normal`

Multiple comparisons Group sequential design: Normal distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Normal distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
MSD_power_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Vector of means of the test arms, one entry per dose or endpoint
mu_c	Mean of the common control arm
std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_OF_boundary_normal(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1),
alpha = 0.025, sampsz_control = 100, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

MSD_power_OF_boundary_poisson

Multiple comparisons Group sequential design: Poisson distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Poisson distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
MSD_power_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
```

```
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Vector of means (rates) of the test arms, one entry per dose or endpoint
lambda_c	Mean (rate) of the common control arm
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

power Power of the trial for the given control arm sample size

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_OF_boundary_poisson(lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

MSD_power_OF_boundary_survival_Schoenfeld

Multiple comparisons Group sequential design: Survival analysis, Power calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Survival analysis, Power calculation, O'Brien-Fleming boundary

Usage

```
MSD_power_OF_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  events_tot,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Vector of hazard ratios of the test arms vs. the control arm, one entry per dose or endpoint
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial (0 < margin < 1 if larger HR is better, margin > 1 if smaller HR is better)
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1

alpha	Type I error for the one-sided test; 0 < alpha < 1
events_tot	Total number of events for the trial, used in place of the control arm sample size
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage; dist1 = 2 is the conservative choice
dist2	Distribution indicator for the second stage; dist2 = 1 is the conservative choice

Value

A named list with the following components:

power Power of the trial for the given total number of events

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

reference Reference for the Schoenfeld event number formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_power_OF_boundary_survival_Schoenfeld(HR = 0.7, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, events_tot = 100,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`msd_power_simu_binary` *Multiple comparisons Group sequential design: Simulations, Binary distribution, Type I error and power*

Description

Multiple comparisons Group sequential design: Simulations, Binary distribution, Type I error and power

Usage

```
msd_power_simu_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

`p_t`	Vector of true event rates of the test arms, one per dose; 0 < p_t < 1
`p_c`	Event rate of the control arm; 0 < p_c < 1
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`bry_type`	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
`alpha_2`	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
`samsz`	Sample size of the control arm used in the simulation; must be > 0
`sim_num`	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary and the rejection rate by look

Summary by arm Matrix with one row per test arm giving the test-arm event rate, the control-arm event rate and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate, the simulated type I error rate, the non-type I error rejection rate, the planned control and total sample sizes and the mean simulated control and total sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
msd_power_simu_binary(p_t = c(0.4,0.4), p_c = 0.4, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

msd_power_simu_neg_binomial

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Type I error and power

---

Description

Multiple comparisons Group sequential design: Simulations, Negative binomial distribution, Type I error and power

Usage

```
msd_power_simu_neg_binomial(
  r_t,
  r_c,
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

r_t	Vector of true mean rates of the test arms, one per dose; must be > 0
r_c	Mean rate of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
samsz	Sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary and the rejection rate by look

Summary by arm Matrix with one row per test arm giving the test-arm mean rate, the control-arm mean rate and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate, the simulated type I error rate, the non-type I error rejection rate, the planned control and total sample sizes and the mean simulated control and total sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
msd_power_simu_neg_binomial(r_t = c(1.1,1.1,1.1), r_c = 1.1, kappa = 1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

msd_power_simu_normal *Multiple comparisons Group sequential design: Simulations, Normal distribution, Type I error and power*

Description

Multiple comparisons Group sequential design: Simulations, Normal distribution, Type I error and power

Usage

```
msd_power_simu_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

mu_t	Vector of true means of the test arms, one per dose
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arm; must be > 0
sigma_c	Standard deviation of the control arm; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
samsz	Sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary and the rejection rate by look

Summary by arm Matrix with one row per test arm giving the test-arm mean, the control-arm mean and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate, the simulated type I error rate, the non-type I error rejection rate, the planned control and total sample sizes and the mean simulated control and total sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
msd_power_simu_normal(mu_t = c(0,0,0), mu_c = 0, sigma_t = 1, sigma_c = 1, direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

msd_power_simu_poisson

Multiple comparisons Group sequential design: Simulations, Poisson distribution, Type I error and power

---

Description

Multiple comparisons Group sequential design: Simulations, Poisson distribution, Type I error and power

Usage

```
msd_power_simu_poisson(
  lambda_c,
  lambda_t,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

lambda_c	Mean event count of the control arm; must be > 0
lambda_t	Vector of true mean event counts of the test arms, one per dose; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
alpha_2	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
samsz	Sample size of the control arm used in the simulation; must be > 0
sim_num	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary and the rejection rate by look

Summary by arm Matrix with one row per test arm giving the test-arm mean, the control-arm mean and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate, the simulated type I error rate, the non-type I error rejection rate, the planned control and total sample sizes and the mean simulated control and total sample sizes

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
msd_power_simu_poisson(lambda_c = 0.8, lambda_t = c(0.8,0.8,0.8), direction = 1,
s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

`msd_power_simu_survival`

Multiple comparisons Group sequential design: Simulations, Survival analysis, Type I error and power

---

Description

Multiple comparisons Group sequential design: Simulations, Survival analysis, Type I error and power

Usage

```
msd_power_simu_survival(HR, s, bry_type, alpha_2, surv_rate, evt_num, sim_num)
```

Arguments

`HR`	Vector of hazard ratios of each test arm vs. the control arm; HR < 1 favours the test arm; must be > 0
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`bry_type`	Critical boundary type: 1 = O'Brien-Fleming, 2 = alpha-spending
`alpha_2`	Type I error for the two-sided test; when bry_type = 2 this is instead the vector of two-sided type I error levels spent at each look, which must sum to the total two-sided type I error
`surv_rate`	Survival rate at the end of follow-up; 0 < surv_rate < 1
`evt_num`	Planned number of events between one test arm and the control arm by the final analysis; must be > 0
`sim_num`	Number of simulation replicates

Value

A named list with the following components:

Design Matrix with one row per look giving the look number, the information fraction, the critical boundary and the rejection rate by look

Summary by arm Matrix with one row per test arm giving the hazard ratio and the rejection rate by arm

simulation results Named numeric vector holding the rejection rate, the simulated type I error rate, the non-type I error rejection rate, the planned two-arm and total event numbers and the mean simulated two-arm and total event numbers

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
msd_power_simu_survival(HR = c(0.8,0.8), s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05,
surv_rate = 0.5, evt_num = 800, sim_num = 20)
```

MSD_Sample_size_alsp_boundary_binary_diff

Multiple comparisons Group sequential design: Binary distribution, Sample size calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Binary distribution, Sample size calculation, Alpha-spending boundary

Usage

```
MSD_Sample_size_alsp_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Vector of event rates of the test arms, one entry per dose or endpoint; 0 < p_t < 1, and the function returns NA if the largest effect size is below 1e-4
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_alsp_boundary_binary_diff( p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0.1,
  direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
   dist1 = 1, dist2 = 1)
```

MSD_Sample_size_alsp_boundary_neg_binomial

Multiple comparisons Group sequential design: Negative binomial distribution, Sample size calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Negative binomial distribution, Sample size calculation, Alpha-spending boundary

Usage

```
MSD_Sample_size_alsp_boundary_neg_binomial(
  r_t,
  r_c,
```

```
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
  dist2
)
```

Arguments

r_t	Vector of mean rates of the test arms, one entry per dose or endpoint; the function returns NA if the largest log rate ratio is below 1e-4 or if any adjusted test arm rate r_t +/- margin is below 1e-4
r_c	Mean rate of the common control arm
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist1	Distribution indicator for the first stage; it has no effect here, because the boundary calculation always uses dist1 = 2
dist2	Distribution indicator for the second stage; it has no effect here, because the information time calculation always uses dist2 = 1

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

Reference Reference for the negative binomial sample size formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_alsp_boundary_neg_binomial( r_t = c(0.2,0.3,0.4), r_c = 0.6, margin = 0.1,
 direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
  nu_t = 1, kappa = 1, dist1 = 1, dist2 = 1)
```

MSD_Sample_size_alsp_boundary_normal

Multiple comparisons Group sequential design: Normal distribution, Sample size calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Normal distribution, Sample size calculation, Alpha-spending boundary

Usage

```
MSD_Sample_size_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Vector of means of the test arms, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
mu_c	Mean of the common control arm
std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_alsp_boundary_normal( mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1, std_c = 1,
  margin = 0, direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1,
  rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`MSD_Sample_size_alsp_boundary_poisson`

Multiple comparisons Group sequential design: Poisson distribution, Sample size calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Poisson distribution, Sample size calculation, Alpha-spending boundary

Usage

```
MSD_Sample_size_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Vector of means (rates) of the test arms, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
lambda_c	Mean (rate) of the common control arm
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_alsp_boundary_poisson( lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5, margin = 0.11,
  direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
   dist1 = 1, dist2 = 1)
```

MSD_Sample_size_alsp_boundary_survival_Schoenfeld

Multiple comparisons Group sequential design: Survival analysis, Sample size calculation, Alpha-spending boundary

---

Description

Multiple comparisons Group sequential design: Survival analysis, Sample size calculation, Alpha-spending boundary

Usage

```
MSD_Sample_size_alsp_boundary_survival_Schoenfeld(
  HR,
  margin,
```

```
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Vector of hazard ratios of the test arms vs. the control arm, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial (0 < margin < 1 if larger HR is better, margin > 1 if smaller HR is better)
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Vector of alpha-spending values for the one-sided test, one per analysis and of the same length as s, summing to the overall one-sided type I error; each value must satisfy 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage; dist1 = 2 is the conservative choice
dist2	Distribution indicator for the second stage; dist2 = 1 is the conservative choice

Value

A named list with the following components:

Combined number of events between a dose and control Total number of events, test arm and control arm combined, required for one dose vs. control comparison

total number of events from all doses and control Total number of events required for the whole trial, i.e. all doses and the common control arm

combined number of events in each dose and control in a two arm study with same critical boudary Vector with the combined number of events for each dose and its control, as if a separate two arm trial were conducted for that dose with the same critical boundary

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

reference Reference for the Schoenfeld event number formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_alsp_boundary_survival_Schoenfeld( HR = c(0.2,0.3,0.4), margin = 1.1,
  direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
   dist1 = 1, dist2 = 1)
```

`MSD_Sample_size_OF_boundary_binary_diff`

Multiple comparisons Group sequential design: Binary distribution, Sample size calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Binary distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
MSD_Sample_size_OF_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Vector of event rates of the test arms, one entry per dose or endpoint; 0 < p_t < 1, and the function returns NA if the largest effect size is below 1e-4
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_OF_boundary_binary_diff( p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

MSD_Sample_size_OF_boundary_neg_binomial

Multiple comparisons Group sequential design: Negative binomial distribution, Sample size calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Negative binomial distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
MSD_Sample_size_OF_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
  dist2
)
```

Arguments

r_t	Vector of mean rates of the test arms, one entry per dose or endpoint; the function returns NA if the largest log rate ratio is below 1e-4 or if any adjusted test arm rate r_t +/- margin is below 1e-4
r_c	Mean rate of the common control arm

margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control; 2 = otherwise. It has no effect here: the boundary calculation always uses dist1 = 2
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control; 2 = otherwise. It has no effect here: the information time calculation always uses dist2 = 1

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

Reference Reference for the negative binomial sample size formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_OF_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1),
alpha = 0.025, beta = 0.1, rand_ratio = 1, nu_t = 6, kappa = 1, dist1 = 1, dist2 = 1)
```

MSD_Sample_size_OF_boundary_normal

Multiple comparisons Group sequential design: Normal distribution, Sample size calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Normal distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
MSD_Sample_size_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Vector of means of the test arms, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
mu_c	Mean of the common control arm

std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_OF_boundary_normal( mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
 margin = 0.1, direction = 1, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1,
 dist1 = 1, dist2 = 1)
```

MSD_Sample_size_OF_boundary_poisson

Multiple comparisons Group sequential design: Poisson distribution, Sample size calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Poisson distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
MSD_Sample_size_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Vector of means (rates) of the test arms, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
lambda_c	Mean (rate) of the common control arm
margin	Non-inferiority margin; must be >= 0, set to 0 for a superiority trial and > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise
dist2	Distribution indicator for the second stage: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions; 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for a test arm; equal to rand_ratio times the control arm sample size

control arm sample size Sample size required for the common control arm

sample size for each dose in a two arm study with same critical boudary Vector with one test arm sample size per dose or endpoint, as if a separate two arm trial were conducted for that dose with the same critical boundary

sample size for control arm corresponding to each dose in a two arm study with same critical boudary Vector with the matching control arm sample size for each dose or endpoint

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_OF_boundary_poisson( lambda_t = 1.1, lambda_c = 1.0, margin = 0.1,
  direction = 1, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1, dist1 = 1,
  dist2 = 1)
```

MSD_Sample_size_OF_boundary_survival_Schoenfeld

Multiple comparisons Group sequential design: Survival analysis, Sample size calculation, O'Brien-Fleming boundary

---

Description

Multiple comparisons Group sequential design: Survival analysis, Sample size calculation, O'Brien-Fleming boundary

Usage

```
MSD_Sample_size_OF_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Vector of hazard ratios of the test arms vs. the control arm, one entry per dose or endpoint; the function returns NA if the largest effect size is below 1e-4
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial (0 < margin < 1 if larger HR is better, margin > 1 if smaller HR is better)
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage; dist1 = 2 is the conservative choice
dist2	Distribution indicator for the second stage; dist2 = 1 is the conservative choice

Value

A named list with the following components:

Combined number of events between a dose and control Total number of events, test arm and control arm combined, required for one dose vs. control comparison

total number of events from all doses and control Total number of events required for the whole trial, i.e. all doses and the common control arm

combined number of events in each dose and control in a two arm study with same critical boudary Vector with the combined number of events for each dose and its control, as if a separate two arm trial were conducted for that dose with the same critical boundary

Type I error control Boundary output of the closed testing procedure: a list with one element per comparison level (the M-level boundary first, down to the 1-level boundary), each element a list containing the vectors 'critical bounadry', 'alpha spent at each interim analysis', 'cumulative alpha' and 'nominal p-value' for the analyses

reference Reference for the Schoenfeld event number formula

References

P. Gao & Y. Li (2024) Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials, Journal of Biopharmaceutical Statistics, 34:3, 424-440, DOI:10.1080/10543406.2023.2233590. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2023.2233590

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
MSD_Sample_size_OF_boundary_survival_Schoenfeld( HR = 0.7, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`new_sample_size_hybrid`

Hybrid: New sample size estimation

Description

Hybrid: New sample size estimation

Usage

```
new_sample_size_hybrid(
  N_planned,
  c_bry,
  t_prior,
  theta_prior,
  N_inter,
  t_inter,
  theta_hat_inter,
  gamma,
  beta
)
```

Arguments

N_planned	Planned sample size: the planned sample size at the final analysis
c_bry	Critical boundary or threshold for rejecting the null hypothesis at the final analysis
t_prior	Prior information time: the prior distribution of theta is assumed to have a normal distribution, and the Fisher's information time is the reciprocal of the variance of the prior distribution; set t_prior = 0 for a non-informative prior
theta_prior	Mean effect size of prior: the mean of the normal prior distribution of theta; set theta_prior = 0 for a non-informative prior
N_inter	Sample size at interim analysis: the number of subjects with data at the interim analysis
t_inter	Information time at interim analysis: the Fisher information at the interim analysis, the reciprocal of the variance of the unbiased maximum likelihood estimate theta_hat_inter
theta_hat_inter	Estimated effect size at interim analysis: the maximum likelihood estimate of theta at the interim analysis
gamma	Parameter chosen for the credible interval modified predictive power (CI_MPP); it defines the (1 - gamma) credible interval of the posterior for theta, e.g. gamma = 0.5 gives a 50 percent interval
beta	Conditional type II error; 1 - beta is the target conditional power used for the sample size re-estimation

Value

A named list with the following components:

New sample sizes A data frame with the columns "prior type", "SSR method" and "new sample size", giving the new sample size for every combination of prior type and sample size re-estimation (SSR) method. The prior types are the non-informative prior (mean of the prior zero and information time zero) and the informative prior entered by the user. Within each prior type the four SSR methods are the conditional power (cp), the predictive power (pp), the modified predictive power (mpp) and the credible interval modified predictive power (ci_mpp),

each being the sample size that provides 1 - beta of that power; the sample size is NA when the target conditional power cannot be reached. For the informative prior the cp entry is based on the Bayesian posterior mean of theta

Reference References for the methods

References

Gao, P. Improving the effectiveness of sample size re-estimation: an operating characteristic focused, hybrid frequentist-Bayesian approach, Statistics in Medicine, 2025; 44:e10310. To link to this article: https://onlinelibrary.wiley.com/doi/10.1002/sim.10310.

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796.

C. R. Mehta, S. J. Pocock. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine. Volume30, Issue28, 10 December 2011, Pages 3267-3284

Examples

```
new_sample_size_hybrid(N_planned = 100, c_bry = 1.96, t_prior = 45, theta_prior = 0.5,
N_inter = 60, t_inter = 50, theta_hat_inter = 0.3, gamma = 0.5, beta = 0.1)
```

---

one_arm_ad_3_stg_binary

Single arm phase 2 oncology trial: Simulations: adaptive three stage design

---

Description

Single arm phase 2 oncology trial: Simulations: adaptive three stage design

Usage

```
one_arm_ad_3_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  n_2,
  r_2,
  r_2_e = NA,
  n_3,
  r_3,
  N_max,
```

```
  beta,
  sim_num
)
```

Arguments

p_1	Assumed response rate
p_0	Response rate indicating low activity with insufficient clinical benefit, i.e. the response rate under the null hypothesis
n_1	Number of patients at first look
r_1	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility
n_2	Number of patients at second look
r_2	If no more than r_2 responses are observed at the second look, then the trial would be stopped for futility
r_2_e	If at least r_2_e responses are observed at the second look, the trial would be stopped early for superiority; if r_2_e is not used in the design, enter NA
n_3	Number of patients at third look
r_3	If more than r_3 responses are observed at the third look, then the null hypothesis will be rejected
N_max	Maximum sample size for the trial
beta	Type II error rate, i.e. 1 - power
sim_num	Number of simulation replicates

Value

A named list with the following components:

rate of rejection– without continity correction Rate of rejection of the null hypothesis over the simulation replicates, using the response-count boundary without continuity correction

rejection rate with continuity correction Rate of rejection of the null hypothesis over the simulation replicates when the continuity correction is applied to the response-count boundary

Average sample size Average sample size over the simulation replicates, EN(p_1)

Rate of early termination for futility Rate of early termination for futility over the simulation replicates, PET(p_1)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
one_arm_ad_3_stg_binary(p_1=0.2,p_0=0.2,n_1=37,r_1=8,n_2=100,r_2=22,r_2_e=33,
n_3=105,r_3=29,N_max=150,beta=0.1,sim_num=20)
```

`one_arm_ad_two_stg_binary` *Single arm phase 2 oncology trial, Simulations: adaptive two stage design*

Description

Single arm phase 2 oncology trial, Simulations: adaptive two stage design

Usage

```
one_arm_ad_two_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  r_1_e = NA,
  n_2,
  r_2,
  N_max,
  beta,
  sim_num
)
```

Arguments

p_1	Assumed response rate
p_0	Response rate indicating low activity with insufficient clinical benefit, i.e. the response rate under the null hypothesis
n_1	Number of patients at first look
r_1	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility
r_1_e	If at least r_1_e responses are observed at the first look, the trial would be stopped early for superiority; if r_1_e is not used in the design, enter NA
n_2	Number of patients at second look
r_2	If more than r_2 responses are observed at the second look, then the null hypothesis will be rejected
N_max	Maximum sample size for the trial
beta	Type II error rate, i.e. 1 - power
sim_num	Number of simulation replicates

Value

A named list with the following components:

rate of rejection– without continity correction Rate of rejection of the null hypothesis over the simulation replicates, using the response-count boundary without continuity correction

rejection rate with continuity correction Rate of rejection of the null hypothesis over the simulation replicates when the continuity correction is applied to the response-count boundary

Average sample size Average sample size over the simulation replicates, EN(p_1)

Rate of early termination for futility Rate of early termination for futility over the simulation replicates, PET(p_1)

summary by case Matrix summarising the simulation results by case, with one column per case and one row per statistic: case rate, mean sample size, rejection rate, conditional power, proportion of replicates with p_hat > p_1, rejection rate using the critical boundary and corrected rejection rate

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
set.seed(1)
one_arm_ad_two_stg_binary(p_1 = 0.33, p_0 = 0.2, n_1 = 75, r_1 = 18, r_1_e = 26, n_2 = 80,
r_2 = 23, N_max = 140, beta = 0.1, sim_num = 20)
```

---

one_arm_rej_2_stg_binary

Single arm phase 2 oncology trial: Simulations, Two stage fixed expanded Simon's design: either hybrid or mid-point design

---

Description

Single arm phase 2 oncology trial: Simulations, Two stage fixed expanded Simon's design: either hybrid or mid-point design

Usage

```
one_arm_rej_2_stg_binary(p_1, p_0, n_1, r_1_f, r_1_e = NA, n_2, r_2, sim_num)
```

Arguments

p_1	Assumed response rate
p_0	Response rate indicating low activity with insufficient clinical benefit, i.e. the response rate under the null hypothesis
n_1	Number of patients at first look
r_1_f	If no more than r_1_f responses are observed at the first look, then the trial would be stopped for futility
r_1_e	If at least r_1_e responses are observed at the first look, the trial would be stopped early for superiority; if r_1_e is not used in the design, enter NA
n_2	Number of patients at second look
r_2	If more than r_2 responses are observed at the second look, then the null hypothesis will be rejected
sim_num	Number of simulation replicates

Value

A named list with the following components:

Rate of rejection Rate of rejection of the null hypothesis over the simulation replicates

Average sample size Average sample size over the simulation replicates, EN(p_1)

Rate of early termination for futility Rate of early termination for futility over the simulation replicates, PET(p_1)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
one_arm_rej_2_stg_binary(p_1=0.2,p_0=0.2,n_1=100,r_1_f=25,r_1_e=33,
n_2=105,r_2=29,sim_num=20)
```

`one_arm_rej_3_stg_binary` *Single arm phase 2 oncology trial: Simulations, Expanded Simon's design: the three stage design, no sample size change*

Description

Single arm phase 2 oncology trial: Simulations, Expanded Simon's design: the three stage design, no sample size change

Usage

```
one_arm_rej_3_stg_binary(
  p_1,
  p_0,
  n_1,
  r_1,
  n_2,
  r_2_f,
  r_2_e = NA,
  n_3,
  r_3,
  sim_num
)
```

Arguments

`p_1`	Assumed response rate
`p_0`	Response rate indicating low activity with insufficient clinical benefit, i.e. the response rate under the null hypothesis
`n_1`	Number of patients at first look
`r_1`	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility
`n_2`	Number of patients at second look
`r_2_f`	If no more than r_2_f responses are observed at the second look, then the trial would be stopped for futility
`r_2_e`	If at least r_2_e responses are observed at the second look, the trial would be stopped early for superiority; if r_2_e is not used in the design, enter NA
`n_3`	Number of patients at third look
`r_3`	If more than r_3 responses are observed at the third look, then the null hypothesis will be rejected
`sim_num`	Number of simulation replicates

Value

A named list with the following components:

Rate of rejection Rate of rejection of the null hypothesis over the simulation replicates

Average sample size Average sample size over the simulation replicates, EN(p_1)

Rate of early termination for futility Rate of early termination for futility over the simulation replicates, PET(p_1)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
one_arm_rej_3_stg_binary(p_1=0.2,p_0=0.2,n_1=37,r_1=8,n_2=100,r_2_f=22,r_2_e=33,
n_3=105,r_3=29,sim_num=20)
```

---

one_arm_rej_simon_binary

Single arm phase 2 oncology trial: Simulations: two stage fixed Simon's design

---

Description

Single arm phase 2 oncology trial: Simulations: two stage fixed Simon's design

Usage

```
one_arm_rej_simon_binary(p_1, p_0, n_1, r_1, n_2, r_2, sim_num)
```

Arguments

p_1	Assumed response rate
p_0	Response rate indicating low activity with insufficient clinical benefit, i.e. the response rate under the null hypothesis
n_1	Number of patients at first look
r_1	If no more than r_1 responses are observed at the first look, then the trial would be stopped for futility

n_2	Number of patients at second look
r_2	If more than r_2 responses are observed at the second look, then the null hypothesis will be rejected
sim_num	Number of simulation replicates

Value

A named list with the following components:

Rate of rejection Rate of rejection of the null hypothesis over the simulation replicates, i.e. the power when p_1 > p_0 and the type I error rate when p_1 = p_0

Average sample size Average sample size over the simulation replicates, EN(p_1)

Rate of early termination for futility Rate of early termination for futility over the simulation replicates, PET(p_1)

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

P. Gao, J.H. Ware, C. Mehta, (2008), Sample size re-estimation for adaptive sequential designs. Journal of Biopharmaceutical Statistics, 18: 1184–1196, 2008.

Examples

```
one_arm_rej_simon_binary(p_1=0.4,p_0=0.2,n_1=37,r_1=9,n_2=53,r_2=16,sim_num=20)
```

---

plot.ph2simon *Plot method for a Simon's two-stage phase II design*

Description

Plot method for a Simon's two-stage phase II design

Usage

```
## S3 method for class 'ph2simon'
plot(x, ...)
```

Arguments

x	An object of class 'ph2simon', as returned by the internal 'ph2simon' helper
...	Further graphical arguments passed to 'plot'

Value

'NULL', invisibly. Called for the side effect of drawing the expected-sample-size curve.

`power_alsp_boundary_binary_diff` *Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, Alpha-spending boundary*

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_binary_diff(
  p_t,
  p_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_binary_diff(p_t = 0.2, p_c = 0.6, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), sampsz_control = 27, rand_ratio = 1)
```

`power_alsp_boundary_binary_diff_NI`

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1

alpha	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_binary_diff_NI(p_t = 0.2, p_c = 0.6, margin = 0.15, direction = 1,
s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), sampsz_control = 14, rand_ratio = 1)
```

---

power_alsp_boundary_neg_binomial

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_alsp_boundary_neg_binomial(r_t = 1, r_c = 0.8, s = 1, alpha_2 = 0.05,
sampsz_control = 897, rand_ratio = 1, nu_t = 1, kappa = 1)
```

`power_alsp_boundary_neg_binomial_NI`

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

`r_t`	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
`r_c`	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
`sampsz_control`	Sample size of the control arm

rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_alsp_boundary_neg_binomial_NI(r_t = 1, r_c = 0.8, margin = 0, direction = 1, s = 1,
alpha = 0.025, sampsz_control = 897, rand_ratio = 1, nu_t = 1, kappa = 1)
```

---

power_alsp_boundary_normal

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
  sampsz_control,
  rand_ratio,
  alpha_2
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_normal(mu_t = 0.2, mu_c = 0, std_t = 1, std_c = 1, s = c(1/3,2/3,1),
sampsz_control = 527, rand_ratio = 1, alpha_2 = c(0.001,0.001,0.048))
```

`power_alsp_boundary_normal_NI`

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  sampsz_control,
  rand_ratio,
  alpha
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`std_t`	Standard deviation of the test arm; must be > 0
`std_c`	Standard deviation of the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
`alpha`	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_normal_NI(mu_t = 0.2, mu_c = 0, std_t = 1, std_c = 1, margin = 0.15,
direction = 1, s = c(1/3,2/3,1), sampsz_control = 534, rand_ratio = 1,
alpha = c(0.001,0.001,0.023))
```

---

power_alsp_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_poisson(lambda_t = 0.2, lambda_c = 0.4, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), sampsz_control = 158, rand_ratio = 1)
```

---

power_alsp_boundary_poisson_NI

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_alsp_boundary_poisson_NI(lambda_t = 0.2, lambda_c = 0.4, margin = 0.15, direction = 1,
s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), sampsz_control = 52, rand_ratio = 1)
```

---

power_alsp_boundary_survival_Schoenfeld

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_survival_Schoenfeld(HR, s, events_tot, alpha_2, rand_ratio)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
events_tot	Total number of events across both the test arm and the control arm
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_alsp_boundary_survival_Schoenfeld(HR = 0.8, s = c(0.5,1), events_tot = 841,
alpha_2 = c(0.001,0.0499), rand_ratio = 1)
```

`power_alsp_boundary_survival_Schoenfeld_NI`

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, Alpha-spending boundary

Usage

```
power_alsp_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  events_tot,
  alpha,
  rand_ratio
)
```

Arguments

`HR`	Hazard ratio of the test arm vs. the control arm; must be > 0
`margin`	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
`direction`	Test direction: 1 = larger HR is better, otherwise smaller HR is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`events_tot`	Total number of events across both the test arm and the control arm
`alpha`	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_alsp_boundary_survival_Schoenfeld_NI(HR = 0.8, margin = 1.1, direction = 1, s = c(0.5,1),
events_tot = 416, alpha = c(0.001,0.024), rand_ratio = 1)
```

---

power_binary_diff *Fixed sample designs: Binary distribution, Superiority trial, Power calculation*

Description

Fixed sample designs: Binary distribution, Superiority trial, Power calculation

Usage

```
power_binary_diff(p_t, p_c, alpha_2, n_control, rand_ratio)
```

Arguments

p_t	Event rate of the test arm; 0 < p_t < 1
p_c	Event rate of the control arm; 0 < p_c < 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_binary_diff(p_t = 0.4, p_c = 0.3, alpha_2 = 0.05, n_control = 53, rand_ratio = 1)
```

`power_binary_diff_NI` *Fixed sample designs: Binary distribution, Non-inferiority trial, Power calculation*

Description

Fixed sample designs: Binary distribution, Non-inferiority trial, Power calculation

Usage

```
power_binary_diff_NI(p_t, p_c, margin, direction, alpha, n_control, rand_ratio)
```

Arguments

`p_t`	Event rate of the test arm; 0 < p_t < 1
`p_c`	Event rate of the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; set to 0 for a superiority trial
`direction`	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`n_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_binary_diff_NI(p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 0, alpha = 0.025,
n_control = 53, rand_ratio = 1)
```

power_OF_boundary_binary_diff *Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary*

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_binary_diff(p_t, p_c, s, alpha_2, sampsz_control, rand_ratio)
```

Arguments

p_t	Response rate (probability of response) in the test arm; 0 < p_t < 1
p_c	Response rate (probability of response) in the control arm; 0 < p_c < 1
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_binary_diff(p_t = 0.4, p_c = 0.3, s = c(1/3, 2/3, 1), alpha_2 = 0.05,
sampsz_control = 100, rand_ratio = 1)
```

power_OF_boundary_binary_diff_NI

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

p_t	Response rate (probability of response) in the test arm; 0 < p_t < 1
p_c	Response rate (probability of response) in the control arm; 0 < p_c < 1
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_binary_diff_NI(p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1)
```

`power_OF_boundary_neg_binomial`

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

`r_t`	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
`r_c`	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_OF_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, sampsz_control = 100, rand_ratio = 1, nu_t = 6, kappa = 1)
```

---

power_OF_boundary_neg_binomial_NI

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_OF_boundary_neg_binomial_NI(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1,
nu_t = 6, kappa = 1)
```

`power_OF_boundary_normal`

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
  sampsz_control,
  rand_ratio,
  alpha_2
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`std_t`	Standard deviation of the test arm; must be > 0
`std_c`	Standard deviation of the control arm; must be > 0
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_normal(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86, s = c(1/3, 2/3, 1),
sampsz_control = 100, rand_ratio = 1, alpha_2 = 0.05)
```

---

power_OF_boundary_normal_NI

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  sampsz_control,
  rand_ratio,
  alpha
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha	Type I error for the one-sided test; 0 < alpha < 1

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_normal_NI(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), sampsz_control = 100, rand_ratio = 1, alpha = 0.025)
```

power_OF_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_poisson(lambda_t = 1.1, lambda_c = 1.0, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, sampsz_control = 100, rand_ratio = 1)
```

`power_OF_boundary_poisson_NI`

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

`lambda_t`	Event rate (mean number of events) in the test arm; must be > 0
`lambda_c`	Event rate (mean number of events) in the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_OF_boundary_poisson_NI(lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1)
```

---

power_OF_boundary_survival_Schoenfeld

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_survival_Schoenfeld(HR, s, events_tot, alpha_2, rand_ratio)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
events_tot	Total number of events across both the test arm and the control arm
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_OF_boundary_survival_Schoenfeld(HR = 0.7, s = c(1/3, 2/3, 1), events_tot = 100,
alpha_2 = 0.05, rand_ratio = 1)
```

---

power_OF_boundary_survival_Schoenfeld_NI

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, O'Brien-Fleming boundary

Usage

```
power_OF_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  events_tot,
  alpha,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
events_tot	Total number of events across both the test arm and the control arm
alpha	Type I error for the one-sided test; 0 < alpha < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_OF_boundary_survival_Schoenfeld_NI(HR = 0.7, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), events_tot = 100, alpha = 0.025, rand_ratio = 1)
```

power_pocock_boundary_binary_diff *Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, Pocock boundary*

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_binary_diff(
  p_t,
  p_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio
)
```

Arguments

p_t	Response rate (probability of response) in the test arm; 0 < p_t < 1
p_c	Response rate (probability of response) in the control arm; 0 < p_c < 1
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_binary_diff(p_t = 0.4, p_c = 0.3, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, sampsz_control = 100, rand_ratio = 1)
```

`power_pocock_boundary_binary_diff_NI`

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_binary_diff_NI(p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1)
```

---

power_pocock_boundary_neg_binomial

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_pocock_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, sampsz_control = 100, rand_ratio = 1, nu_t = 6, kappa = 1)
```

power_pocock_boundary_neg_binomial_NI

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, Pocock boundary

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Examples

```
power_pocock_boundary_neg_binomial_NI(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1,
nu_t = 6, kappa = 1)
```

---

power_pocock_boundary_normal

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
  sampsz_control,
  rand_ratio,
  alpha_2
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_normal(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
s = c(1/3, 2/3, 1), sampsz_control = 100, rand_ratio = 1, alpha_2 = 0.05)
```

---

power_pocock_boundary_normal_NI

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  sampsz_control,
  rand_ratio,
  alpha
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
alpha	Type I error for the one-sided test; 0 < alpha < 1

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_normal_NI(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
margin = 0.1, direction = 0, s = c(1/3, 2/3, 1), sampsz_control = 100,
rand_ratio = 1, alpha = 0.025)
```

---

power_pocock_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  sampsz_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_poisson(lambda_t = 1.1, lambda_c = 1.0, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, sampsz_control = 100, rand_ratio = 1)
```

---

power_pocock_boundary_poisson_NI

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1

alpha	Type I error for the one-sided test; 0 < alpha < 1
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Examples

```
power_pocock_boundary_poisson_NI(lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1)
```

---

power_pocock_boundary_survival_Schoenfeld

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_survival_Schoenfeld(
  HR,
  s,
  events_tot,
  alpha_2,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
events_tot	Total number of events across both the test arm and the control arm
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_pocock_boundary_survival_Schoenfeld(HR = 0.7, s = c(1/3, 2/3, 1), events_tot = 100,
alpha_2 = 0.05, rand_ratio = 1)
```

---

power_pocock_boundary_survival_Schoenfeld_NI

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Power calculation, Pocock boundary

Usage

```
power_pocock_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  events_tot,
  alpha,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
events_tot	Total number of events across both the test arm and the control arm
alpha	Type I error for the one-sided test; 0 < alpha < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

power The achieved power

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Examples

```
power_pocock_boundary_survival_Schoenfeld_NI(HR = 0.7, margin = 0.1, direction = 0,
s = c(1/3, 2/3, 1), events_tot = 100, alpha = 0.025, rand_ratio = 1)
```

power_two_sample_neg_binomial *Fixed sample designs: Negative binomial distribution, Superiority trial, Power calculation*

Description

Fixed sample designs: Negative binomial distribution, Superiority trial, Power calculation

Usage

```
power_two_sample_neg_binomial(
  r_t,
  r_c,
  alpha_2,
  n_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate of the test arm for the negative binomial endpoint; must be > 0
r_c	Event rate of the control arm for the negative binomial endpoint; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time of the test arm; the Poisson part of the variance of the log rate ratio is (1 / nu_t) * (1 / r_c + 1 / (rand_ratio * r_t)), so nu_t must be > 0
kappa	Dispersion parameter of the negative binomial model; adds the over-dispersion term (1 + rand_ratio) * kappa / rand_ratio to the variance of the log rate ratio; must be > 0

Value

A named list with the following components:

power Power of the two-sided test of r_t = r_c

Reference Character string giving the reference for the Zhu and Lakkis sample size formula

Examples

```
power_two_sample_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, alpha_2 = 0.05,
n_control = 53, rand_ratio = 1, nu_t = 6, kappa = 1)
```

power_two_sample_neg_binomial_NI *Fixed sample designs: Negative binomial distribution, Non-inferiority trial, Power calculation*

Description

Fixed sample designs: Negative binomial distribution, Non-inferiority trial, Power calculation

Usage

```
power_two_sample_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  alpha,
  n_control,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate of the test arm for the negative binomial endpoint; must be > 0
r_c	Event rate of the control arm for the negative binomial endpoint; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha	Type I error for the one-sided test; 0 < alpha < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time of the test arm; the Poisson part of the variance of the log rate ratio is (1 / nu_t) * (1 / r_c + 1 / (rand_ratio * r_t)), so nu_t must be > 0
kappa	Dispersion parameter of the negative binomial model; adds the over-dispersion term (1 + rand_ratio) * kappa / rand_ratio to the variance of the log rate ratio; must be > 0

Value

A named list with the following components:

power Power of the non-inferiority test comparing the event rates with the margin

Reference Character string giving the reference for the Zhu and Lakkis sample size formula

Examples

```
power_two_sample_neg_binomial_NI(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1, direction = 0,
alpha = 0.025, n_control = 53, rand_ratio = 1, nu_t = 6, kappa = 1)
```

---

power_two_sample_normal

Fixed sample designs: Normal distribution, Superiority trial, Power calculation

---

Description

Fixed sample designs: Normal distribution, Superiority trial, Power calculation

Usage

```
power_two_sample_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  alpha_2,
  n_control,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arm; must be > 0
sigma_c	Standard deviation of the control arm; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_two_sample_normal(mu_t = 2.6, mu_c = 0.6, sigma_t = 9.43, sigma_c = 9.86,
alpha_2 = 0.05, n_control = 53, rand_ratio = 1)
```

power_two_sample_normal_NI

Fixed sample designs: Normal distribution, Non-inferiority trial, Power calculation

Description

Fixed sample designs: Normal distribution, Non-inferiority trial, Power calculation

Usage

```
power_two_sample_normal_NI(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  margin,
  direction,
  alpha,
  n_control,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arm; must be > 0
sigma_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha	Type I error for the one-sided test; 0 < alpha < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_two_sample_normal_NI( mu_t = 2.6, mu_c = 0.6, sigma_t = 9.43, sigma_c = 9.86,
  margin = 0.1, direction = 1, alpha = 0.025, n_control = 53, rand_ratio = 1)
```

power_two_sample_Poisson *Fixed sample designs: Poisson distribution, Superiority trial, Power calculation*

Description

Fixed sample designs: Poisson distribution, Superiority trial, Power calculation

Usage

```
power_two_sample_Poisson(lambda_t, lambda_c, alpha_2, n_control, rand_ratio)
```

Arguments

lambda_t	Event rate of the test arm under the Poisson model; must be > 0
lambda_c	Event rate of the control arm under the Poisson model; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_two_sample_Poisson(lambda_t = 1.1, lambda_c = 1.0, alpha_2 = 0.05,
n_control = 53, rand_ratio = 1)
```

power_two_sample_Poisson_NI *Fixed sample designs: Poisson distribution, Non-inferiority trial, Power calculation*

Description

Fixed sample designs: Poisson distribution, Non-inferiority trial, Power calculation

Usage

```
power_two_sample_Poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  alpha,
  n_control,
  rand_ratio
)
```

Arguments

lambda_t	Event rate of the test arm under the Poisson model; must be > 0
lambda_c	Event rate of the control arm under the Poisson model; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha	Type I error for the one-sided test; 0 < alpha < 1
n_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A numeric value giving the power.

Examples

```
power_two_sample_Poisson_NI(lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 0,
alpha = 0.025, n_control = 53, rand_ratio = 1)
```

---

power_two_sample_surv_Schoenfeld

Fixed sample designs: Survival analysis, Superiority trial, Power calculation

---

Description

Fixed sample designs: Survival analysis, Superiority trial, Power calculation

Usage

```
power_two_sample_surv_Schoenfeld(HR, alpha_2, event_tot, rand_ratio)
```

Arguments

HR	Hazards ratio of test arm vs. the control arm; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
event_tot	Total number of events across both arms
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Power Power of the two-sided test of HR = 1

Reference Character string giving the reference for the Schoenfeld sample size formula

Examples

```
power_two_sample_surv_Schoenfeld(HR = 0.7, alpha_2 = 0.05, event_tot = 100, rand_ratio = 1)
```

---

power_two_sample_surv_Schoenfeld_NI

Fixed sample designs: Survival analysis, Non-inferiority trial, Power calculation

---

Description

Fixed sample designs: Survival analysis, Non-inferiority trial, Power calculation

Usage

```
power_two_sample_surv_Schoenfeld_NI(
  HR,
  margin,
  direction,
  alpha,
  event_tot,
  rand_ratio
)
```

Arguments

HR	Hazards ratio of test arm vs. the control arm; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better

alpha	Type I error for the one-sided test; 0 < alpha < 1
event_tot	Total number of events across both arms
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Power Power of the non-inferiority test comparing the hazard ratio with the margin

Reference Character string giving the reference for the Schoenfeld sample size formula

Examples

```
power_two_sample_surv_Schoenfeld_NI(HR = 0.7, margin = 0.1, direction = 0, alpha = 0.025,
event_tot = 100, rand_ratio = 1)
```

---

print.ph2simon *Print method for a Simon's two-stage phase II design*

Description

Print method for a Simon's two-stage phase II design

Usage

```
## S3 method for class 'ph2simon'
print(x, ...)
```

Arguments

x	An object of class 'ph2simon', as returned by the internal 'ph2simon' helper
...	Further arguments passed to 'print'

Value

'NULL', invisibly, or the warning message, invisibly, if the optimal sample size is too close to 'nmax'. Called for the side effect of printing the optimal and minimax designs.

`Sample_size_alsp_boundary_binary_diff`

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_binary_diff(p_t, p_c, s, alpha_2, beta, rand_ratio)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_alsp_boundary_binary_diff(p_t = 0.2, p_c = 0.6, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), beta = 0.1, rand_ratio = 1)
```

`Sample_size_alsp_boundary_binary_diff_NI`

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_alsp_boundary_binary_diff_NI( p_t = 0.2, p_c = 0.6, margin = 0.15, direction = 2,
  s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1)
```

Sample_size_alsp_boundary_neg_binomial

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_alsp_boundary_neg_binomial(r_t = 0.2, r_c = 0.4, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

Sample_size_alsp_boundary_neg_binomial_NI

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_alsp_boundary_neg_binomial_NI( r_t = 0.2, r_c = 0.4, margin = 0.1, direction = 2,
  s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1, nu_t = 1,
  kappa = 1)
```

Sample_size_alsp_boundary_normal

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
```

```
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_alsp_boundary_normal(mu_t = 0.2, mu_c = 0, std_t = 1, std_c = 1, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), beta = 0.1, rand_ratio = 1)
```

Sample_size_alsp_boundary_normal_NI

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_alsp_boundary_normal_NI( mu_t = 0.2, mu_c = 0, std_t = 1, std_c = 1, margin = 0.15,
  direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1)
```

Sample_size_alsp_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_alsp_boundary_poisson(lambda_t = 0.2, lambda_c = 0.4, s = c(1/3,2/3,1),
alpha_2 = c(0.001,0.001,0.048), beta = 0.1, rand_ratio = 1)
```

`Sample_size_alsp_boundary_poisson_NI`

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`lambda_t`	Event rate (mean number of events) in the test arm; must be > 0
`lambda_c`	Event rate (mean number of events) in the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_alsp_boundary_poisson_NI( lambda_t = 0.2, lambda_c = 0.4, margin = 0.15,
 direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1)
```

`Sample_size_alsp_boundary_survival_Schoenfeld`

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_survival_Schoenfeld(HR, s, alpha_2, beta, rand_ratio)
```

Arguments

`HR`	Hazard ratio of the test arm vs. the control arm; must be > 0
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test, entered for the alpha-spending boundary as the vector of the two-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha_2
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_alsp_boundary_survival_Schoenfeld(HR = 0.59, s = c(0.596,1),
alpha_2 = c(0.001,0.0249), beta = 0.1, rand_ratio = 1)
```

Sample_size_alsp_boundary_survival_Schoenfeld_NI

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, Alpha-spending boundary

Usage

```
Sample_size_alsp_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test, entered for the alpha-spending boundary as the vector of the one-sided alpha-spending values alpha_1, ..., alpha_K at the K analyses; each element must be > 0 and the elements must sum to alpha
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when HR is not on the required side of margin for the specified direction.

Examples

```
Sample_size_alsp_boundary_survival_Schoenfeld_NI( HR = 0.59, margin = 1, direction = 2,
  s = c(0.596,1), alpha = c(0.005,0.02), beta = 0.1, rand_ratio = 1)
```

sample_size_binary_diff

Fixed sample designs: Binary distribution, Superiority trial, Sample size calculation

Description

Fixed sample designs: Binary distribution, Superiority trial, Sample size calculation

Usage

```
sample_size_binary_diff(p_t, p_c, alpha_2, beta, rand_ratio)
```

Arguments

p_t	Event rate of the test arm; 0 < p_t < 1
p_c	Event rate of the control arm; 0 < p_c < 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for control arm Sample size required for the control arm

sample size for experimental arm Sample size required for the experimental (test) arm

Examples

```
sample_size_binary_diff(p_t = 0.2, p_c = 0.4, alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

sample_size_binary_diff_NI

Fixed sample designs: Binary distribution, Non-inferiority trial, Sample size calculation

Description

Fixed sample designs: Binary distribution, Non-inferiority trial, Sample size calculation

Usage

```
sample_size_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

p_t	Event rate of the test arm; 0 < p_t < 1
p_c	Event rate of the control arm; 0 < p_c < 1
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for control arm Sample size required for the control arm

sample size for experimental arm Sample size required for the experimental (test) arm

Examples

```
sample_size_binary_diff_NI( p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 1, alpha = 0.025,
  beta = 0.1, rand_ratio = 1)
```

---

sample_size_neg_binomial

Fixed sample designs: Negative binomial distribution, Superiority trial, Sample size calculation

---

Description

Fixed sample designs: Negative binomial distribution, Superiority trial, Sample size calculation

Usage

```
sample_size_neg_binomial(r_t, r_c, alpha_2, beta, rand_ratio, nu_t, kappa)
```

Arguments

r_t	Event rate of the test arm for the negative binomial endpoint; must be > 0
r_c	Event rate of the control arm for the negative binomial endpoint; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time of the test arm; the Poisson part of the variance of the log rate ratio is (1 / nu_t) * (1 / r_c + 1 / (rand_ratio * r_t)), so nu_t must be > 0
kappa	Dispersion parameter of the negative binomial model; adds the over-dispersion term (1 + rand_ratio) * kappa / rand_ratio to the variance of the log rate ratio; must be > 0

Value

A named list with the following components:

Standardized effect size Standardized effect size, i.e. the absolute log rate ratio divided by the square root of the variance

Sample size for test arm Sample size required for the test (experimental) arm

Sample size for control arm Sample size required for the control arm

Reference Character string giving the reference for the Zhu and Lakkis sample size formula

Examples

```
sample_size_neg_binomial(r_t = 0.85, r_c = 1.25, alpha_2 = 0.05, beta = 0.2, rand_ratio = 1,
nu_t = 1, kappa = 1)
```

---

sample_size_neg_binomial_NI

Fixed sample designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation

---

Description

Fixed sample designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation

Usage

```
sample_size_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate of the test arm for the negative binomial endpoint; must be > 0
r_c	Event rate of the control arm for the negative binomial endpoint; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time of the test arm; the Poisson part of the variance of the log rate ratio is (1 / nu_t) * (1 / r_c + 1 / (rand_ratio * r_t)), so nu_t must be > 0
kappa	Dispersion parameter of the negative binomial model; adds the over-dispersion term (1 + rand_ratio) * kappa / rand_ratio to the variance of the log rate ratio; must be > 0

Value

A named list with the following components:

Standardized effect size Standardized effect size, i.e. the absolute log rate ratio divided by the square root of the variance

Sample size for test arm Sample size required for the test (experimental) arm

Sample size for control arm Sample size required for the control arm

Reference Character string giving the reference for the Zhu and Lakkis sample size formula

Examples

```
sample_size_neg_binomial_NI(r_t = 0.9, r_c = 1, margin = 0.3, direction = 1, alpha = 0.025,
beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

`Sample_size_OF_boundary_binary_diff`
Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_binary_diff(p_t, p_c, s, alpha_2, beta, rand_ratio)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_OF_boundary_binary_diff(p_t = 0.4, p_c = 0.3, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_OF_boundary_binary_diff_NI`

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_OF_boundary_binary_diff_NI( p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_OF_boundary_neg_binomial

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_OF_boundary_neg_binomial(r_t = 0.2, r_c = 0.4, s = c(1/3,2/3,1), alpha_2 = 0.05,
beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

Sample_size_OF_boundary_neg_binomial_NI

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_OF_boundary_neg_binomial_NI( r_t = 0.2, r_c = 0.4, margin = 0.1, direction = 2,
  s = c(1/3,2/3,1), alpha = 0.025, beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

Sample_size_OF_boundary_normal

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_OF_boundary_normal(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
s = c(1/3, 2/3, 1), alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_OF_boundary_normal_NI` *Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary*

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`std_t`	Standard deviation of the test arm; must be > 0
`std_c`	Standard deviation of the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_OF_boundary_normal_NI( mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
  margin = 0.1, direction = 1, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_OF_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_OF_boundary_poisson(lambda_t = 1.1, lambda_c = 1.0, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_OF_boundary_poisson_NI`
Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`lambda_t`	Event rate (mean number of events) in the test arm; must be > 0
`lambda_c`	Event rate (mean number of events) in the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_OF_boundary_poisson_NI( lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_OF_boundary_survival_Schoenfeld

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_survival_Schoenfeld(HR, s, alpha_2, beta, rand_ratio)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_OF_boundary_survival_Schoenfeld(HR = 0.7, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

Sample_size_OF_boundary_survival_Schoenfeld_NI

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, O'Brien-Fleming boundary

Usage

```
Sample_size_OF_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when HR is not on the required side of margin for the specified direction.

Examples

```
Sample_size_OF_boundary_survival_Schoenfeld_NI( HR = 0.7, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

`Sample_size_pocock_boundary_binary_diff`
Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, Pocock boundary

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Superiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_binary_diff(p_t, p_c, s, alpha_2, beta, rand_ratio)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_pocock_boundary_binary_diff(p_t = 0.4, p_c = 0.3, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_pocock_boundary_binary_diff_NI`

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Binary distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_binary_diff_NI(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`p_t`	Response rate (probability of response) in the test arm; 0 < p_t < 1
`p_c`	Response rate (probability of response) in the control arm; 0 < p_c < 1
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_pocock_boundary_binary_diff_NI( p_t = 0.4, p_c = 0.3, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_pocock_boundary_neg_binomial

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Superiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_neg_binomial(
  r_t,
  r_c,
  s,
  alpha_2,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_pocock_boundary_neg_binomial(r_t = 0.2, r_c = 0.4, s = c(1/3,2/3,1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

Sample_size_pocock_boundary_neg_binomial_NI

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Description

Group sequential designs / Adaptive sequential designs: Negative binomial distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_neg_binomial_NI(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa
)
```

Arguments

r_t	Event rate (mean number of events per unit of exposure time) in the test arm; must be > 0
r_c	Event rate (mean number of events per unit of exposure time) in the control arm; must be > 0
margin	Non-inferiority margin; must be > 0
direction	Test direction: 1 = larger r_t is better, otherwise smaller r_t is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time (follow-up time) of each subject, used to convert the number of events into a rate; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Reference Reference for the sample size formula (Zhu and Lakkis, 2014)

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_pocock_boundary_neg_binomial_NI( r_t = 0.2, r_c = 0.4, margin = 0.1, direction = 2,
  s = c(1/3,2/3,1), alpha = 0.025, beta = 0.1, rand_ratio = 1, nu_t = 1, kappa = 1)
```

Sample_size_pocock_boundary_normal

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Superiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

mu_t	Mean of the test arm
mu_c	Mean of the control arm
std_t	Standard deviation of the test arm; must be > 0
std_c	Standard deviation of the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_pocock_boundary_normal(mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
s = c(1/3, 2/3, 1), alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_pocock_boundary_normal_NI` *Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, Pocock boundary*

Description

Group sequential designs / Adaptive sequential designs: Normal distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_normal_NI(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`std_t`	Standard deviation of the test arm; must be > 0
`std_c`	Standard deviation of the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger mu is better, otherwise smaller mu is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_pocock_boundary_normal_NI( mu_t = 2.6, mu_c = 0.6, std_t = 9.43, std_c = 9.86,
  margin = 0.1, direction = 1, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_pocock_boundary_poisson

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Superiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_poisson(
  lambda_t,
  lambda_c,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

lambda_t	Event rate (mean number of events) in the test arm; must be > 0
lambda_c	Event rate (mean number of events) in the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_pocock_boundary_poisson(lambda_t = 0.2, lambda_c = 0.4, s = c(1/3,2/3,1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

`Sample_size_pocock_boundary_poisson_NI`
Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Description

Group sequential designs / Adaptive sequential designs: Poisson distribution, Non-inferiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`lambda_t`	Event rate (mean number of events) in the test arm; must be > 0
`lambda_c`	Event rate (mean number of events) in the control arm; must be > 0
`margin`	Non-inferiority margin; must be > 0
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power; 0 < beta < 1
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

Returns NA when the implied effect size is not positive.

Examples

```
Sample_size_pocock_boundary_poisson_NI( lambda_t = 1.1, lambda_c = 1.0, margin = 0.1,
  direction = 1, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

Sample_size_pocock_boundary_survival_Schoenfeld

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Superiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_survival_Schoenfeld(
  HR,
  s,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when the two arms have the same endpoint parameter.

Examples

```
Sample_size_pocock_boundary_survival_Schoenfeld(HR = 0.7, s = c(1/3, 2/3, 1),
alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

Sample_size_pocock_boundary_survival_Schoenfeld_NI

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, Pocock boundary

---

Description

Group sequential designs / Adaptive sequential designs: Survival analysis, Non-inferiority trial, Sample size calculation, Pocock boundary

Usage

```
Sample_size_pocock_boundary_survival_Schoenfeld_NI(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

HR	Hazard ratio of the test arm vs. the control arm; must be > 0
margin	Non-inferiority margin on the hazard ratio scale; must be > 0, with HR > margin required when direction is 1 and HR < margin required otherwise
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

total number of events Total number of events required across both the test arm and the control arm

Critical boundaries Critical boundaries c_1, ..., c_K at the K analyses

1-sided nominal alpha One-sided nominal alpha at each analysis

1-sided alpha spending One-sided alpha spending at each analysis

1-sided cummulative alpha One-sided cumulative alpha spending at each analysis

1-sided sum_nom_alpha Sum of the one-sided nominal alphas

2-sided nominal alpha Two-sided nominal alpha at each analysis

2-sided alpha spending Two-sided alpha spending at each analysis

2-sided cummulative alpha Two-sided cumulative alpha spending at each analysis

2-sided sum_nom_alpha Sum of the two-sided nominal alphas

reference Reference for the sample size formula (Schoenfeld, 1983)

Returns NA when HR is not on the required side of margin for the specified direction.

Examples

```
Sample_size_pocock_boundary_survival_Schoenfeld_NI( HR = 0.7, margin = 0.1, direction = 1,
  s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

`sample_size_two_sample_normal` *Fixed sample designs: Normal distribution, Superiority trial, Sample size calculation*

Description

Fixed sample designs: Normal distribution, Superiority trial, Sample size calculation

Usage

```
sample_size_two_sample_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`sigma_t`	Standard deviation of the test arm; must be > 0
`sigma_c`	Standard deviation of the control arm; must be > 0
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1
`beta`	Type II error rate, i.e. 1 - power
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for control arm Sample size required for the control arm

Sample size for test arm Sample size required for the test arm

Examples

```
sample_size_two_sample_normal(mu_t = 2, mu_c = 0, sigma_t = 9.79, sigma_c = 9.79,
alpha_2 = 0.05, beta = 0.2, rand_ratio = 1)
```

`sample_size_two_sample_normal_NI` *Fixed sample designs: Normal distribution, Non-inferiority trial, Sample size calculation*

Description

Fixed sample designs: Normal distribution, Non-inferiority trial, Sample size calculation

Usage

```
sample_size_two_sample_normal_NI(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  margin,
  direction,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`mu_t`	Mean of the test arm
`mu_c`	Mean of the control arm
`sigma_t`	Standard deviation of the test arm; must be > 0
`sigma_c`	Standard deviation of the control arm; must be > 0
`margin`	Non-inferiority margin; set to 0 for a superiority trial
`direction`	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for control arm Sample size required for the control arm

Sample size for test arm Sample size required for the test arm

Examples

```
sample_size_two_sample_normal_NI(mu_t = 2, mu_c = 2.5, sigma_t = 9.79, sigma_c = 9.79,
margin = 0.2, direction = 2, alpha = 0.05, beta = 0.2, rand_ratio = 1)
```

---

sample_size_two_sample_Poisson

Fixed sample designs: Poisson distribution, Superiority trial, Sample size calculation

---

Description

Fixed sample designs: Poisson distribution, Superiority trial, Sample size calculation

Usage

```
sample_size_two_sample_Poisson(lambda_t, lambda_c, alpha_2, beta, rand_ratio)
```

Arguments

lambda_t	Event rate of the test arm under the Poisson model; must be > 0
lambda_c	Event rate of the control arm under the Poisson model; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for experimental arm Sample size required for the experimental (test) arm

Sample size for control arm Sample size required for the control arm

Examples

```
sample_size_two_sample_Poisson(lambda_t = 1.1, lambda_c = 1.0, alpha_2 = 0.05,
beta = 0.1, rand_ratio = 1)
```

`sample_size_two_sample_Poisson_NI` *Fixed sample designs: Poisson distribution, Non-inferiority trial, Sample size calculation*

Description

Fixed sample designs: Poisson distribution, Non-inferiority trial, Sample size calculation

Usage

```
sample_size_two_sample_Poisson_NI(
  lambda_t,
  lambda_c,
  margin,
  direction,
  alpha,
  beta,
  rand_ratio
)
```

Arguments

`lambda_t`	Event rate of the test arm under the Poisson model; must be > 0
`lambda_c`	Event rate of the control arm under the Poisson model; must be > 0
`margin`	Non-inferiority margin; set to 0 for a superiority trial
`direction`	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
`alpha`	Type I error for the one-sided test; 0 < alpha < 1
`beta`	Type II error rate, i.e. 1 - power
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Sample size for experimental arm Sample size required for the experimental (test) arm

Sample size for control arm Sample size required for the control arm

Examples

```
sample_size_two_sample_Poisson_NI( lambda_t = 1.1, lambda_c = 1.0, margin = 0.1, direction = 1,
  alpha = 0.025, beta = 0.1, rand_ratio = 1)
```

sample_size_two_sample_surv_Schoenfeld

Fixed sample designs: Survival analysis, Superiority trial, Sample size calculation

Description

Fixed sample designs: Survival analysis, Superiority trial, Sample size calculation

Usage

```
sample_size_two_sample_surv_Schoenfeld(HR, alpha_2, beta, rand_ratio)
```

Arguments

HR	Hazards ratio of test arm vs. the control arm; must be > 0
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Total number of events Total number of events required for the two-arm comparison

Reference Character string giving the reference for the Schoenfeld sample size formula

Examples

```
sample_size_two_sample_surv_Schoenfeld(HR = 0.7, alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

sample_size_two_sample_surv_Schoenfeld_NI

Fixed sample designs: Survival analysis, Non-inferiority trial, Sample size calculation

Description

Fixed sample designs: Survival analysis, Non-inferiority trial, Sample size calculation

Usage

```
sample_size_two_sample_surv_Schoenfeld_NI(
  HR,
  margin,
  direction,
  alpha_2,
  beta,
  rand_ratio
)
```

Arguments

HR	Hazards ratio of test arm vs. the control arm; must be > 0
margin	Non-inferiority margin; set to 0 for a superiority trial
direction	Test direction: 1 = larger values of the endpoint parameter are better, otherwise smaller values are better
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
beta	Type II error rate, i.e. 1 - power
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

Value

A named list with the following components:

Total number of events Total number of events required for the two-arm comparison

Reference Character string giving the reference for the Schoenfeld sample size formula

Examples

```
sample_size_two_sample_surv_Schoenfeld_NI( HR = 0.7, margin = 0.1, direction = 1,
  alpha_2 = 0.05, beta = 0.1, rand_ratio = 1)
```

---

simon_ph2_sz *Single arm phase 2 oncology trial: Two-stage design, Simon's design*

Description

Single arm phase 2 oncology trial: Two-stage design, Simon's design

Usage

```
simon_ph2_sz(alpha, beta, p_0, p_1)
```

Arguments

alpha	Type I error for the one-sided test
beta	Type II error rate, i.e. 1 - power
p_0	Response rate indicating low activity with insufficient clinical benefit
p_1	Assumed response rate

Value

A matrix with one row for each of the minimax design (smallest n_2), the optimal design (smallest EN(p_0)) and the average design (an augmentation of the original Simon's design, Gao and Zhang 2024), and one column per design quantity:

r1 If no more than r1 responses are observed at the first look, then the trial would be stopped for futility

n1 Number of patients at first look

r_2 The null hypothesis will be rejected if at least r_2 responses are observed at the end of the trial

n_2 Number of patients at second look; n_2 is also the total sample size

EN(p_0) Expected sample size under the null hypothesis

PET(p_0) Probability of early termination under the null hypothesis

t1_err Type I error, the probability of rejecting the null hypothesis under p <= p_0

PET_p_1 Probability of early termination under p = p_1

power_p_1 Power under p = p_1

References

R. Simon. Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clinical Trials 10:1-10 (1989).

P. Gao & W. Zhang (15 Apr 2024): Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2341673. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2341673.

Examples

```
simon_ph2_sz(alpha=0.025,beta=0.1,p_0=0.2,p_1=0.33)
```

`Two_stage_asd_simu_OC_binary` *Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Optimizing adaptive sequential design*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Optimizing adaptive sequential design

Usage

```
Two_stage_asd_simu_OC_binary(
  groups,
  p_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

`groups`	Matrix of assumed event rates for the test arms under study: one row per candidate test-arm scenario and one column per dose, so that the number of doses is the number of columns; each event rate must be > 0 and < 1
`p_c`	Event rate of the control arm; must be > 0 and < 1
`direction`	Test direction: 1 = larger p is better, otherwise smaller p is better
`s1`	Vector of information fractions of the first interim analysis schedule; the last element must be 1
`s2`	Vector of information fractions of the second interim analysis schedule; the last element must be 1
`alpha_2`	Type I error for the two-sided test; 0 < alpha_2 < 1
`alpha_2_alps_s1`	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s1; each element must be > 0 and the elements must sum to alpha_2

`alpha_2_alps_s2`
: Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s2; each element must be > 0 and the elements must sum to alpha_2

`theta_cut`
: Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy

`samsz_1`
: Planned sample size of the control arm for the first sample size scenario

`samsz_2`
: Planned sample size of the control arm for the second sample size scenario

`N_max_1`
: Maximum sample size (control arm) allowed after sample size re-estimation for the first maximum sample size scenario

`N_max_2`
: Maximum sample size (control arm) allowed after sample size re-estimation for the second maximum sample size scenario

`beta`
: Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1

`sim_num`
: Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with O'Brien-Fleming boundaries

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with O'Brien-Fleming boundaries

Alpha-spending boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with alpha-spending boundaries

Alpha-spending boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with alpha-spending boundaries

Each of these four lists has the components "Group sequential design" (data frame with the columns "Looks", "Information fractions" and the critical boundaries, plus "Alpha-spending" and "Alpha-spending boundaries" for the alpha-spending schedules) and the "Simulation results: Information fractions ..., Sample size ..., N_max ..." operating characteristics of the corresponding adaptive design, one data frame per combination of interim analysis schedule, planned sample size and maximum sample size, with one row per assumed event-rate scenario.

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
Two_stage_asd_simu_OC_binary(
groups = rbind(c(0.3,0.4,0.5),c(0.1,0.2,0.3),c(0.1,0.2,0.3),c(0.1,0.2,0.3)), p_c = 0.2,
direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
samsz_1 = 100, samsz_2 = 150, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

Two_stage_asd_simu_OC_neg_binomial

Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Optimizing adaptive sequential design

Usage

```
Two_stage_asd_simu_OC_neg_binomial(
  groups,
  r_c,
  kappa,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
```

```
  beta,
  sim_num
)
```

Arguments

groups	Matrix of assumed mean event rates for the test arms under study: one row per candidate test-arm scenario and one column per dose, so that the number of doses is the number of columns; each mean event rate must be > 0
r_c	Mean event rate of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s1	Vector of information fractions of the first interim analysis schedule; the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule; the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s1; each element must be > 0 and the elements must sum to alpha_2
alpha_2_alps_s2	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s2; each element must be > 0 and the elements must sum to alpha_2
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
samsz_1	Planned sample size of the control arm for the first sample size scenario
samsz_2	Planned sample size of the control arm for the second sample size scenario
N_max_1	Maximum sample size (control arm) allowed after sample size re-estimation for the first maximum sample size scenario
N_max_2	Maximum sample size (control arm) allowed after sample size re-estimation for the second maximum sample size scenario
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with O'Brien-Fleming boundaries

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with O'Brien-Fleming boundaries

Alpha-spending boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with alpha-spending boundaries

Alpha-spending boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with alpha-spending boundaries

Each of these four lists has the components "Group sequential design" (data frame with the columns "Looks", "Information fractions" and the critical boundaries, plus "Alpha-spending" and "Alpha-spending boundaries" for the alpha-spending schedules) and the "Simulation results: Information fractions ..., Sample size ..., N_max ..." operating characteristics of the corresponding adaptive design, one data frame per combination of interim analysis schedule, planned sample size and maximum sample size, with one row per assumed mean event-rate scenario.

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
Two_stage_asd_simu_OC_neg_binomial(
groups = rbind(c(0.3,0.4,0.5),c(0.2,0.2,0.5),c(0.2,0.2,0.3),c(0.2,0.3,0.4)), r_c = 0.2,
kappa = 1, direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
samsz_1 = 100, samsz_2 = 150, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

Two_stage_asd_simu_OC_normal

Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Optimizing adaptive sequential design

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Optimizing adaptive sequential design

Usage

```
Two_stage_asd_simu_OC_normal(
  groups,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of assumed effect sizes for the test arms under study: one row per candidate test-arm scenario and one column per dose, so that the number of doses is the number of columns
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arms
sigma_c	Standard deviation of the control arm
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s1	Vector of information fractions of the first interim analysis schedule; the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule; the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s1; each element must be > 0 and the elements must sum to alpha_2
alpha_2_alps_s2	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s2; each element must be > 0 and the elements must sum to alpha_2

theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
samsz_1	Planned sample size of the control arm for the first sample size scenario
samsz_2	Planned sample size of the control arm for the second sample size scenario
N_max_1	Maximum sample size (control arm) allowed after sample size re-estimation for the first maximum sample size scenario
N_max_2	Maximum sample size (control arm) allowed after sample size re-estimation for the second maximum sample size scenario
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list of four elements, one per boundary type and interim analysis schedule, with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with O'Brien-Fleming boundaries

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with O'Brien-Fleming boundaries

Alpha-spending boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with alpha-spending boundaries

Alpha-spending boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with alpha-spending boundaries

Each of these four lists has the components "Group sequential design" (data frame with the columns "Looks", "Information fractions" and the critical boundaries, plus "Alpha-spending" and "Alpha-spending boundaries" for the alpha-spending schedules) and "Simulation results: Information fractions ..., Sample size ..., N_max ..." (the operating characteristics of the corresponding adaptive design).

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
Two_stage_asd_simu_OC_normal(groups = rbind(c(0.2, 0.3, 0.4), c(0.3, 0.4, 0.5)), mu_c = 0,
sigma_t = 1, sigma_c = 1, direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
samsz_1 = 100, samsz_2 = 150, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

Two_stage_asd_simu_OC_poisson

Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Optimizing adaptive sequential design

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Optimizing adaptive sequential design

Usage

```
Two_stage_asd_simu_OC_poisson(
  groups,
  lambda_c,
  direction,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  theta_cut,
  samsz_1,
  samsz_2,
  N_max_1,
  N_max_2,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of assumed means for the test arms under study: one row per candidate test-arm scenario and one column per dose, so that the number of doses is the number of columns; each mean must be > 0
lambda_c	Mean of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s1	Vector of information fractions of the first interim analysis schedule; the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule; the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s1; each element must be > 0 and the elements must sum to alpha_2
alpha_2_alps_s2	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s2; each element must be > 0 and the elements must sum to alpha_2
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
samsz_1	Planned sample size of the control arm for the first sample size scenario
samsz_2	Planned sample size of the control arm for the second sample size scenario
N_max_1	Maximum sample size (control arm) allowed after sample size re-estimation for the first maximum sample size scenario
N_max_2	Maximum sample size (control arm) allowed after sample size re-estimation for the second maximum sample size scenario
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with O'Brien-Fleming boundaries

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with O'Brien-Fleming boundaries

Alpha-spending boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with alpha-spending boundaries

Alpha-spending boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with alpha-spending boundaries

Each of these four lists has the components "Group sequential design" (data frame with the columns "Looks", "Information fractions" and the critical boundaries, plus "Alpha-spending" and "Alpha-spending boundaries" for the alpha-spending schedules) and the "Simulation results: Information fractions ..., Sample size ..., N_max ..." operating characteristics of the corresponding adaptive design, one data frame per combination of interim analysis schedule, planned sample size and maximum sample size, with one row per assumed mean scenario.

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
Two_stage_asd_simu_OC_poisson(
groups = rbind(c(0.3,0.4,0.5),c(0.2,0.2,0.5),c(0.2,0.2,0.3),c(0.2,0.3,0.4)), lambda_c = 0.2,
direction = 1, s1 = c(1/3,2/3,1), s2 = c(0.5,1), alpha_2 = 0.05,
alpha_2_alps_s1 = c(0.001,0.001,0.048), alpha_2_alps_s2 = c(0.001,0.049), theta_cut = 0.01,
samsz_1 = 100, samsz_2 = 150, N_max_1 = 1000, N_max_2 = 1500, beta = 0.1, sim_num = 2)
```

Two_stage_asd_simu_OC_survival

Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Optimizing adaptive sequential design

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Optimizing adaptive sequential design

Usage

```
Two_stage_asd_simu_OC_survival(
  groups,
  s1,
  s2,
  alpha_2,
  alpha_2_alps_s1,
  alpha_2_alps_s2,
  surv_rate,
  evt_num_1,
  evt_num_2,
  evt_max_1,
  evt_max_2,
  HR_cut,
  beta,
  sim_num
)
```

Arguments

groups	Matrix of assumed hazard ratios for the test arms under study: one row per candidate test-arm scenario and one column per dose, so that the number of doses is the number of columns; each hazard ratio is relative to the control arm, must be > 0, with HR < 1 indicating a beneficial effect and HR = 1 the null hypothesis
s1	Vector of information fractions of the first interim analysis schedule; the last element must be 1
s2	Vector of information fractions of the second interim analysis schedule; the last element must be 1
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
alpha_2_alps_s1	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s1; each element must be > 0 and the elements must sum to alpha_2
alpha_2_alps_s2	Vector of two-sided alpha to be spent at each analysis of the alpha-spending schedule s2; each element must be > 0 and the elements must sum to alpha_2
surv_rate	Survival rate at the end of follow-up, used to translate the number of events into a sample size
evt_num_1	Planned number of events between a test arm and the control arm for the first event number scenario
evt_num_2	Planned number of events between a test arm and the control arm for the second event number scenario
evt_max_1	Maximum number of events between a test arm and the control arm allowed after sample size re-estimation for the first maximum event number scenario
evt_max_2	Maximum number of events between a test arm and the control arm allowed after sample size re-estimation for the second maximum event number scenario

`HR_cut`	Hazard-ratio cut-off for lack of efficacy at the interim analysis: the test drug is not considered to provide clinically meaningful efficacy when the observed hazard ratio is greater than HR_cut
`beta`	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
`sim_num`	Number of simulation replicates

Value

A named list with the following components:

O'Brien-Fleming boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with O'Brien-Fleming boundaries

O'Brien-Fleming boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with O'Brien-Fleming boundaries

Alpha-spending boundaries, interim analysis schedule=s1 List holding the group sequential design and the operating characteristics simulated under the schedule s1 with alpha-spending boundaries

Alpha-spending boundaries, interim analysis schedule=s2 List holding the group sequential design and the operating characteristics simulated under the schedule s2 with alpha-spending boundaries

Each of these four lists has the components "Group sequential design" (data frame with the columns "Looks", "Information fractions" and the critical boundaries, plus "Alpha-spending" and "Alpha-spending boundaries" for the alpha-spending schedules) and the "Simulation results: Information fractions ..., Sample size ..., evt_max ..." operating characteristics of the corresponding adaptive design, one data frame per combination of interim analysis schedule, planned event number and maximum number of events, with one row per assumed hazard-ratio scenario.

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
set.seed(1)
Two_stage_asd_simu_OC_survival(
groups = rbind(c(0.8, 0.83, 0.85), c(0.78, 0.8, 0.82), c(0.75, 0.78, 0.8)), s1 = c(1/3,2/3,1),
s2 = c(0.5,1), alpha_2 = 0.05, alpha_2_alps_s1 = c(0.001,0.001,0.048),
alpha_2_alps_s2 = c(0.01,0.04), surv_rate = 0.5, evt_num_1 = 200, evt_num_2 = 300,
evt_max_1 = 2000, evt_max_2 = 3000, HR_cut = 0.95, beta = 0.1, sim_num = 2)
```

---

two_stage_ci_0 *Phase 2/3 seamless combination Group sequential design: Final analysis, Without sample size change, last_vt == 1*

Description

Phase 2/3 seamless combination Group sequential design: Final analysis, Without sample size change, last_vt == 1

Usage

```
two_stage_ci_0(s, theta_hat_0, theta_hat_0_sd, alpha_2, dist)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
theta_hat_0	Vector of naive point estimates of the treatment effect for the comparisons at the end of the phase 2 stage (the first interim analysis); its length is the number of comparisons
theta_hat_0_sd	Common standard error of 'theta_hat_0' at the end of the phase 2 stage, shared by all comparisons; must be > 0
alpha_2	Type I error for the two-sided test
dist	Distribution indicator of the endpoint: 1 = the endpoint is normally distributed and the comparison is between multiple doses and a common control, otherwise the non-normal branch is used

Value

A named list with the following components:

p-value The p-value for the hypothesis test

confidence interval Numeric vector of length 3 giving the lower confidence limit, the median unbiased point estimate and the upper confidence limit; the lower limit is consistent with the p-value

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_ci_0(s = c(1/3, 2/3, 1), theta_hat_0 = 0.2, theta_hat_0_sd = 0.5,
alpha_2 = 0.05, dist = 1)
```

`two_stage_ci_1` *Phase 2/3 seamless combination Group sequential design: Final analysis, Without sample size change, last_vt > 1*

Description

Phase 2/3 seamless combination Group sequential design: Final analysis, Without sample size change, last_vt > 1

Usage

```
two_stage_ci_1(
  s,
  c_bry_two_stg,
  c_bry_p3,
  comp,
  theta_hat_p3,
  theta_hat_p3_sd,
  theta_hat_last,
  theta_hat_last_sd,
  last_vt,
  alpha_2,
  dist
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1; here the length of 's' must be 2 or 3, i.e. the phase 2 stage plus one or two phase 3 analyses
c_bry_two_stg	Vector of critical boundaries of the two-stage design for the overall test, one per analysis; must have the same length as 's'
c_bry_p3	Vector of critical boundaries of the prior (phase 3) study, one per phase 3 analysis; must have 'length(s) - 1' elements
comp	Number of comparisons in the phase 2 stage, e.g. the number of doses or the number of endpoints; must be at least 2
theta_hat_p3	Treatment effect estimate observed at the analysis at which the trial stopped, using phase 3 data only
theta_hat_p3_sd	Standard error of 'theta_hat_p3'; must be > 0
theta_hat_last	Treatment effect estimate observed at the analysis at which the trial stopped, based on all data accumulated by then
theta_hat_last_sd	Standard error of 'theta_hat_last'; must be > 0
last_vt	Index of the analysis at which the trial stopped; must be > 1 because the trial stopped in the phase 3 stage
alpha_2	Type I error for the two-sided test
dist	Distribution indicator of the endpoint: 1 = the endpoint is normally distributed and the comparison is between multiple doses and a common control, otherwise the non-normal branch is used

Value

A named list with the following components:

p-value The p-value for the hypothesis test

confidence interval Numeric vector of length 3 giving the lower confidence limit, the median unbiased point estimate and the upper confidence limit; the lower limit is consistent with the p-value, while the point estimate and the upper limit use phase 3 data only

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_ci_1(s = c(1/3,2/3,1), c_bry_two_stg = c(3.938325, 2.784816,2.273793),
c_bry_p3 = c(3.954862,1.977431), comp = 3, theta_hat_p3 = 0.45, theta_hat_p3_sd = 0.6,
theta_hat_last = 2.784816*0.12, theta_hat_last_sd = 0.12, last_vt = 2, alpha_2 = 0.05, dist = 1)
```

---

two_stage_est_back *Phase 2/3 seamless combination Group sequential design: Final analysis, With one sample size change*

Description

Phase 2/3 seamless combination Group sequential design: Final analysis, With one sample size change

Usage

```
two_stage_est_back(
  s,
  c_bry_two_stg,
  c_bry_p3,
  comp,
  snew,
  c_bry_new,
  c_bry_new_p3,
  theta_hat_inter,
  theta_hat_inter_sd,
  inter_vt,
  theta_hat_last_ad,
  theta_hat_last_ad_sd,
  last_vt_ad,
  theta_hat_inter_p3,
  theta_hat_inter_p3_sd,
  theta_hat_last_ad_p3,
  theta_hat_last_ad_p3_sd,
  alpha_2,
  dist
)
```

Arguments

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
c_bry_two_stg	Vector of critical boundaries of the two-stage design for the overall test, one per analysis; must have the same length as 's'
c_bry_p3	Vector of critical boundaries of the prior (phase 3) study, one per phase 3 analysis; must have 'length(s) - 1' elements
comp	Number of comparisons in the phase 2 stage, e.g. the number of doses or the number of endpoints; must be at least 2
snew	Vector of new information fractions after the sample size is changed, one per analysis after the change; must have at least 'last_vt_ad' elements
c_bry_new	Vector of critical boundaries after the sample size is changed, one per analysis after the change; must have the same length as 'snew'
c_bry_new_p3	Vector of critical boundaries after the sample size is changed on the prior (phase 3) study scale, one per analysis after the change; must have the same length as 'snew'
theta_hat_inter	Treatment effect estimate observed at the interim analysis at which the sample size is changed
theta_hat_inter_sd	Standard error of 'theta_hat_inter'; must be > 0
inter_vt	Index of the interim analysis at which the sample size is re-estimated (1-based); must be less than 'length(s)', so that at least one further analysis remains
theta_hat_last_ad	Treatment effect estimate observed at the last analysis after the sample size change
theta_hat_last_ad_sd	Standard error of 'theta_hat_last_ad'; must be > 0
last_vt_ad	Index of the last analysis after the sample size change
theta_hat_inter_p3	Treatment effect estimate observed at the interim analysis at which the sample size is changed, using phase 3 data only
theta_hat_inter_p3_sd	Standard error of 'theta_hat_inter_p3'; must be > 0
theta_hat_last_ad_p3	Treatment effect estimate observed at the last analysis after the sample size change, using phase 3 data only
theta_hat_last_ad_p3_sd	Standard error of 'theta_hat_last_ad_p3'; must be > 0
alpha_2	Type I error for the two-sided test
dist	Distribution indicator of the endpoint: 1 = the endpoint is normally distributed and the comparison is between multiple doses and a common control, otherwise the non-normal branch is used

Value

A named list with the following components:

p-value The p-value for the hypothesis test

confidence interval Numeric vector of length 3 giving the lower confidence limit, the median unbiased point estimate and the upper confidence limit; the lower limit is consistent with the p-value, while the point estimate and the upper limit use phase 3 data only

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_est_back(s=c(1/3,2/3,1), c_bry_two_stg=c(3.776606,2.670463,2.180424),
c_bry_p3=c(3.954862,1.977431), comp=2, snew=c(0.5,1), c_bry_new=c(3,2.2),
c_bry_new_p3=c(3.2,2.4), theta_hat_inter=0.4, theta_hat_inter_sd=0.35, inter_vt=1,
theta_hat_last_ad=0.5, theta_hat_last_ad_sd=0.23, last_vt_ad=1, theta_hat_inter_p3=0.2,
theta_hat_inter_p3_sd=0.4, theta_hat_last_ad_p3=0.32, theta_hat_last_ad_p3_sd=0.4,
alpha_2=0.05, dist=1)
```

---

two_stage_power_alsp_boundary_binary_diff

Phase 2/3 seamless combination Group sequential design: Binary distribution, Power calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Binary distribution, Power calculation, Alpha-spending boundary

Usage

```
two_stage_power_alsp_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Event rates of the test arms; a vector of length >= 2 with 0 < p_t < 1
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_alsp_boundary_binary_diff(p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0.15,
direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), sampsz_control = 82,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`two_stage_power_alsp_boundary_neg_binomial`

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Power calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Power calculation, Alpha-spending boundary

Usage

```
two_stage_power_alsp_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
```

```
  dist2
)
```

Arguments

r_t	Mean event rates of the test arms; a vector of length >= 2
r_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.048)
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

Reference Reference for the negative binomial sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_alsp_boundary_neg_binomial(r_t = c(0.2,0.3,0.4), r_c = 0.6, margin = 0.1,
direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.048), sampsz_control = 111,
rand_ratio = 1, nu_t = 1, kappa = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_power_alsp_boundary_normal

Phase 2/3 seamless combination Group sequential design: Normal distribution, Power calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Normal distribution, Power calculation, Alpha-spending boundary

Usage

```
two_stage_power_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Means of the test arms; a vector of length >= 2
mu_c	Mean of the common control arm

std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_alsp_boundary_normal(mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1, std_c = 1,
margin = 0.01, direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023),
sampsz_control = 180, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_power_alsp_boundary_poisson

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Power calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Power calculation, Alpha-spending boundary

Usage

```
two_stage_power_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Mean event rates of the test arms; a vector of length >= 2
lambda_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
sampsz_control	Sample size of the control arm

`rand_ratio` Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

`dist1` First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

`dist2` Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_alsp_boundary_poisson(lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5, margin = 0.12,
direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), sampsz_control = 150,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`two_stage_power_alsp_boundary_survival_Schoenfeld` *Phase 2/3 seamless combination Group sequential design: Survival analysis, Power calculation, Alpha-spending boundary*

Description

Phase 2/3 seamless combination Group sequential design: Survival analysis, Power calculation, Alpha-spending boundary

Usage

```
two_stage_power_alsp_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  events_tot,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

`HR`	Hazard ratios of the test arms vs. the control arm; a vector of length >= 2
`margin`	Non-inferiority margin for the hazard ratio; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial
`direction`	Test direction: 1 = larger HR is better, otherwise smaller HR is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
`events_tot`	Total number of events available for the trial
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
`dist1`	Distribution indicator for the first stage: 2 for this survival endpoint setting (this is conservative)
`dist2`	Distribution indicator for the second stage: 1 for this survival endpoint setting (this is conservative)

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each HR, the exit probability for each HR, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected HR

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

reference Reference for the Schoenfeld sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_alsp_boundary_survival_Schoenfeld(HR = c(0.2,0.3,0.4), margin = 1.1,
direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), events_tot = 20,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_power_OF_boundary_binary_diff

Phase 2/3 seamless combination Group sequential design: Binary distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Binary distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
two_stage_power_OF_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Event rates of the test arms; a vector of length >= 2 with 0 < p_t < 1
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_OF_boundary_binary_diff(p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0.15,
direction = 1, s = c(1/3,2/3,1), alpha = 0.025,
sampsz_control = 82, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_power_OF_boundary_neg_binomial

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
two_stage_power_OF_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
```

```
  dist2
)
```

Arguments

r_t	Mean event rates of the test arms; a vector of length >= 2
r_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

Reference Reference for the negative binomial sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_OF_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), alpha = 0.025, sampsz_control = 100, rand_ratio = 1,
nu_t = 6, kappa = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_power_OF_boundary_normal

Phase 2/3 seamless combination Group sequential design: Normal distribution, Power calculation, O'Brien-Fleming boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Normal distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
two_stage_power_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Means of the test arms; a vector of length >= 2
mu_c	Mean of the common control arm
std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0

margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
sampsz_control	Sample size of the control arm
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_OF_boundary_normal(mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1, std_c = 1,
margin = 0.01, direction = 1, s = c(1/3,2/3,1), alpha = 0.025, sampsz_control = 180,
rand_ratio = 1, dist1 = 1, dist2 = 1)
```

`two_stage_power_OF_boundary_poisson` *Phase 2/3 seamless combination Group sequential design: Poisson distribution, Power calculation, O'Brien-Fleming boundary*

Description

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Power calculation, O'Brien-Fleming boundary

Usage

```
two_stage_power_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  sampsz_control,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

`lambda_t`	Mean event rates of the test arms; a vector of length >= 2
`lambda_c`	Mean event rate of the common control arm
`margin`	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
`direction`	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
`s`	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
`alpha`	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
`sampsz_control`	Sample size of the control arm
`rand_ratio`	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
`dist1`	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
`dist2`	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_OF_boundary_poisson(lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5, margin = 0.12,
direction = 1, s = c(1/3,2/3,1), alpha = 0.025, sampsz_control = 150, rand_ratio = 1,
dist1 = 1, dist2 = 1)
```

---

two_stage_power_OF_boundary_survival_Schoenfeld

Phase 2/3 seamless combination Group sequential design: Survival analysis, Power calculation, O'Brien-Fleming boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Survival analysis, Power calculation, O'Brien-Fleming boundary

Usage

```
two_stage_power_OF_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  events_tot,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Hazard ratios of the test arms vs. the control arm; a vector of length >= 2
margin	Non-inferiority margin for the hazard ratio; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
events_tot	Total number of events available for the trial
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 2 for this survival endpoint setting (this is conservative)
dist2	Distribution indicator for the second stage: 1 for this survival endpoint setting (this is conservative)

Value

A named list with the following components:

power Nested list with the total power, the selection probability for each HR, the exit probability for each HR, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected HR

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

reference Reference for the Schoenfeld sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_power_OF_boundary_survival_Schoenfeld(HR = c(0.55,0.55), margin = 1, direction = 2,
s = c(1/3,2/3,1), alpha = 0.025,
events_tot = 137, rand_ratio = 1, dist1 = 2, dist2 = 1)
```

`two_stage_Sample_size_alsp_boundary_binary_diff`

Phase 2/3 seamless combination Group sequential design: Binary distribution, Sample size calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Binary distribution, Sample size calculation, Alpha-spending boundary

Usage

```
two_stage_Sample_size_alsp_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Event rates of the test arms; a vector of length >= 2 with 0 < p_t < 1
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_alsp_boundary_binary_diff( p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0.15,
 direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
  dist1 = 1, dist2 = 1)
```

`two_stage_Sample_size_alsp_boundary_neg_binomial`

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Sample size calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Sample size calculation, Alpha-spending boundary

Usage

```
two_stage_Sample_size_alsp_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
  dist2
)
```

Arguments

r_t	Mean event rates of the test arms; a vector of length >= 2
r_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

Reference Reference for the negative binomial sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_alsp_boundary_neg_binomial( r_t = c(0.2,0.3,0.4), r_c = 0.6, margin = 0.1,
 direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
  nu_t = 1, kappa = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_Sample_size_alsp_boundary_normal

Phase 2/3 seamless combination Group sequential design: Normal distribution, Sample size calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Normal distribution, Sample size calculation, Alpha-spending boundary

Usage

```
two_stage_Sample_size_alsp_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
```

```
  dist1,
  dist2
)
```

Arguments

mu_t	Means of the test arms; a vector of length >= 2. The largest implied mean effect must be > 1e-4, otherwise the function returns NA
mu_c	Mean of the common control arm
std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_alsp_boundary_normal( mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1,
  std_c = 1, margin = 0.1, direction = 1, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023),
  beta = 0.1, rand_ratio = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_Sample_size_alsp_boundary_poisson

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Sample size calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Sample size calculation, Alpha-spending boundary

Usage

```
two_stage_Sample_size_alsp_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Mean event rates of the test arms; a vector of length >= 2
lambda_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_alsp_boundary_poisson( lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5,
  margin = 0.3, direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1,
  rand_ratio = 1, dist1 = 1, dist2 = 1)
```

---

two_stage_Sample_size_alsp_boundary_survival_Schoenfeld

Phase 2/3 seamless combination Group sequential design: Survival analysis, Sample size calculation, Alpha-spending boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Survival analysis, Sample size calculation, Alpha-spending boundary

Usage

```
two_stage_Sample_size_alsp_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Hazard ratios of the test arms vs. the control arm; a vector of length >= 2
margin	Non-inferiority margin for the hazard ratio; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; for the alpha-spending boundary this is the vector of alpha-spending values at each analysis, with one value per element of s and the values summing to the overall one-sided type I error, e.g. c(0.001, 0.001, 0.023)
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 2 for this survival endpoint setting (this is conservative)
dist2	Distribution indicator for the second stage: 1 for this survival endpoint setting (this is conservative)

Value

A named list with the following components:

Combined number of events between a dose and control Number of events required for a single dose compared with the control

total number of events from all doses and control Total number of events required for all doses and the control

combined number of events in each dose and control in a two arm study with same critical boudary Number of events for each dose and the control in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each HR, the exit probability for each HR, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected HR

reference Reference for the Schoenfeld sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_alsp_boundary_survival_Schoenfeld( HR = c(0.2,0.3,0.4), margin = 1.1,
 direction = 2, s = c(1/3,2/3,1), alpha = c(0.001,0.001,0.023), beta = 0.1, rand_ratio = 1,
  dist1 = 1, dist2 = 1)
```

---

two_stage_Sample_size_OF_boundary_binary_diff

Phase 2/3 seamless combination Group sequential design: Binary distribution, Sample size calculation, O'Brien-Fleming boundary

---

Description

Phase 2/3 seamless combination Group sequential design: Binary distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
two_stage_Sample_size_OF_boundary_binary_diff(
  p_t,
  p_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

p_t	Event rates of the test arms; a vector of length >= 2 with 0 < p_t < 1
p_c	Event rate of the common control arm; 0 < p_c < 1
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025

beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_OF_boundary_binary_diff( p_t = c(0.2,0.3,0.4), p_c = 0.5, margin = 0,
  direction = 2, s = c(1/3,2/3,1), alpha = 0.025, beta = 0.1, rand_ratio = 1, dist1 = 1,
  dist2 = 1)
```

two_stage_Sample_size_OF_boundary_neg_binomial *Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Sample size calculation, O'Brien-Fleming boundary*

Description

Phase 2/3 seamless combination Group sequential design: Negative binomial distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
two_stage_Sample_size_OF_boundary_neg_binomial(
  r_t,
  r_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  nu_t,
  kappa,
  dist1,
  dist2
)
```

Arguments

r_t	Mean event rates of the test arms; a vector of length >= 2
r_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
nu_t	Exposure time; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0

`dist1` First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise

`dist2` Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

Reference Reference for the negative binomial sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_OF_boundary_neg_binomial(r_t = c(1.1, 1.1, 1.1), r_c = 1.1, margin = 0.1,
direction = 0, s = c(1/3, 2/3, 1), alpha = 0.025, beta = 0.1, rand_ratio = 1, nu_t = 6,
kappa = 1, dist1 = 1, dist2 = 1)
```

two_stage_Sample_size_OF_boundary_normal *Phase 2/3 seamless combination Group sequential design: Normal distribution, Sample size calculation, O'Brien-Fleming boundary*

Description

Phase 2/3 seamless combination Group sequential design: Normal distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
two_stage_Sample_size_OF_boundary_normal(
  mu_t,
  mu_c,
  std_t,
  std_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

mu_t	Means of the test arms; a vector of length >= 2. The largest implied mean effect must be > 1e-4, otherwise the function returns NA
mu_c	Mean of the common control arm
std_t	Common standard deviation of the test arms; must be > 0
std_c	Standard deviation of the control arm; must be > 0
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0

dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_OF_boundary_normal( mu_t = c(0.2,0.3,0.4), mu_c = 0, std_t = 1, std_c = 1,
 margin = 0.1, direction = 1, s = c(1/3,2/3,1), alpha = 0.025, beta = 0.1, rand_ratio = 1,
 dist1 = 1, dist2 = 1)
```

two_stage_Sample_size_OF_boundary_poisson *Phase 2/3 seamless combination Group sequential design: Poisson distribution, Sample size calculation, O'Brien-Fleming boundary*

Description

Phase 2/3 seamless combination Group sequential design: Poisson distribution, Sample size calculation, O'Brien-Fleming boundary

Usage

```
two_stage_Sample_size_OF_boundary_poisson(
  lambda_t,
  lambda_c,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

lambda_t	Mean event rates of the test arms; a vector of length >= 2
lambda_c	Mean event rate of the common control arm
margin	Non-inferiority margin; margin >= 0, with margin = 0 for a superiority trial and margin > 0 for a non-inferiority trial
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	First-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise
dist2	Second-stage distribution indicator: 1 = the sample size calculation is for multiple dose vs. a common control, with normal distributions, 2 = otherwise

Value

A named list with the following components:

test arm sample size Sample size required for the test arm

control arm sample size Sample size required for the control arm

sample size for each dose in a two arm study with same critical boudary Sample size for each dose in a two-arm study using the same critical boundary

sample size for control arm in a two arm study with same critical boudary Sample size for the control arm in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each mu, the exit probability for each mu, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected mu

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_OF_boundary_poisson( lambda_t = c(0.2,0.3,0.4), lambda_c = 0.5,
 margin = 0.15, direction = 2, s = c(1/3,2/3,1), alpha = 0.025, beta = 0.1, rand_ratio = 1,
  dist1 = 1, dist2 = 1)
```

two_stage_Sample_size_OF_boundary_survival_Schoenfeld
Phase 2/3 seamless combination Group sequential design: Survival analysis, Sample size calculation, O'Brien-Fleming boundary

Description

Phase 2/3 seamless combination Group sequential design: Survival analysis, Sample size calculation, O'Brien-Fleming boundary

Usage

```
two_stage_Sample_size_OF_boundary_survival_Schoenfeld(
  HR,
  margin,
  direction,
  s,
  alpha,
  beta,
  rand_ratio,
  dist1,
  dist2
)
```

Arguments

HR	Hazard ratios of the test arms vs. the control arm; a vector of length >= 2
margin	Non-inferiority margin for the hazard ratio; must be > 0, with margin = 1 for a superiority trial and margin != 1 for a non-inferiority trial
direction	Test direction: 1 = larger HR is better, otherwise smaller HR is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
alpha	Type I error for the one-sided test; 0 < alpha < 1, typically 0.025
beta	Type II error rate, i.e. 1 - power; 0 < beta < 1
rand_ratio	Randomization ratio: number of subjects in the test arm vs. the number of subjects in the control arm; must be > 0
dist1	Distribution indicator for the first stage: 2 for this survival endpoint setting (this is conservative)
dist2	Distribution indicator for the second stage: 1 for this survival endpoint setting (this is conservative)

Value

A named list with the following components:

Combined number of events between a dose and control Number of events required for a single dose compared with the control

total number of events from all doses and control Total number of events required for all doses and the control

combined number of events in each dose and control in a two arm study with same critical boudary Number of events for each dose and the control in a two-arm study using the same critical boundary

type I error control Nested list with the two-stage critical boundaries, the one-sided alpha spending, nominal alpha and cumulative alpha at each interim analysis, and the phase 3 information fraction, phase 3 critical boundary and nominal p-value for phase 3

exit probabilities Nested list with the selection probability for each HR, the exit probability for each HR, the total phase 2 probability, the total exit probability and the conditional exit probability given the selected HR

reference Reference for the Schoenfeld sample size formula used

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stage_Sample_size_OF_boundary_survival_Schoenfeld( HR = c(1.1,1.2,1.25), margin = 1,
  direction = 1, s = c(0.3,0.7,1), alpha = 0.025, beta = 0.1, rand_ratio = 1, dist1 = 2,
  dist2 = 1)
```

two_stg_adapt_power_simu_binary *Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Operating characteristics*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Operating characteristics

Usage

```
two_stg_adapt_power_simu_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  theta_cut,
  N_max,
  samsz,
  beta,
  sim_num
)
```

Arguments

p_t	Event rate of the test arm; each element must be > 0 and < 1
p_c	Event rate of the control arm; must be > 0 and < 1
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
N_max	Maximum sample size (control arm) allowed after sample size re-estimation
samsz	Planned sample size of the control arm used in the simulation
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned adaptive group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries", "rejection by look" and "Sample size increase"

Results by arm Matrix with one row per dose and the columns "p_{t1},...", "p_c", "selection rate", "rejection rate by each p_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the "Rejection rate without SSR", the "Rejection rate with SSR", the "rate of sample size increase", the "Rejection rate without SSR/(meeting sample size incerase criteria)", the "Rejection rate with SSR/(sample size incerase)", the "Type I error", the "Non-Type I error rejection rate", the "Futility rate", the "Planned control sample size", the "Maximum control sample size", the "Mean control sample size", the "Planned total sample size", the "Mean total sample size" and the "mean control sample size conditional on increase"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_adapt_power_simu_binary(p_t = c(0.4,0.5), p_c = 0.3, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, theta_cut = 0.05, N_max = 1000, samsz = 100,
beta = 0.1, sim_num = 20)
```

two_stg_adapt_power_simu_neg_binomial *Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Operating characteristics*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Operating characteristics

Usage

```
two_stg_adapt_power_simu_neg_binomial(
  r_t,
  r_c,
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  theta_cut,
  samsz,
  N_max,
  beta,
  sim_num
)
```

Arguments

r_t	Mean event rates of the test arms; each element must be > 0
r_c	Mean event rate of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
samsz	Planned sample size of the control arm used in the simulation
N_max	Maximum sample size (control arm) allowed after sample size re-estimation
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned adaptive group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries", "rejection by look" and "Sample size increase"

Results by arm Matrix with one row per dose and the columns "r_{t1},...", "r_c", "selection rate", "rejection rate by each r_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the "Rejection rate without SSR", the "Rejection rate with SSR", the "rate of sample size increase", the "Rejection rate without SSR/(meeting sample size incerase criteria)", the "Rejection rate with SSR/(sample size incerase)", the "Type I error", the "Non-Type I error rejection rate", the "Futility rate", the "Planned control sample size", the "Maximum control sample size", the "Mean control sample size", the "Planned total sample size", the "Mean total sample size" and the "mean control sample size conditional on increase"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_adapt_power_simu_neg_binomial(
r_t = c(1.1,1.1,1.1), r_c = 1.1, kappa = 1, direction = 1,
s = c(1/3,1), bry_type = 1, alpha_2 = 0.05, theta_cut = 0.05, samsz = 100, N_max = 1000,
beta = 0.1, sim_num = 20)
```

two_stg_adapt_power_simu_normal *Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Operating characteristics*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Operating characteristics

Usage

```
two_stg_adapt_power_simu_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  theta_cut,
  samsz,
  N_max,
  beta,
  sim_num
)
```

Arguments

mu_t	Vector of means of the test arms, one entry per dose
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arms
sigma_c	Standard deviation of the control arm
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
samsz	Planned sample size of the control arm used in the simulation
N_max	Maximum sample size (control arm) allowed after sample size re-estimation

`beta`	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
`sim_num`	Number of simulation replicates

Value

A named numeric vector with the following components:

Rejection rate without SSR Rejection rate of the trial if the sample size is not re-estimated

Rejection rate with SSR Rejection rate of the trial under the adaptive procedure with sample size re-estimation

rate of sample size increase Rate of simulations in which the sample size is increased

Rejection rate without SSR/(meeting sample size incerase criteria) Rejection rate without sample size re-estimation among the simulations that meet the sample size increase criteria

Rejection rate with SSR/(sample size incerase) Rejection rate with sample size re-estimation among the simulations in which the sample size is increased

Type I error Simulated one-sided type I error rate

Non-Type I error rejection rate Simulated rejection rate when the true effect is non-zero

Futility rate Rate of simulations stopped for lack of efficacy, i.e. for which the observed interim effect size is below theta_cut

Planned control sample size Planned sample size of the control arm

Maximum control sample size Maximum permitted sample size of the control arm

Mean control sample size Mean simulated sample size of the control arm

Planned total sample size Planned total sample size of the trial

Mean total sample size Mean simulated total sample size of the trial

mean control sample size conditional on increase Mean simulated control sample size among the simulations in which the sample size is increased

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_adapt_power_simu_normal(mu_t = c(0,0,0), mu_c = 0, sigma_t = 1, sigma_c = 1,
direction = 1, s = c(1/3,2/3,1), bry_type = 2, alpha_2 = c(0.001,0.001,0.048),
theta_cut = 0.05, samsz = 100, N_max = 500, beta = 0.1, sim_num = 20)
```

---

two_stg_adapt_power_simu_poisson

Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Operating characteristics

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Operating characteristics

Usage

```
two_stg_adapt_power_simu_poisson(
  lambda_t,
  lambda_c,
  direction,
  s,
  bry_type,
  alpha_2,
  theta_cut,
  N_max,
  samsz,
  beta,
  sim_num
)
```

Arguments

lambda_t	Mean of the test arm; each element must be > 0
lambda_c	Mean of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
theta_cut	Lack-of-efficacy threshold: an effect size below which the test drug is not considered to provide clinically meaningful efficacy
N_max	Maximum sample size (control arm) allowed after sample size re-estimation

samsz	Planned sample size of the control arm used in the simulation
beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned adaptive group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries", "rejection by look" and "Sample size increase"

Results by arm Matrix with one row per dose and the columns "lambda_t1,...", "lambda_c", "selection rate", "rejection rate by each lambda_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the "Rejection rate without SSR", the "Rejection rate with SSR", the "rate of sample size increase", the "Rejection rate without SSR/(meeting sample size incerase criteria)", the "Rejection rate with SSR/(sample size incerase)", the "Type I error", the "Non-Type I error rejection rate", the "Futility rate", the "Planned control sample size", the "Maximum control sample size", the "Mean control sample size", the "Planned total sample size", the "Mean total sample size" and the "mean control sample size conditional on increase"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_adapt_power_simu_poisson(lambda_t = c(1.1,1.1,1.1), lambda_c = 1.1, direction = 1,
s = c(1/3,1), bry_type = 1, alpha_2 = 0.05,
theta_cut = 0.05, N_max = 1000, samsz = 100, beta = 0.1, sim_num = 20)
```

two_stg_adapt_power_simu_survival *Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Operating characteristics*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Operating characteristics

Usage

```
two_stg_adapt_power_simu_survival(
  HR,
  s,
  bry_type,
  alpha_2,
  evt_num,
  evt_max,
  HR_cut,
  surv_rate,
  beta,
  sim_num
)
```

Arguments

HR	Vector of hazard ratios of each test arm vs. the control arm, one entry per dose; must be > 0, with HR < 1 indicating a beneficial effect and HR = 1 the null hypothesis
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
evt_num	Planned number of events between a test arm and the control arm at the final analysis
evt_max	Maximum number of events between a test arm and the control arm allowed after sample size re-estimation
HR_cut	Hazard-ratio cut-off for lack of efficacy at the interim analysis: the test drug is not considered to provide clinically meaningful efficacy when the observed hazard ratio is greater than HR_cut
surv_rate	Survival rate at the end of follow-up, used to translate the number of events into a sample size

beta	Conditional type II error; 1 - beta is the target conditional power for the sample size re-estimation; 0 < beta < 1
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned adaptive group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries", "rejection by look" and "Sample size increase"

Results by arm Matrix with one row per dose and the columns "HR", "selection rate", "rejection rate by each HR" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the "rejection rate without SSR", the "rejection rate with SSR", the "Rate of sample size increase", the "Rejection rate without SSR/(meeting sample size incerase criteria)", the "Rejection rate with SSR/(sample size incerase)", the "Type I error", the "Non-Type I error rejection rate", the "Futility rate", the "Planned event number for two arms", the "Maximum number of events for two arms", the "Mean event number for two arms", the "Planned total number of events", the "total number of events" and the "Mean event number for two arms conditional on increase"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_adapt_power_simu_survival(HR = rep(1,2), s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05,
evt_num = 150, evt_max = 1500, HR_cut = 0.95, surv_rate = 0.5, beta = 0.1, sim_num = 20)
```

two_stg_power_simu_binary *Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Type I error and power*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Binary distribution, Type I error and power

Usage

```
two_stg_power_simu_binary(
  p_t,
  p_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

p_t	Event rate of the test arm
p_c	Event rate of the control arm
direction	Test direction: 1 = larger p is better, otherwise smaller p is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
samsz	Planned sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries" and "rejection by look"

Results by arm Matrix with one row per dose and the columns "p_{t1},...", "p_c", "selection rate", " rejection rate by each p_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the overall "rejection rate", the "Type I error", the "Non-Type I error rejection rate", the "Planned control sample size", the "Mean control sample size", the "Planned total sample size" and the "Mean total sample size"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_power_simu_binary(p_t = c(0.4,0.4,0.4), p_c = 0.4, direction = 1, s = c(1/3,2/3,1),
bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

two_stg_power_simu_neg_binomial

Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Type I error and power

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Negative binomial distribution, Type I error and power

Usage

```
two_stg_power_simu_neg_binomial(
  r_t,
  r_c,
```

```
  kappa,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

r_t	Mean event rates of the test arms; each element must be > 0
r_c	Mean event rate of the control arm; must be > 0
kappa	Dispersion parameter of the negative binomial model; must be > 0
direction	Test direction: 1 = larger r is better, otherwise smaller r is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
samsz	Planned sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries" and "rejection by look"

Results by arm Matrix with one row per dose and the columns "r_{t1},...", "r_c", "selection rate", "rejection rate by each r_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the overall "rejection rate", the "Type I error", the "Non-Type I error rejection rate", the "Planned control sample size", the "Mean control sample size", the "Planned total sample size" and the "Mean total sample size"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024

May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_power_simu_neg_binomial(r_t = c(1.1,1.1,1.1), r_c = 1.1, kappa = 1, direction = 1,
s = c(1/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

---

two_stg_power_simu_normal

Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Type I error and power

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Normal distribution, Type I error and power

Usage

```
two_stg_power_simu_normal(
  mu_t,
  mu_c,
  sigma_t,
  sigma_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

mu_t	Vector of means of the test arms, one entry per dose
mu_c	Mean of the control arm
sigma_t	Standard deviation of the test arms
sigma_c	Standard deviation of the control arm
direction	Test direction: 1 = larger mu is better, otherwise smaller mu is better

s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
samsz	Planned sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries" and "rejection by look"

Results by arm Matrix with one row per dose and the columns "mu_t1,...", "mu_c", "selection rate", " rejection rate by each mu_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the overall "rejection rate", the "Type I error", the "Non-Type I error rejection rate", the "Planned control sample size", the "Mean control sample size", the "Planned total sample size" and the "Mean total sample size"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_power_simu_normal(mu_t = c(0,0,0), mu_c = 0, sigma_t = 1, sigma_c = 1, direction = 1,
s = c(1/3,1), bry_type = 1, alpha_2 = 0.05, samsz = 100, sim_num = 20)
```

two_stg_power_simu_poisson *Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Type I error and power*

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Poisson distribution, Type I error and power

Usage

```
two_stg_power_simu_poisson(
  lambda_t,
  lambda_c,
  direction,
  s,
  bry_type,
  alpha_2,
  samsz,
  sim_num
)
```

Arguments

lambda_t	Mean of the test arm; each element must be > 0
lambda_c	Mean of the control arm; must be > 0
direction	Test direction: 1 = larger lambda is better, otherwise smaller lambda is better
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
samsz	Planned sample size of the control arm used in the simulation
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries" and "rejection by look"

Results by arm Matrix with one row per dose and the columns "lambda_t1,...", "lambda_c", "selection rate", "rejection rate by each lambda_t" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the overall "rejection rate", the "Type I error", the "Non-Type I error rejection rate", the "Planned control sample size", the "Mean control sample size", the "Planned total sample size" and the "Mean total sample size"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_power_simu_poisson(lambda_t = c(1.1,1.3,1.4), lambda_c = 1.1, direction = 1,
s = c(1/3,1), bry_type = 1, alpha_2 = 0.05,
samsz = 100, sim_num = 20)
```

---

two_stg_power_simu_survival

Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Type I error and power

---

Description

Phase 2/3 seamless combination Group sequential design: Simulations, Survival analysis, Type I error and power

Usage

```
two_stg_power_simu_survival(
  HR,
  s,
  bry_type,
  alpha_2,
  surv_rate,
  evt_num,
  sim_num
)
```

Arguments

HR	Vector of hazard ratios of each test arm vs. the control arm, one entry per dose; HR < 1 indicates a beneficial effect
s	Vector of information fractions of each analysis, e.g. c(1/3, 2/3, 1); the last element must be 1
bry_type	Critical boundary type: 1 = O'Brien-Fleming, 2 = Pocock; any other value leaves the boundaries undefined
alpha_2	Type I error for the two-sided test; 0 < alpha_2 < 1
surv_rate	Survival rate at the end of follow-up, used to translate the number of events into a sample size
evt_num	Number of events between a test arm and the control arm at the final analysis, used as the planned number of events
sim_num	Number of simulation replicates

Value

A named list with the following components:

Sequential design Matrix of the planned group sequential design, with one row per analysis and the columns "Look", "Information fraction", "Critical boundaries" and "rejection by look"

Results by arm Matrix with one row per dose and the columns "HR", "selection rate", "rejection rate by each HR" and "conditional rejection rate"; the selection rate is the probability that the dose is selected to proceed to phase 3, the rejection rate is the probability that the dose is selected and the null hypothesis is rejected, and the conditional rejection rate is the rejection rate divided by the selection rate

Simulation results Named vector of the overall "rejection rate", the "Type I error", the "Non-Type I error rejection rate", the "Planned event number for two arms", the "Mean event number for two arms", the "Planned total number of events" and the "total number of events"

References

P. Gao, Y. Li (05 May 2024): Adaptive two-stage seamless sequential design for clinical trials, Journal of Biopharmaceutical Statistics, DOI: 10.1080/10543406.2024.2342518. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2342518

Gao, P., Zhang, W. (2024). A systematic approach to adaptive sequential design for clinical trials: using simulations to select a design with desired operating characteristics. Journal of Biopharmaceutical Statistics,2024 Aug;34(5):737-752. doi:10.1080/10543406.2024.2358796. Epub 2024 May 30. To link to this article: https://www.tandfonline.com/doi/full/10.1080/10543406.2024.2358796

H.H. Müller, H. Schäfer. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches. BIOMETRICs 57, 886-891. September 2001.

P. Gao, J. H. Ware, C. Mehta. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008;18(6):1184-96.

Examples

```
two_stg_power_simu_survival(HR = c(0.8,0.8), s = c(1/3,2/3,1), bry_type = 1, alpha_2 = 0.05,
surv_rate = 0.5, evt_num = 800, sim_num = 20)
```

Index

asd_ci_est_back, 6
asd_ci_est_one_arm_2_stage, 8
asd_ci_est_one_arm_3_stage, 9
asd_new_design, 11
asd_new_design_survival, 13
asd_new_design_theta, 14
asd_new_design_theta_survival, 16
asd_power_simu_binary, 17
asd_power_simu_neg_binomial, 19
asd_power_simu_normal, 21
asd_power_simu_poisson, 23
asd_power_simu_survival, 25
asd_simu_OC_binary, 26
asd_simu_OC_neg_binomial, 29
asd_simu_OC_normal, 32
asd_simu_OC_poisson, 34
asd_simu_OC_survival, 37

EXP_3_stg_sz, 39

fixed_rej_nbglm_simu, 40
fixed_rej_rate_binary, 41
fixed_rej_rate_normal, 42
fixed_rej_rate_poisson, 43
fixed_rej_rate_surv_cox, 44

gsd_ci_est, 45
gsd_ci_est_2_stage, 46
gsd_ci_est_3_stage, 47
gsd_power_simu_binary, 48
gsd_power_simu_negbinom, 50
gsd_power_simu_normal, 51
gsd_power_simu_poisson, 53
gsd_power_simu_survival, 54

hybrid_fixed_prior_rej_binary_simu, 56
hybrid_fixed_prior_rej_negbinom_simu, 58
hybrid_fixed_prior_rej_normal_simu, 60
hybrid_fixed_prior_rej_poisson_simu, 62
hybrid_fixed_prior_rej_survival_simu, 64
hybrid_random_prior_rej_binary_simu, 66
hybrid_random_prior_rej_negbinom_simu, 68
hybrid_random_prior_rej_normal_simu, 71
hybrid_random_prior_rej_poisson_simu, 73
hybrid_random_prior_rej_survival_simu, 75
hybrid_sz, 77

interim_analysis, 78

masd_est_back_no_drop, 80
masd_est_back_with_drop, 82
masd_est_ci, 84
masd_new_samsz, 86
masd_new_samsz_survival, 88
masd_new_samsz_theta, 91
masd_new_samsz_theta_survival, 93
masd_power_simu_adapt_binary, 96
masd_power_simu_adapt_neg_binomial, 98
masd_power_simu_adapt_normal, 100
masd_power_simu_adapt_poisson, 102
masd_power_simu_adapt_survival, 104
masd_simu_OC_binary, 105
masd_simu_OC_neg_binomial, 108
masd_simu_OC_normal, 110
masd_simu_OC_poisson, 112
masd_simu_OC_survival, 115
midpnt_sz, 117
MSD_power_alsp_boundary_binary_diff, 118
MSD_power_alsp_boundary_neg_binomial, 120
MSD_power_alsp_boundary_normal, 122
MSD_power_alsp_boundary_poisson, 123

MSD_power_alsp_boundary_survival_Schoenfeld, 125
MSD_power_OF_boundary_binary_diff, 127
MSD_power_OF_boundary_neg_binomial, 129
MSD_power_OF_boundary_normal, 130
MSD_power_OF_boundary_poisson, 132
MSD_power_OF_boundary_survival_Schoenfeld, 134
msd_power_simu_binary, 136
msd_power_simu_neg_binomial, 137
msd_power_simu_normal, 139
msd_power_simu_poisson, 140
msd_power_simu_survival, 142
MSD_Sample_size_alsp_boundary_binary_diff, 143
MSD_Sample_size_alsp_boundary_neg_binomial, 145
MSD_Sample_size_alsp_boundary_normal, 147
MSD_Sample_size_alsp_boundary_poisson, 149
MSD_Sample_size_alsp_boundary_survival_Schoenfeld, 151
MSD_Sample_size_OF_boundary_binary_diff, 153
MSD_Sample_size_OF_boundary_neg_binomial, 155
MSD_Sample_size_OF_boundary_normal, 157
MSD_Sample_size_OF_boundary_poisson, 159
MSD_Sample_size_OF_boundary_survival_Schoenfeld, 161

new_sample_size_hybrid, 162

one_arm_ad_3_stg_binary, 164
one_arm_ad_two_stg_binary, 166
one_arm_rej_2_stg_binary, 167
one_arm_rej_3_stg_binary, 169
one_arm_rej_simon_binary, 170

plot.ph2simon, 171
power_alsp_boundary_binary_diff, 172
power_alsp_boundary_binary_diff_NI, 173
power_alsp_boundary_neg_binomial, 174
power_alsp_boundary_neg_binomial_NI, 176
power_alsp_boundary_normal, 177
power_alsp_boundary_normal_NI, 179
power_alsp_boundary_poisson, 180
power_alsp_boundary_poisson_NI, 181
power_alsp_boundary_survival_Schoenfeld, 183
power_alsp_boundary_survival_Schoenfeld_NI, 184
power_binary_diff, 185
power_binary_diff_NI, 186
power_OF_boundary_binary_diff, 187
power_OF_boundary_binary_diff_NI, 188
power_OF_boundary_neg_binomial, 189
power_OF_boundary_neg_binomial_NI, 190
power_OF_boundary_normal, 192
power_OF_boundary_normal_NI, 193
power_OF_boundary_poisson, 195
power_OF_boundary_poisson_NI, 196
power_OF_boundary_survival_Schoenfeld, 197
power_OF_boundary_survival_Schoenfeld_NI, 198
power_pocock_boundary_binary_diff, 200
power_pocock_boundary_binary_diff_NI, 201
power_pocock_boundary_neg_binomial, 202
power_pocock_boundary_neg_binomial_NI, 204
power_pocock_boundary_normal, 205
power_pocock_boundary_normal_NI, 206
power_pocock_boundary_poisson, 208
power_pocock_boundary_poisson_NI, 209
power_pocock_boundary_survival_Schoenfeld, 210
power_pocock_boundary_survival_Schoenfeld_NI, 211
power_two_sample_neg_binomial, 213
power_two_sample_neg_binomial_NI, 214
power_two_sample_normal, 215
power_two_sample_normal_NI, 216
power_two_sample_Poisson, 217
power_two_sample_Poisson_NI, 217
power_two_sample_surv_Schoenfeld, 218
power_two_sample_surv_Schoenfeld_NI, 219

print.ph2simon, 220

Sample_size_alsp_boundary_binary_diff, 221
Sample_size_alsp_boundary_binary_diff_NI, 222
Sample_size_alsp_boundary_neg_binomial, 223
Sample_size_alsp_boundary_neg_binomial_NI, 225
Sample_size_alsp_boundary_normal, 226
Sample_size_alsp_boundary_normal_NI, 228
Sample_size_alsp_boundary_poisson, 229
Sample_size_alsp_boundary_poisson_NI, 231
Sample_size_alsp_boundary_survival_Schoenfeld, 232
Sample_size_alsp_boundary_survival_Schoenfeld_NI, 233
sample_size_binary_diff, 235
sample_size_binary_diff_NI, 235
sample_size_neg_binomial, 236
sample_size_neg_binomial_NI, 237
Sample_size_OF_boundary_binary_diff, 239
Sample_size_OF_boundary_binary_diff_NI, 240
Sample_size_OF_boundary_neg_binomial, 241
Sample_size_OF_boundary_neg_binomial_NI, 243
Sample_size_OF_boundary_normal, 244
Sample_size_OF_boundary_normal_NI, 246
Sample_size_OF_boundary_poisson, 247
Sample_size_OF_boundary_poisson_NI, 249
Sample_size_OF_boundary_survival_Schoenfeld, 250
Sample_size_OF_boundary_survival_Schoenfeld_NI, 251
Sample_size_pocock_boundary_binary_diff, 253
Sample_size_pocock_boundary_binary_diff_NI, 254
Sample_size_pocock_boundary_neg_binomial, 255
Sample_size_pocock_boundary_neg_binomial_NI, 257
Sample_size_pocock_boundary_normal, 258
Sample_size_pocock_boundary_normal_NI, 260
Sample_size_pocock_boundary_poisson, 261
Sample_size_pocock_boundary_poisson_NI, 263
Sample_size_pocock_boundary_survival_Schoenfeld, 264
Sample_size_pocock_boundary_survival_Schoenfeld_NI, 265
sample_size_two_sample_normal, 267
sample_size_two_sample_normal_NI, 268
sample_size_two_sample_Poisson, 269
sample_size_two_sample_Poisson_NI, 270
sample_size_two_sample_surv_Schoenfeld, 271
sample_size_two_sample_surv_Schoenfeld_NI, 271
simon_ph2_sz, 272

Two_stage_asd_simu_OC_binary, 274
Two_stage_asd_simu_OC_neg_binomial, 276
Two_stage_asd_simu_OC_normal, 278
Two_stage_asd_simu_OC_poisson, 281
Two_stage_asd_simu_OC_survival, 283
two_stage_ci_0, 286
two_stage_ci_1, 287
two_stage_est_back, 289
two_stage_power_alsp_boundary_binary_diff, 291
two_stage_power_alsp_boundary_neg_binomial, 293
two_stage_power_alsp_boundary_normal, 295
two_stage_power_alsp_boundary_poisson, 297
two_stage_power_alsp_boundary_survival_Schoenfeld, 299
two_stage_power_OF_boundary_binary_diff, 300
two_stage_power_OF_boundary_neg_binomial, 302
two_stage_power_OF_boundary_normal, 304
two_stage_power_OF_boundary_poisson, 306

two_stage_power_OF_boundary_survival_Schoenfeld, 307
two_stage_Sample_size_alsp_boundary_binary_diff, 309
two_stage_Sample_size_alsp_boundary_neg_binomial, 311
two_stage_Sample_size_alsp_boundary_normal, 313
two_stage_Sample_size_alsp_boundary_poisson, 315
two_stage_Sample_size_alsp_boundary_survival_Schoenfeld, 317
two_stage_Sample_size_OF_boundary_binary_diff, 319
two_stage_Sample_size_OF_boundary_neg_binomial, 321
two_stage_Sample_size_OF_boundary_normal, 323
two_stage_Sample_size_OF_boundary_poisson, 325
two_stage_Sample_size_OF_boundary_survival_Schoenfeld, 327
two_stg_adapt_power_simu_binary, 329
two_stg_adapt_power_simu_neg_binomial, 331
two_stg_adapt_power_simu_normal, 333
two_stg_adapt_power_simu_poisson, 335
two_stg_adapt_power_simu_survival, 337
two_stg_power_simu_binary, 339
two_stg_power_simu_neg_binomial, 340
two_stg_power_simu_normal, 342
two_stg_power_simu_poisson, 344
two_stg_power_simu_survival, 345